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Magnetic nanoparticles hold tremendous potential to change the way that we study 
the body at the smallest level and can revolutionize how we diagnose and treat diseases. 
By reducing iron oxide down to the nanoscale, unique material properties are unlocked that 
drastically change how the particles interact with each other and respond to external 
magnetic fields. These unique properties of iron oxide nanoparticles (IONPs) enable a 
number of biomedical applications which covers nearly every possible area in biomedicine 
and continues to grow. Magnetic attraction can be utilized for bioseparation of tagged 
proteins or cells, directing stem cells to an injury site within the body, trigger protein 
signaling through forced interactions of cell surface receptors, or focus a drug carrier 
specifically to a tumor. The ability to influence the proton relaxation times of surrounding 
water molecules enables magnetic resonance contrast which can be utilized for cancer 
diagnostics or tracking stem cell fate following transplantation into the body. When 
exposed to an alternating magnetic field (AMF), the particles generate heat which can be 
used to either kill cancer cells directly or mediate the release of a chemotherapeutic. Each 
of these functions can be easily integrated with one another to create a truly multifunctional 
platform, but development of a nanoparticle for multiple simultaneous applications 
requires careful optimization of the common parameters for each function. For any 
biomedical application, the surface chemistry of the nanoparticle plays a critical role 
governing how the particle interacts with the physiological environment, prompting the 
design and evaluation of numerous iron oxide nanoparticle formulations over the years. 
Our lab has concentrated on phospholipid-PEG coated iron oxide nanoparticles that have 
been shown to be tunable in terms of composition, amenable to various bioconjugation 
strategies, stable in physiological buffers, and exhibit strong in vivo performance following 
systemic delivery. The overall goal with this project was to optimize the coating 
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composition and magnetic core size of phospholipid-PEG iron oxide nanoparticles for drug 
delivery, magnetic fluid hyperthermia, and magnetic resonance contrast applications and 
utilize these functions in combination for cancer therapy.  
To evaluate the potential of the IONPs for a combination hyperthermia-
chemotherapy cancer treatment, monodisperse, superparamagnetic iron oxide 
nanoparticles (SPIOs) 14 nm in diameter were synthesized via thermal decomposition and 
coated with either DSPE-PEG 2000 or DSPE-PEG 5000 (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000/5000]) using a dual solvent 
exchange technique. The particles were initially characterized in terms of their core size, 
hydrodynamic diameter, and magnetic properties. The drug Doxorubicin (DOX) was 
loaded onto the particles through hydrophilic/hydrophobic and electrostatic interactions 
with the phospholipid-PEG coating at a high capacity and allowed for sustained release. 
The heat generation of the particles was determined by measuring the temperature of the 
ferrofluids when exposed to an alternating magnetic field generated by an inductor coil. By 
comparing the two PEG lengths, it was found that DOX loading and release were inhibited 
by longer PEG, but heat generation was unaffected.  
Due to the variances between different cancer cell lines, three types of cancer 
(HeLa, U87, MCF7) were initially evaluated for their heat sensitivity. The HeLa cell line 
was chosen to examine the interaction of hyperthermia with DOX and two other drugs, 
Paclitaxel and Camptothecin. The SPIO-based delivery of DOX was capable of delivering 
the drug to the cell nuclei, and the SPIOs themselves were also internalized into the cells. 
The vesicles containing the nanoparticles could then be disrupted by MFH allowing for 
cytosolic release. Exposure of the cells to the DOX-SPIOs in a dose dependent manner 
confirmed that the DOX activity was not altered through loading and release from the SPIO 
carrier. The combination of MFH with SPIO-based DOX delivery enhanced the efficacy 
over that of either treatment alone, but a truly synergistic response could not be confirmed. 
When injected systemically, the SPIOs exhibited a long circulation half-life (~100 min) 
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and localized to the tumor and organs associated with the reticuloendothelial system (liver, 
kidneys, and spleen) while minimal uptake was found in the heart, lungs, and muscle.  
It was hypothesized that by incorporating phospholipids with a phase transition 
above body temperature, a controlled drug release mechanism could be utilized to further 
control drug biodistribution. To this end, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC) was integrated into the coating at varying molar ratios (0-75%) with the DSPE-
PEG. While the composition of the coating layer could be controlled by the initial molar 
ratios used in the coating process, increasing the amount of DPPC caused an increase in 
particles size and polydispersity. On the other hand, neither dye loading nor heat generation 
showed significant differences between the different coating compositions. Unfortunately, 
a distinct temperature-dependent release was not observed with any of the coating 
compositions. 
Lastly, the effect of magnetic core size on heat generation and magnetic resonance 
contrast was evaluated. An initial numerical simulation was conducted using the linear 
response theory to identify the optimal core size for magnetic fluid hyperthermia using 
superparamagnetic particles and analyzed how polydispersity, magnetic anisotropy, and 
the alternating magnetic field parameters affected the size dependency. A systematic array 
of monodisperse iron oxide cores between 6 to 40 nm were synthesized through iterative 
regrowth thermal decomposition and coated with DSPE-PEG using the dual solvent 
exchange method. The saturation magnetization increased from 6-10 nm in size, but larger 
sizes did not show much change. All of the cores displayed magnetization curves indicative 
of superparamagnetism at room temperature despite the presumed superparamagnetic limit 
of ~20 nm. Furthermore, the coercivity remained relatively unchanged for the range of 
sizes tested. Both heat generation and MR contrast displayed a linear dependence with core 
size indicating a single mechanism governing each function throughout the size range. 
With equivalent iron concentrations, the cellular response to MFH using different sized 
cores reflected the large increases in specific absorption rate as the core size increased from 
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6 to 19 to 40 nm.  Each of those core sizes was able to generate significant contrast in vivo 
to discern the ferrofluid distribution in a mouse tumor following intratumoral injection. 
Only the 40 nm nanoparticles were able to achieve temperatures relevant for apoptosis 
within the tumor during AMF exposure. The combination of MFH and nanoparticle DOX 
delivery inhibited tumor growth relative to a saline control, but differences with the 
individual treatments could not be distinguished within the measurement timespan of one 
week.  
In summary, this work has examined the phospholipid-PEG coated iron oxide 
nanoparticle platform in the context of drug delivery, magnetic fluid hyperthermia, and 
magnetic resonance imaging for cancer therapy applications. The coating layer can be 
tuned in terms of the PEG length and lipid composition in a controlled manner through the 
dual solvent exchange method, and it was found that the drug delivery kinetics could be 
altered with PEG length. By increasing the core size up to 40 nm, exceptional heat 
generation and T2 contrast were achieved that were relevant in an in vivo tumor model to 
visualize IONP distribution within the tumor using MRI and trigger apoptosis through 
MFH. These studies lay the foundation for the development of next generation 








Iron oxide nanoparticles (IONPs) are unique compared to other types of 
nanoparticles because of their superparamagnetic property at nanoscale sizes which allows 
for magnetic resonance (MR) contrast, localization through magnetic force, and generation 
of heat through a process called magnetic fluid hyperthermia (MFH) when subjected to an 
alternating magnetic field (AMF). Various strategies have also been employed to develop 
IONPs as drug carriers. These functions of IONPs are attractive to cancer therapy where 
they can be used in both a diagnostic and therapeutic capacity. The inherent 
multifunctionality of the IONP platform poses a challenge when optimizing the 
nanoparticle design to excel at each application. The IONP system comprises two parts: 
the metallic core composed of magnetite (Fe3O4)/ maghemite (Fe2O3) and a coating layer 
of polysaccharide, polymer, or monomer. Previous studies have examined how IONPs can 
contribute to hyperthermia or drug delivery as individual cancer treatments, but 
combinatorial therapy remains limited. The IONP coating governs drug loading and can 
influence magnetic fluid hyperthermia which has spurred development of many different 
IONP coating formulations to achieve peak efficiencies. The magnetic core size determines 
whether the iron oxide nanoparticles fall within the superparamagnetic, single domain, or 
multidomain regimes which alter the underlying processes for MR contrast and MFH. Our 
lab has developed phospholipid-PEG coated IONPs that can achieve fine tuning of the core 
size from 6-40 nm and tailoring of the coating layer. The phospholipid-PEG enables 
hydrophobic drugs to be loaded passively due to hydrophobic/hydrophilic interactions with 
the coating for high drug loading without affecting the chemical structure of the drug. Thus, 
the objective of this work was to engineer the phospholipid-PEG-coated SPIO platform 
for optimal chemotherapeutic drug delivery, hyperthermia, and magnetic resonance 
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contrast. The central hypothesis is that the phospholipid-PEG coating layer and iron oxide 
core size can be tailored to enhance thermo-chemotherapy and MR contrast for cancer 
therapy. This hypothesis was investigated through the following aims: 
Specific Aim 1: Develop a SPIO-based platform to enable MFH and drug 
delivery for enhanced cancer therapy. 
The working hypothesis was that by coating SPIOs with phospholipids/phospholipid-PEG 
conjugates, the nanoparticles would be amenable to high drug loading and generating 
sufficient heat to raise the local temperature to apoptotic levels, enhancing cancer cell death 
through combination therapy. A dual-solvent exchange method was used to coat the SPIOs 
with either DSPE-PEG 2000, DSPE-PEG 5000. The chemotherapeutic Doxorubicin 
(DOX) was used as the model drug, as its hydrophobicity enabled loading into the lipid 
layer of the SPIO coating, and its fluorescent properties could quantify loading and release. 
The drug loading and release and heat generation during exposure to an AMF were 
compared between the two PEG lengths. Three different cancer cell lines (HeLa, U87, and 
MCF7) were evaluated for their sensitivity to hyperthermia over a range of temperatures 
and durations. DOX along with two additional drugs (Camptothecin and Paclitaxel) were 
assessed for their interaction with hyperthermia to enhance cell death. The DOX 
localization within the cells following DOX-SPIO incubation was examined through 
fluorescent microscopy, and SPIO internalization was measured via ferrozine assay for iron 
content. The viability of HeLa cells treated with DOX-SPIOs and MFH was analyzed for 
a combinatorial effect between MFH and DOX delivery. The DOX-SPIOs were translated 
to an in vivo xenograft mouse tumor model to determine circulation half-life and 
biodistribution via ferrozine assay on blood samples and ex vivo fluorescent imaging of the 
organs, respectively. 
 
Specific Aim 2: Determine the effect of IONP core size on magnetic resonance 
contrast and heat generation.  
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The working hypothesis was that core size is a strong determinant for MR contrast and heat 
generation of IONPs, and a systematic comparison of cores sizes that cover the multiple 
magnetic regimes of IONPs could yield an optimal core size for both of these 
functionalities.  Monodisperse iron oxide cores of 6, 8, 10, 15, 19, 25, 32, and 40 nm were 
synthesized via thermal decomposition and coated with phospholipid-PEG. The particles 
were characterized by measuring their size through TEM and dynamic light scattering and 
magnetic properties using a SQUID magnetometer. The specific absorption rates of the 
IONPs were evaluated by measuring the temperature increase when the IONPs were 
exposed to an AMF at two magnetic field strengths. The core size effect on T2 relaxivity 
was determined by measuring the relaxation times of each core size over a range of 
concentrations. The signal enhancements of the different cores were compared via 
magnetic resonance imaging. The effect of magnetic fluid hyperthermia on U87 cell 
viability was assessed with an MTT assay. The SPIOs were intratumorally injected into 
U87 tumor-bearing mice, and the SPIO distribution was analyzed with MRI. To compare 
the heating efficiencies in a physiological environment, the intratumoral temperatures of 
the mice were measured during AMF exposure and the subsequent cell death was analyzed 
via histology. 
 
This work is innovative because it is the first time phospholipid-PEG coated SPIOs 
have been used for a combined magnetic fluid hyperthermia and drug delivery application. 
The comparison of the efficacy of these two treatments alone and in combination can help 
elucidate potential synergistic effects with the two forms of therapy. Further, the recent 
advances in core synthesis have enabled this systematic study of core sizes that span 
multiple magnetic size regimes, and how those regimes relate to MFH and MR contrast 
efficiencies. The impact of this work is significant because it will optimize the SPIO 
platform for multimodal applications and raises questions as to the exact size cutoffs for 
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IONP magnetic properties. This work will lay the foundation for future clinical studies 






A material’s magnetic property stems from unpaired electron spins giving rise to a net 
atomic dipole moment, and the collective moments and alignments of each magnetic dipole 
with its neighbors in the crystal lattice determines the bulk material magnetism. There are 
several classes of magnetism including: paramagnetism, ferromagnetism, anti 
ferromagnetism, and superparamagnetism. With paramagnetic materials, thermal energy 
causes the magnetic dipoles to be randomly oriented such that there is no net magnetization 
when there is no external magnetic field. Exposure to a magnetic field causes the dipoles 
to align with the field causing the magnetization to be proportional to the strength of the 
applied field. The crystal lattice of ferromagnetic materials creates a state where it is 
energetically favorable for the magnetic dipoles to align in parallel with one another 
without the need of an external field. Bulk ferromagnetic materials have uniformly oriented 
dipoles regions organized into multiple magnetic Weiss domains where the overall 
magnetization of the material is the summation of each of the domains.[1] 
Antiferromagnetism is similar to ferromagnetism, but is the result of a favored anti-parallel 
orientation of the neighboring dipoles where the equal but opposite magnitudes cancel each 
other; therefore there is no net magnetization. Ferrimagnetism is related to 
antiferromagnetism, but the magnitudes of the neighboring dipoles are unequal creating an 
overall magnetization.  
When an external magnetic field is applied to a multidomain material, the 
individual domains will attempt to align themselves with the external field until all of the 
domains are aligned, resulting in an increase in the total magnetization up to the saturation 
magnetization. The tendency for the domains to be aligned in this orientation after removal 
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of the external field is called the remanent magnetization, and to restore the original 
magnetic state, a specific magnetic field strength is required called coercivity. The 
mismatch between the applied field and the magnetization of the material leads to 
hysteresis loops in the magnetization curve. 
The superparamagnetic property represents a special case of ferromagnetic or 
ferrimagnetic materials when the size of the material is reduced to the nanoscale. The 
magnetostatic energy increases proportionally with volume, but the energy associated with 
the walls between magnetic domains increases with surface area. The high surface area to 
volume ratio of nanomaterials makes the existence of multiple magnetic domains 
unfavorable, so a single domain system dominates. The magnetization of single domain 
particles is subject to thermal fluctuations, and the mechanism of magnetic dipole rotation 
was first theorized by Stoner and Wohlfarth.[2] When the magnetic anisotropy energy 
barrier, energy necessary to rotate between the easy axes (stable directions of 
magnetization), of a particle is comparable to its thermal energy (kT), the magnetization 
direction can randomly flip between the parallel and antiparallel directions along the easy 




axis (Fig 2-1).[3] The relaxation time for magnetic reversal is given by the Néel-Brown 
expression [4, 5]: 




where 𝜏0 ~ 10
-10s is the inverse attempt frequency, K is the anisotropy energy density, V is 
the magnetic core volume, kB is the Boltzman constant, and T is the temperature. The 
magnetic anisotropy is based on both the crystal structure and shape of the particle. The 
blocking temperature, Tb, is reached upon cooling to the point where τ becomes longer than 








Below the blocking temperature, the particle does not exhibit the superparamagnetic 
property of random magnetic reversals. Hence, the term superparamagnetism is 
specifically attributed to particles whose blocking temperature is below room temperature.  
A solution of superparamagnetic particles has similar magnetic properties as a bulk 
paramagnetic material. When there is no applied magnetic field, the random flipping of the 
magnetic dipoles concurrent with Brownian motion results in zero net magnetic moment, 
but when a field is applied, the particles align their dipoles with the field direction, creating 
a strong net magnetization. Whereas the magnetization of paramagnetic materials is 
proportional to the magnitude of the applied field, superparamagnetic particles have a much 
larger magnetic susceptibility, so the magnetization plateaus to higher magnetic saturations 
even at relatively low external field strengths. The magnetic field response curves for 
superparamagnetism display a sigmoidal shape with very low coercivity and magnetic 
remanence compared to the open hysteresis loops of ferromagnetic/ferrimagnetic materials 
(Fig. 2-2).[6] The lack of magnetic remanence is important for biomedical applications so 





The saturation magnetization for superparamagnetic particles is determined by the 
chemical composition and crystal structure of the nanoparticle. Iron oxide is the most well-
studied type of superparamagnetic particle and while doping with elements such as nickel, 
cobalt, and manganese is characterized by higher saturation magnetization, these materials 
raise biocompatibility risks for in vivo use. In order to maximize the magnetization of iron 
oxide nanocrystals, a high purity magnetite (Fe3O4) structure is required though it is not 
very stable, and the particle surface is subject to oxidative transformation to the less 
magnetic maghemite (γFe2O3) when in contact with oxygen. Thus, the lower surface area 
to volume ratio of larger nanoparticles enables higher magnetic saturation through the 
increased magnetite crystal purity. 
Superparamagnetic iron oxide nanoparticles for biomedical applications. 
Superparamagnetic iron oxide nanoparticles are single magnetic domain particles 
composed of magnetite (Fe3O4) and/or maghemite (Fe2O3). The superparamagnetic 
property enables iron oxide nanoparticles to only exhibit magnetism when under the 
Fig. 2-2 Magnetic field response curves for ferromagnetic, ferromagnetic, paramagnetic, 
antiferromagnetic, and superparamagnetic materials. Ms is saturation magnetization and 
Mr is remanent magnetization. 
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influence of an external magnetic field, so they are stable in solution and will not 
spontaneously aggregate. This property also enables unique features, as they can influence 
the magnetic relaxation of the protons around them, experience force through magnetic 
field gradients, and generate heat when exposed to an alternating magnetic field. 
Biomedical applications have been developed which utilize these features, such as MRI 
contrast, bioseparation processes, magnetic targeting, and heat mediators in hyperthermia 
treatment.[7-13] Since other features, such as magnetic guidance and MR contrast, are 
intrinsic to the SPIO-based core, these functionalities can be applied without much 
additional modification of the nanoparticle. Specifically, the MR contrast allows for 
theranostic capabilities in which pharmacokinetics and dosimetry can be more accurately 
monitored by following drug-loaded SPIOs.[14-16] This is important for oncologists to 
determine whether the failure of the treatment to reach its expected therapeutic outcome is 
due to resistance to the treatment or because an inadequate dose reached the tumor.[17] 
The magnetic guidance can further enhance accumulation within the tumor by placing 
magnets proximal to the tumor during circulation which may enhance extravasation of 
SPIOs from the tumor vasculature into the interstitium.[18-20] These multifunctional 
features are exclusive to magnetic nanoparticles and make the SPIO a valuable nanoparticle 
platform for biomedical applications.   
Toxicity and biocompatibility are of particular importance for in vivo applications 
of metallic nanoparticles. Of all the metal-based nanoparticles, iron oxide appears to be the 
safest, as there are well-known degradation and clearance mechanisms in the body for iron 
such as its incorporation into chelating proteins like hemoglobin, ferritin, and transferrin. 
Studies have found that these metabolic mechanisms apply to SPIOs, as systemic delivery 
of SPIOs led the particles to be broken down in the liver without observable toxic 
effects.[12, 21-23] SPIO formulations have been FDA approved as MRI contrast agents 
for years and more recently as the iron supplement Ferumoxytol.[24] While more studies 
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regarding the toxicity and safety of SPIOs are warranted, the clinical translation and FDA 
approval of these nanoparticles for other applications appears favorable.  
Synthesis methods of iron oxide nanoparticles. 
The classical method for synthesizing iron oxide nanoparticles is coprecipitation which 
involves aging stoichiometric mixtures of ferrous and ferric salts in an alkaline aqueous 
solution.[25, 26] The chemical equation for this reaction is given by:  
𝐹𝑒2+ + 2𝐹𝑒3+ + 8𝑂𝐻− → 𝐹𝑒3𝑂4 + 4𝐻2𝑂, 
To stabilize the particles in solution, polymers such as dextran are added to coat the particle 
surface.[27, 28] Coprecipitation is a facile synthesis method which can produce large 
quantities of nanoparticles in a single reaction, but there is poor size control of size and 
crystallinity, resulting in polydisperse samples with weak magnetic properties. 
 Microemulsion builds off of the coprecipitation principle, but aims for better size 
and shape control during the synthesis.[29] This method uses a water-in-oil system that 
creates micro or nanodroplets of aqueous iron salts stabilized by amphiphilic surfactants 
(reverse micelles).[30-32] The synthesis reaction is carried out within the droplets to 
control nucleation and growth of the nanocrystals. While this approach offers better size 
control, crystallinity is still low, and the yield is reduced.  
 Numerous other methods have also been developed to synthesize magnetic 
nanoparticles such as hydrothermal techniques,[33] ultrasound irradiation,[34] spray 
pyrolysis,[35] laser pyrolysis,[36] sol-gel,[37] and the use of magnetic bacteria.[38, 39] 
These methods often require stringent control of experimental conditions or expensive 
equipment while still not attaining the desired size, shape, and crystallinity for the produced 
nanoparticles. 
 The recently developed thermal decomposition method has become the gold 
standard for iron oxide nanoparticle synthesis. This technique, originally developed for 
semiconductor quantum dots, involves heating iron salts or organometallic precursors with 
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surfactants in a high-boiling point organic solvent up to 300oC to trigger spontaneous 
nanoparticle nucleation and growth.[40-42] The process can be described as first, heating 
causes the precursors to reduce to their molecular species, increasing the monomer 
concentration. When the monomer concentration reaches a critical supersaturation point, 
spontaneous nucleation of the nanocrystals occurs. Nucleation causes a reduction in the 
monomer concentration which prevents further nucleation and proceeds to the growth 
stage. Remaining monomers in solution then interact with the nanocrystal seeds to increase 
their size. The transient changes in monomer concentration corresponding with the key 
steps in the nanoparticle synthesis were first described by Lamer and Dinegar and are 
represented in Fig. 2-3.[43] The surfactant molecules coordinate the addition of monomers 
to the growing crystal through dynamic solvation at high temperatures and determine the 
final equilibrium size of the nanoparticle population. The synthesized particles are capped 
by a hydrophobic surfactant layer which prevents further growth and aggregation. The size 
and shape of the nanocrystals can be controlled by the initial precursor and surfactant 
concentrations as well as the duration, ramp rate, and temperature of the reaction. In this 
manner, large quantities of monodisperse iron oxide nanoparticles with high crystallinity 
with tunable size and shape can be produced.[43-48] One unique benefit to this technique 
is that it allows for doping of other magnetic species such as manganese and cobalt which 




Coating IONPs with phospholipid-PEG molecules. 
The majority of IONP synthesis methods produce a colloid suspension that is stabilized in 
an organic solvent by hydrophobic surfactant molecules. The hydrophobic surface of the 
iron oxide cores requires a stable coating that will confer water solubility and prevent 
uptake by macrophages for in vivo applications. Many different coating molecules have 
been investigated, but most show poor long-term stability in physiological buffers, exhibit 
heterogeneity in terms of size/composition, are cytotoxic, or do not adequately protect the 
IONP during circulation.[8, 52] The most common coatings are made up of starch or 
dextran which can then be cross-linked to further stabilize the coating layer.[53, 54] While 
these coated IONPs have shown success in various biomedical applications, there remain 
questions as to how well the coating prevents recognition by macrophages, as they display 
relatively short circulation half-lives.[55] One strategy for coating IONP with hydrophobic 
surfactants is to adsorb amphiphilic molecules such that the hydrophobic region of the 
molecule interacts with the surfactants and the hydrophilic region is exposed to the aqueous 
Fig. 2-3 LaMer model of colloidal synthesis.  
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environment.[56, 57] Phospholipid-PEG conjugates are one such amphiphilic polymer 
with a low critical micelle concentration that were originally developed as surface 
modifiers for liposomes to improve circulation half-life and were later used to form micelle 
nanoparticle drug carriers.[58, 59] Polyethylene glycol (PEG), a commonly used coating 
agent for other nanoparticles, is conjugated to the lipid phosphate group to increase 
amphiphilicity and confer water solubility as well as prevent protein binding due to steric 
hindrance. Our lab has applied phospholipid-PEG to coating IONPs through the 
development of a dual solvent exchange method which is a modification of the film 
hydration method used to coat nanocrystals or form micelles and liposomes.[59-65] The 
final IONPs are coated with the 16 carbon chain lipid (1,2-Distearoyl-sn-glycero-3-
phosphoethanolamine) PEG conjugate (DSPE-PEG). The 16 carbon length of the lipid 
matches the 16 carbon oleic acid surfactant on the SPIOs to promote interdigitation for a 
more stable coating. 
Limitations of conventional chemotherapy. 
While chemotherapy is one of the most common forms of treatment for various types of 
cancer, there are still high rates of recurrence and resistance to the treatment, indicating 
that substantial improvements are required. The available chemotherapeutic compounds 
require continual dosing to be effective and are often characterized by severe dose-limiting 
side effects that can be as harmful as the cancer itself. These adverse effects are attributed 
to nonspecific mechanisms of action and drug distribution to healthy tissue. In addition, 
many highly active drugs suffer from poor solubility, which decreases their bioavailability 
and thus inhibits their clinical effectiveness. It has been estimated that approximately 40% 
of potential drug candidates identified through high-throughput screening programs are 
discontinued due to their poor water solubility.[66, 67] Current trends in the drug lead 
identification process are beginning to relax the initial filter parameters in order to increase 
the possible chemical space, leading to more candidates with high lipophilicity and poor 
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aqueous solubility.[66, 67] Those compounds that do pass clinical trials often require 
excipients to ensure the drug has viable pharmacokinetics, but these can pose issues for 
dose escalation. Finding new ways to modify the pharmacokinetics and pharmacodynamics 
of these drugs is of key importance to make chemotherapy safer and more effective for the 
patient.[68]  
Benefits of nanoparticle-based drug delivery. 
The use of nanoparticles for drug delivery offers exciting possibilities to address many of 
the issues that hinder conventional chemotherapy. Loading the drug onto nanoparticles can 
protect the drug from degradation and oxidation while in circulation, as the drug will be 
sequestered away from the proteins and enzymes responsible for those functions. The size 
range for nanoparticles (10-100 nm) is one of the main determining factors for improving 
circulation half-life. The nanoparticles can be designed to be large enough not to be 
removed via kidney filtration, but small enough to avoid uptake and clearance by 
macrophages of the reticuloendothelial system.[69] Specifically for tumor delivery, 
nanoparticles can passively accumulate in the tumor interstitium via the enhanced 
permeability and retention (EPR) effect.[70] The heterogeneous angiogenesis of the 
developing tumor vasculature leads to gaps within the endothelial layer which are large 
enough (~100 nm) for nanoparticles to extravasate through. Once the nanoparticles enter 
the tumor, there is reduced drainage due to the poorly developed lymphatic system, leading 
to retention of the nanoparticles in the tumor interstitium. Through these mechanisms, 
nanoparticle-based drug delivery enables a higher localization within the tumor and 
reduces the potential of drug-specific side effects that result from accumulation in healthy 
tissue. Nanoparticle-based drug delivery can also enable a slow sustained release of drug 
molecules that can be more clinically effective and potentially require less frequent dosing. 
At the cellular level, nanoparticle-based drug delivery provides an alternative form of entry 
into the cell through receptor-mediated endocytosis, rather than by diffusion through the 
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cell membrane. Since the drug does not diffuse through the cell membrane, the drug efflux 
pumps, which would otherwise attempt to remove the drug from the cell, are not activated. 
The activation of these efflux pumps is inherent to multidrug resistance (MDR), which is 
observed in many types of cancer where chemotherapy has been ineffective.[71] 
Specifically, it has been observed that conjugating DOX to the surface of SPIOs is able to 
circumvent the ATP-binding cassette transporters associated with MDR.[72] For these 
reasons, delivering a drug using a nanoparticle can reduce systemic toxicity, lower the 
dosage needed and make that dosage more effective, and help mitigate the effects of 
multidrug resistance.  
Methods of SPIO drug loading. 
The most well-studied nanoparticles for drug delivery are liposomes, which carry drugs 
within an aqueous core enclosed by a lipid membrane. The inner volume of the particle is 
large and allows for water soluble drugs to be encapsulated with fairly high efficiency.[60, 
73-78] Liposomal drug formulations have been successful and have resulted in FDA 
approval of DOXIL, which is a form of liposome-encapsulated Doxorubicin. In contrast to 
liposomes, IONPs have an inner core composed of iron oxide which limits interior cargo 
space. To compensate, IONP-based drug delivery is most often achieved through the 
conjugation of the drug molecule to the surface of the nanoparticles, exploiting the high 
surface area to volume ratio characteristic of particles at this size.[10, 16, 79] The 
downsides of this conjugation approach are that loading capacity is limited and 
complicated by the fact that each drug would need to be attached on a case-by-case basis 
to develop the proper conjugation scheme and even then, the activity of the drug could be 
compromised if the active site is unavailable for proper binding. Having the drug on the 
outer surface of the nanoparticle does not confer the same protective effects as loading 
within the particle and can also alter the charge and stability of the particle itself, further 
complicating the process by changing the pharmacokinetics.[80, 81] Moreover, the release 
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profile from these SPIOs is often very rapid, while a more sustained release is desirable in 
order to retain a clinically relevant local drug concentration.  
An alternative loading approach would be to partition the drug within the coating 
layer on the SPIO. This type of loading is generally accomplished by using hydrophobic 
drug molecules that associate with the hydrophobic coating layer due to 
hydrophobic/hydrophilic interaction with the surrounding aqueous solvent. The loading of 
poorly soluble drugs is important from the pharmaceutical standpoint because many of the 
top chemotherapeutic compounds have issues with solubility which causes unfavorable 
pharmacokinetics. In the initial drug screening process, 40% of potential candidates are 
screened out early on due to hydrophobicity, and with the millions of candidates that are 
screened, a suitable nanoparticle carrier could help bring many of these drug candidates to 
market.[82] Previous studies have coated SPIOs with Pluronic, oleic acid-conjugated PEG, 
or glycerol monooleate and subsequently loaded DOX into an oleic acid surfactant layer. 
Each resulted in large particles (~200 nm) that still had limited drug loading and relatively 
short circulation half-life which can be attributed to the coating.[83-87] The large size 
makes extravasation difficult and increases likelihood of uptake by the RES system, both 
of which limit in vivo efficacy. The previous studies show that loading into the hydrophobic 
layer of the coating is possible, but a better coating method could be developed that would 
allow for a smaller particle size with a high drug loading capacity and long circulation half-
life in vivo. 
Hyperthermia as a cancer treatment. 
Hyperthermia is a unique form of therapy which involves raising the temperature of a 
region of the body in order to treat a disease. The temperature necessary to elicit a heat 
response  varies for different cell types in vitro and in vivo, but generally increasing the 
temperature of the tumor to 41-46oC for approximately one hour triggers apoptosis, with 
thermal ablation occurring above 46oC.[88-91] At ~43oC, the heat can denature 
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intracellular proteins which then accumulate and set off signaling cascades for apoptosis 
in the cell. Conversely, higher temperatures induce necrosis. Additional targets influenced 
by  heat are membranes, the cytoskeleton, and the proteins involved with DNA repair, all 
of which further destabilize the cell and offset homeostasis, making the cells more 
vulnerable to other forms of treatment.[92, 93] Tumors are especially susceptible to 
hyperthermia when compared to normal tissues because of their rapid cell division, 
increased hypoxia, low pH, and limited temperature regulation due to poor fluid transfer. 
While increasing blood flow in response to increasing temperatures is one of the body’s 
main methods for thermal regulation, the tumor vasculature actually causes a decrease in 
blood flow with temperatures exceed 42oC, causing tumors to be less capable of countering 
hyperthermia.[94-96] Overall, these characteristics make hyperthermia more selective for 
cancerous tissue over healthy tissue.[97]  
Traditionally the application of hyperthermia has been performed through either 
water bath, high intensity focused ultrasound, radio-frequency interstitial tumor ablation, 
or laser induced thermal therapy, but all of these methods suffer from some combination 
of poor localization, short penetration depths, or high invasiveness.[98] These 
shortcomings limit the temperatures that can be applied, pose risks of damaging the 
surrounding tissue, and make sustaining a sufficiently high temperature throughout the 
whole tumor difficult for extended periods of time. Additionally, hyperthermia treatment 
alone has not been shown to be effective enough to fully remove the cancer. For these 
reasons, widespread clinical use of hyperthermia has been limited, but new methods of 
applying hyperthermia could make the treatment more localized and effective.  
Hyperthermia is most often administered as an adjuvant to another form of therapy 
such as radiotherapy or chemotherapy.[97, 99] The increased heat aids both forms of 
therapy by causing vasodilation below 42oC, which raises blood flow to the area and thus 
increases the amount of drug (in the case of chemotherapy) or oxygen (in the case of 
radiation) reaching the area. There are several different modes of interaction between heat 
18 
 
and drugs at the cellular level, including additive or superadditive interactions  in which a 
linear increase in efficacy with increasing temperature is observed, threshold-behavior 
where an increased cytotoxic effect is only seen above a certain temperature, or 
independent effects where there is no interaction at all.[97] Specifically for Doxorubicin, 
the exact interaction with heat is inconclusive, as there are conflicting reports stating it is 
either additive, superadditive, or exhibits threshold-like behavior when used in conjunction 
with hyperthermia.[100-103] In order to take advantage of the interactions between 
hyperthermia and chemotherapy, there exists the need to develop agents that can deliver 
both forms of therapy concurrently in order to effectively couple the treatments at the 
disease site and maximize their interactions.  
Magnetic fluid hyperthermia. 
Magnetic fluid hyperthermia is the process by which magnetic nanoparticles generate heat 
when exposed to an alternating magnetic field. In this process, the thermal energy of the 
particle overcomes the barrier between the two easy axes of orientation, and the magnetic 
dipole re-aligns with the field each time the polarity is changed. For micron-sized, multi-
magnetic domain particles, heat generation is mainly due to hysteretic losses which are not 
very efficient for the radio frequency energy delivered. For nano-sized, single magnetic 
domain particles, the re-alignment may occur through two mechanisms: Néelian 
paramagnetic switching where the magnetic dipole moves within the particle and is resisted 
by the magnetic anisotropy due to the crystal lattice and shape effects; or Brownian rotation 
in which the physical particle rotates to align with the external field and  is resisted by shear 
stress from the surrounding fluid.[104, 105] The dominating mechanism is determined by 
the shorter relaxation time for the particle which is dependent on the magnetic core and 
coating properties.[106, 107]  
MFH offers distinct advantages over conventional forms of hyperthermia 
application because it allows for the remote heating of the tumor from outside of the body 
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by delivering the heat source inside the tumor through a minimally invasive procedure. The 
envisioned therapy would only require an IV injection of the SPIOs followed by exposure 
to an AMF which would be akin to the fields sustained during an MRI. MFH is actuated 
by magnetic fields that are not attenuated by biological tissue, so there is no effective 
penetration limit for this form of therapy, which can be an issue for gold nanoparticle-based 
photothermal therapy.[108] The heat is generated from within the tumor itself so, with 
proper control of the external field parameters, heating of surrounding tissue should be 
minimal and heating of deep-seated tumors is possible. A nanoparticle heat source also 
offers the potential for localized heating inside the cell following endocytosis of the 
nanoparticle. Recent work suggests that bulk solution temperature does not need to be 
raised for a therapeutic effect; intracellular MFH could disrupt lysosomal membranes 
releasing proteolytic enzymes and increase reactive oxygen species to trigger cell 
death.[109] Compared to traditional hyperthermia treatments, MFH improves on the 
penetration depth and heat localization (including the ability for intracellular heating), 
which would make this form of hyperthermia more effective and safer for the patient.  
MFH was first pioneered by Gilchrist et al. in 1957 using iron oxide 
microparticles.[110] Since then, intratumoral injection of SPIOs followed by MFH has 
been shown effective in pancreatic and skin cancer animal models.[111, 112] Systemic 
delivery of targeted dextran-coated SPIOs has been shown to slow breast cancer tumor 
growth in vivo.[55] In 2006, a phase I clinical trial was carried out in Germany using a 
direct injection of the SPIOs into various types of tumors and using a whole body magnetic 
field applicator. The study showed that this therapy is feasible and well-tolerated in human 
patients, but the heat distribution in the tumors were inadequate, suggesting that further 
optimization of the AMF and SPIO distribution in the tumor is needed.[113] While MFH 
addresses some of the main issues with conventional hyperthermia application and has 
shown feasibility in a clinical setting, it still does not have sufficient therapeutic effect to 
treat cancer as a singular treatment. Coupling chemotherapy or radiotherapy to MFH could 
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enhance the overall therapy for complete tumor regression by utilizing the synergistic 
interactions.  
Iron oxide nanoparticle-based magnetic resonance contrast. 
Magnetic resonance imaging is based on the nuclear spin magnetic relaxation processes of 
water molecule protons. The nuclear spins are first aligned with an external magnetic field 
followed by a radio frequency (RF) transverse pulse with a perpendicular alignment which 
temporarily perturbs the spins off of the original alignment. Upon removal of the RF pulse, 
the spins return to their original alignment according to two different relaxation 
mechanisms: longitudinal (T1) and transverse (T2) relaxation. T1 relaxation concerns the 
realignment of the magnetic moment with the original field, and T2 relaxation is described 
as the loss of signal in the perpendicular plane. When superparamagnetic nanoparticles are 
exposed to magnetic fields used in MR imaging, their dipole moments rotate to align with 
the field, creating a strong net magnetization which enhances the local magnetic flux. This 
phenomena has a strong effect on the MR signal from the surrounding water molecule 
protons as they are rapidly dephased. Specifically, the SPIOs cause a shortening of the 
spin-spin T2 relaxation of the protons during MRI which is represented by negative contrast 
(loss of signal/darkening) on the MR image. The relaxivity of SPIOs is a measure of the 
inverse T2 shortening time normalized to the molar concentration of iron expressed as s
-1 
mM-1. In accordance to the outer sphere theory of relaxation, the SPIO MR contrast is 
dependent on strength of the local magnetic field inhomogeneities and the size of that field 
in relation to the number of protons influenced.[114-116] Two SPIO formulations Feridex 
I.V. and Resovist have been FDA approved as clinical MRI contrast agents for imaging of 
liver lesions. The MR contrast capability of SPIOs has been utilized for a number of 
applications ranging from tracking hematopoietic and neural progenitor cells in vivo,[117] 
imaging transgene expression,[118] delineating brain tumor borders,[119] atherosclerotic 
plaque detection in rabbits and humans,[120, 121] and tissue transplant monitoring of 
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pancreatic islets for diabetes therapy.[122, 123] While these studies provide a strong proof 
of concept for using SPIOs as MR contrast agents, sensitivity is still low compared to other 
imaging modalities, so there is a need to improve the relaxivity to enhance the signal 




OPTIMIZING SUPERPARAMAGNETIC IRON OXIDE 
NANOPARTICLE COATING FOR A COMBINED DRUG 
DELIVERY AND HYPERTHERMIA CANCER TREATMENT1 
Abstract 
Superparamagnetic iron oxide nanoparticles (SPIOs) have the potential for use as a 
multimodal cancer therapy agent due to their ability to carry anticancer drugs and generate 
localized heat when exposed to an alternating magnetic field, resulting in combined 
chemotherapy and hyperthermia.  To explore this potential, we synthesized SPIOs with a 
phospholipid-polyethylene glycol (PEG) coating, and loaded Doxorubicin (DOX) with 
30.8% w/w loading capacity when the PEG length is optimized.  We found that DOX-
loaded SPIOs exhibited a sustained DOX release over 72 hours where the release kinetics 
could be altered by PEG length. In contrast, the heating efficiency of the SPIOs showed 
minimal change with PEG length. With a core size of 14 nm, the SPIOs could generate 
sufficient heat to raise the local temperature to 43oC, enough to trigger apoptosis in cancer 
cells. Further, we found that DOX-loaded SPIOs resulted in cell death comparable to free 
DOX, and that the combined effect of DOX and SPIO-induced hyperthermia enhanced 
cancer cell death in vitro. This study demonstrates the potential of using phospholipid-PEG 
coated SPIOs for chemotherapy-hyperthermia combinatorial cancer treatment with 
increased efficacy.   
Introduction 
Conventional cancer chemotherapy treatments are often compromised by systemic toxicity 
which stems from a lack of tumor specificity when anticancer drugs are delivered. The side 
effects limit the dose of the drug used, rendering effective cancer treatment difficult. 
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Nanoparticle-based drug delivery has the potential to overcome this challenge by targeted 
delivery to tumor and taking the advantage of tumor’s natural leaky vasculature to increase 
the accumulation of drug-loaded nanoparticles within the tumor interstitium.[69, 70] By 
loading anticancer drug into nanoparticles, the more favorable pharmacokinetics and 
tunable biodistribution of nanoparticles can increase the efficacy of the drug.[76, 77] Drug 
molecules loaded into a nanoparticle may also be protected from degradation and oxidation 
while in circulation.[124, 125]  A similar approach has been used with liposomal carriers in 
the form of Doxil; however, while having some reduction in cardiotoxicity, the efficacy in 
reducing tumor burden was not improved over free Doxorubicin.[75] Specifically, the use 
of liposomes as a drug carrier is hindered by their large size (>100 nm) which makes deep 
penetration into the tumor tissue difficult following extravasation from the blood vessel.[126, 
127] Despite its shortcomings, the use of Doxil has stimulated the development of more 
advanced multi-functional nanoparticles. 
Superparamagnetic iron oxide nanoparticles (SPIOs) have the potential to improve 
cancer treatment by generating local heat when exposed to an alternating magnetic field 
(AMF). Cancer cells are susceptible to hyperthermia, as raising the temperature to ~43oC 
for 30-60 minutes can trigger apoptosis.[88, 90, 91] It is also possible that the cell membrane, 
cytoskeleton, and proteins involved in DNA damage repair could be affected by the 
increased temperature  which further destabilizes the cell and offsets homeostasis, making 
cancer cells more vulnerable to chemotherapy.[92, 93, 128] It has been shown that tumors are 
especially susceptible to hyperthermia compared to normal tissues because of their faster 
cell division, increased hypoxia, low pH, and limited temperature regulation due to poor 
fluid transfer.[129, 130] However, hyperthermia alone may not be sufficient for cancer 
treatment and thus is often used as an adjuvant to other forms of therapy such as 
radiotherapy and chemotherapy.[97, 99] Further, the application of hyperthermia through 
high-intensity focused ultrasound, radio-frequency interstitial tumor ablation, or laser 
induced thermal therapy may pose risks of damaging the surrounding tissue, thus 
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preventing the widespread use of hyperthermia for cancer therapies.[98] Although previous 
studies have utilized SPIOs for hyperthermia[7, 131, 132] and drug delivery[84, 85, 133] separately, 
with different core synthesis methods and coating compositions, only very limited efforts 
have been made to optimize the SPIO-based approach for a combinatorial hyperthermia 
and chemotherapy for cancer treatment.[134]  
Here we report the development and optimization of phospholipid-PEG coated 
SPIOs for simultaneous local heat generation and delivery of chemotherapeutic agents. The 
SPIO nanoparticle is composed of an iron oxide core of ~14 nm coated with a 
phospholipid-PEG layer which renders the SPIO water soluble and enables a high degree 
of drug loading through hydrophobic/hydrophilic and/or electrostatic interactions (Fig. 3-
1). The SPIOs can generate a high amount of heat when an alternating magnetic field 
(AMF) is applied.[106] We quantified the effect of PEG length on drug loading and release, 
as well as temperature change, and identified PEG 2000 to be the optimal length. We 
demonstrate that the DSPE-PEG 2000 coated SPIOs can enhance cancer cell death through 
the concurrent delivery of local heat and chemotherapeutic drugs. Using the SPIOs as both 
drug carrier and heat source has the clear advantage of ensuring a close coupling between 






Iron acetylacetonate (Fe(acac)3 99%), 1,2-hexadecanediol (technical grade, 90%), oleic 
acid (technical grade, 90%), and oleylamine (technical grade, 70%), toluene (>99.9%), 
chloroform (99%), dimethyl sulfoxide (DMSO 99%) benzyl ether (98%), hydrochloric 
acid, hydroxylamine HCl, sodium hydroxide, ammonium acetate, ferrozine, and 
thioglycolic acid (>98%) were purchased from Sigma-Aldrich and used as received; 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000/5000] (DSPE-PEG 2000/5000) was purchased from Avanti Polar Lipids. 
Doxorubicin hydrochloride (98.0-102.0% HPLC) was purchased from Sigma-Aldrich and 
dissolved in an aqueous solution at 1 mg/ml. 
Fig. 3-1 Phospholipid PEG-coated iron oxide nanoparticle loaded with doxorubicin. The 
nanoparticle consists of an inner iron oxide core, covered with a surfactant layer of oleic 
acid and oleylamine, and an outer coating of phospholipid-PEG. 
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Synthesis of iron oxide nanoparticles 
Iron oxide nanoparticle cores of 6 nm diameter were synthesized by an adapted published 
procedure.[51] Iron acetylacetonate (6 mmol), 1,2-hexadecanediol (30 mmol), oleic acid 
(18 mmol), and oleylamine (18 mmol) were mixed in benzyl ether (60 ml) in a 500 ml 
round bottom flask and magnetically stirred. A vacuum was applied for 40 minutes, then 
the solution was raised to 120oC by a heating mantle attached to a temperature controller. 
After another 40 minutes, the vacuum was removed and replaced by a flow of Nitrogen. 
The solution was then raised to 200oC and held for 2 hours before ramping to 300oC and 
holding for 1 hour. The solution was then cooled to room temperature and ethanol (240 ml) 
was added to separate and precipitate the nanoparticle cores via three rounds of 
centrifugation. Finally, the cores were redispersed in toluene. To obtain larger core sizes, 
an iterative regrowth method was used that involves a modification of the seed synthesis 
protocol. Briefly, iron oxide nanoparticle seeds are mixed with an amount of iron 
acetylacetonate equivalent to mass necessary to increase the size of the cores by ~2 nm. 
Oleic acid and oleylamine are added at a 3:1 molar ratio to the iron acetylacetonate amount 
and 1,2-hexadecanediol is added at a 5:1 molar ratio to the iron acetylacetonate. Benzyl 
ether is then added to obtain a final iron acetylacetonate concentration of 20 mg/ml. The 
following heating and subsequent purification are the same as the synthesis procedure. 
Dual solvent exchange coating method 
To coat 1 mg Fe of SPIOs, 200 µl of the ferrofluid at 5 mg/ml Fe was mixed with DSPE-
PEG (2000, 5000) in 400 µl of chloroform in a 100 ml round bottom flask. The amount of 
DSPE-PEG was determined based on a ratio of 8 DSPE-PEG molecules per nm2 SPIO 
surface area. Then, 4 ml of DMSO was incrementally added followed by a 30-minute 
incubation at room temperature. The toluene and chloroform was removed via vaporization 
under vacuum. Afterwards, 20 ml of deionized water was then slowly added to the solution. 
DMSO was removed and replaced with deionized water through three rounds of 
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centrifugation in Vivaspin 20 centrifugal filter tubes with molecular weight cut-off 100 
kDa (Sartorius, Goettingen, Germany). Finally, the solution was passed through a 0.2 µm 
HT Tuffryn syringe filter membrane (Pall Life Sciences, Ann Arbor, MI) and stored in 
deionized water at 4oC. 
Characterization 
Transmission electron microscopy (TEM)  
The average core diameter of the SPIOs was measured via transmission electron 
microscopy. The polymer coating layer on the SPIOs was visualized by negative staining 
with phosphotungstic acid on glow discharged copper grids prior to imaging. TEM images 
were recorded with a transmission electron microscope (Hitachi H-7500, Tokyo, Japan) 
connected to a CCD camera. The negative staining and TEM procedures were conducted 
by the Robert P. Apkarian Integrated Electron Microscopy Core at Emory University. The 
images were analyzed using ImageProPlus® software. 
SQUID magnetization measurements 
Magnetization measurements on uncoated iron oxide cores were carried out using a 
superconducting quantum interference device (SQUID) magnetometer (Quantum Design 
MPMS-5S, San Diego, CA). Field-dependent magnetization curves were measured at 300 
K as a function of the external magnetic field in the range of 0-5x104 Gauss. 
Dynamic light scattering 
The hydrodynamic diameter of the coated SPIOs was measured using a dynamic light 
scattering device (DynaPro Nanostar, Wyatt Technology, Santa Barbara, CA). The SPIOs 
were dispersed in deionized water at 100 µg/ml Fe and measured at 25oC. The mass 
weighted size distribution was reported.  
Zeta potential measurements 
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The zeta potentials of DSPE-PEG 2000 and 5000 coated SPIOs and DOX-SPIOs were 
measured using a Malvern Instruments Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, United Kingdom). Non-loaded and DOX-loaded SPIO samples were 
suspended at 50 µg/ml Fe in phosphate buffered saline (13.7 mM NaCl, 1 mM Na2HPO4, 
0.27 mM KCl) at pH 4, 7, and 10 in a disposable folded capillary cell. 
Iron concentration measurement 
Iron content of samples was determined using a ferrozine assay. Briefly, 50 µl of sample 
was mixed with 50 µl of 12 M HCl and incubated at room temperature for 30 minutes. 
Then, 240 µl of 2 M NaOH, 50 µl of 4 M ammonium acetate, 110 µl 5% hydroxylamine 
HCl, and 500 µl water were added to the solution sequentially. After 30 minutes of 
incubation, 50 µl of the solution were mixed with 0.02% ferrozine solution in a 384 well 
plate. Light absorption was read at 562 nm with 810 nm as the reference wavelength using 
a microplate reader (Safire2, Tecan Group Ltd., Männedorf, Switzerland). The absorption 
was compared to a molecular iron standard to determine the concentration. The number of 
SPIOs per gram of iron was estimated to be 1.35E17 based on the volume of a spherical 
14 nm diameter SPIO and the density of magnetite (5.17 g/cm3) assuming the cores were 
made up of Fe3O4. 
Drug delivery 
Drug loading 
The chemotherapeutic drug Doxorubicin was loaded into the SPIOs by incubating the drug 
with nanoparticles at a 1:1 mass ratio in deionized water for 24 hours undisturbed at room 
temperature. The free drug was then removed via three rounds of ultracentrifugation for 1 
hour at 40,000 g. The amount of Doxorubicin loaded was quantified by first incubating the 
SPIOs in thiogylcolic acid for 3 hours. Then the light absorption of Doxorubicin was 
measured using a microplate reader (Safire2, Tecan Group Ltd., Männedorf, Switzerland) 
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at 480 nm with 810 nm as the reference wavelength.  The absorption was compared to a 
standard to determine the concentration. The DOX concentration was then divided by the 
iron concentration measured by a ferrozine assay to determine the DOX loading as % w/w 
DOX/Fe.  
Drug release 
The drug release profile was characterized by injecting 1 mg of SPIOs into a 20 kDa 
MWCO dialysis cassette (Slide-A-Lyzer, Pierce, Rockford, Ill). The cassette was placed in 
a release buffer of 80 ml PBS with 5% BSA kept at 37oC and stirred. At the given time 
points, 100 µl aliquots were removed and replaced with fresh buffer to ensure sink 
conditions during the release period. The DOX fluorescence intensity of the aliquots was 
measured at 595 nm via UV-Vis spectrophotometer and the concentration of the aliquots 
was determined with a known standard. The amount released was compared to the initial 
amount loaded into the SPIOs to estimate the percent released.  
Dye loading 
The lipophilic dye, DiI, was loaded into SPIOs by incubating the dye with nanoparticles at 
a 40:1 mass ratio in deionized water for 24 hours undisturbed at room temperature. The 
free dye was then removed via passing through a 0.2 µm HT Tuffryn syringe filter 
membrane (Pall Life Sciences, Ann Arbor, MI) and stored protected from light in deionized 
water at 4oC. 
Magnetic fluid hyperthermia 
A 1 ml volume of coated SPIOs at 0.4 mg/ml Fe was placed inside a polystyrene-insulated 
7.5-turn, 2.54 cm inner diameter inductor coil (EasyHeat 2.4kW, Ameritherm, Scottsville, 
NY). The field strength within the coil was estimated according to the Biot-Savart law and 
the profile was modelled in matlab (Figure S1). An alternating magnetic field (23.77 kA/m, 
355 kHz) was generated within the coil, causing the SPIOs to produce heat. The resulting 
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temperature rise in the ferrofluid was measured over three minutes with a fiber optic 
temperature probe (FLUOTEMP, Photon Control Inc., Burnaby BC, Canada) and recorded 
in real time. The slope of the linear region of the temperature vs. time plot was normalized 








where 𝑚𝐹𝑒 is the mass of the iron in the sample, 𝐶𝐻2𝑂 is the specific heat of water, 𝑚𝐻2𝑂 
is the mass of the water, and 
𝑑𝑇
𝑑𝑡
 is the temperature rise of the fluid. For the cellular 
experiments, the water circulating through the coil was adjusted to maintain a 37oC 
temperature in a 1 ml sample of media without SPIO during the AMF treatment. This 
baseline was chosen to mimic body temperature.  
Modeling magnetic field profile within inductor coil 
The normalized magnetic field strength profile within a 7.5-turn inductor coil (EasyHeat 
2.4kW, Ameritherm, Scottsville, NY) of 3 cm length and 2.54 cm inner diameter was 
modeled using the Biot-Savart law in Matlab. 
Cell culture 
HeLa, U87, and MCF-7 cells were obtained from ATCC, USA and cultured in T75 cell 
culture dishes following ATCC instructions. Cells were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Sigma-Aldrich) supplemented with 10% fetal bovine serum 
(ATCC). Cultures were replenished with fresh media every other day and passaged upon 
reaching 70% confluence. 
Sensitivity to hyperthermia 
HeLa, U87, and MCF-7 cells were seeded in 6-well plates in 3 ml of phenol red-free media 
and allowed to attach overnight. The media was replaced with prewarmed media at 37, 43, 
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44, 45, or 46oC and left in a cell culture incubator set to the same temperature for 30 minutes 
or one hour. The media was then replaced with 37oC media and left in the 37oC incubator 
overnight. 24 hours post treatment, phase contrast images of the cells were taken with a 
fluorescent microscope (AxioVert S100, Zeiss, Jena, Germany) before being trypsinized, 
stained, and analyzed according to the established propidium iodide flow cytometry 
apoptosis protocol.[135] As an alternative method to assess cell viability, on the third day 
an MTT assay was performed. Briefly, the media in the wells was replaced with phenol 
red-free DMEM with 0.5 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, Invitrogen) and incubated at 37oC for 2 h. The formazan 
crystals were dissolved in 200 µl of DMSO and the absorbance was read at 570 nm with 
810 nm as the reference. The cell viability was normalized to the 37 oC control.  
Drug and hyperthermia synergy 
HeLa cells were seeded into a 96 well plate at 5000 cells per well. After an overnight 
incubation, free Doxorubicin, Camptothecin, or Paclitaxel was added to the wells at a range 
of concentrations. The plate was then placed in a water bath to maintain a hyperthermia 
temperature of 43oC for 1 hour. Following the hyperthermia, the plate was returned to a 
37oC incubator. Cell viability was measured 48 hours post treatment using an MTT assay. 
DOX dose response 
HeLa cells were seeded in 96-well plates at 3000 cells per well in 100 µl of media and 
allowed to attach overnight. The media was replaced with either free DOX or DOX-loaded 
SPIOs (DOX-SPIOs) at a range of DOX concentrations from 0.1-50 µg/ml and incubated 
for 48 hours. An MTT assay was performed to assess cell viability. The cell viability was 
compared to the untreated control, and a dose response curve was generated to determine 




HeLa cells were seeded onto eight chamber glass slides at 5 x 104 cells per chamber and 
allowed to attach overnight. The media was replaced with either free DOX or DOX-SPIOs 
at 1 µg/ml DOX. At 2 and 8 hours of incubation, cells were washed with PBS, fixed with 
paraformaldehyde, and stained with DAPI. Cells were imaged with a DeltaVision 
deconvolution fluorescent microscope equipped with DAPI, TRITC, and Cy5 filters 
(Applied Precision, Issaquah, WA). Confocal image processing was done using the 
DeltaVision Softworx program (Applied Precision, Issaquah, WA). The fluorescent 
intensity of the images was normalized using ImageJ (NIH, Bethesda, MD). The iron 
internalization was measured by trypsinizing the cells, performing a cell count, and 
measuring the iron content of the cell population with a ferrozine assay and subtracting the 
endogenous iron measured from an untreated sample.  
MFH-mediated intracellular release 
HeLa cells were seeded onto 12 mm circular coverslips within a 24-well plate at 3 x 104 
cells per well and allowed to attach overnight. The media was replaced with fresh media 
containing 200 µg/ml Alexafluor 488-conjugated dextran (10,000 MW) and 100 µg/ml Fe 
DiI-labelled SPIO. The cells were placed over an array of NdFeB, N42 circular magnets 
(K&J Magnetics, Jamison, PA) as used in the previous study by Landzuri et al. for 2 hours 
to internalize the SPIOs with magnetic force and dextran through endocytosis.[9] The cells 
were then washed twice with PBS and the media replaced with fresh media containing 10 
mM of HEPES. A single coverslip is transferred to an isolated well of a 24-well plate to be 
placed in the 7.5-turn, 2.54 cm inner diameter insulated inductor coil and exposed to an 
alternating magnetic field (23.77 kA/m, 355 kHz) for two hours. The cells were then 
washed three times with PBS, stained with Hoescht, and mounted for fluorescent 
microscopy. The colocalization of the Alexafluor and DiI signals was analyzed by 
calculating the Pearson’s correlation coefficient and Mander’s colocalization coefficient 
33 
 
using the JACoP plugin for the ImageJ software. Background was corrected by using 
threshold value to remove noise and background signal for all channels. 
Evaluation of combinatorial response to magnetic fluid hyperthermia and 
Doxorubicin delivery  
HeLa cells were grown to 80% confluency in a T-75 cell culture flask. The cells were 
detached with 0.05% trypsin/EDTA and resuspended in cell culture media with 10 µM 
HEPES. The cells were counted and 5x104 cells were pipetted into eight different cryovials. 
The vials were then filled to 1 ml of either media, media with 100 µg/ml Fe SPIO (without 
DOX), 100 µg/ml Fe DOX-loaded SPIO (16.6 µg/ml DOX), or an equivalent free DOX 
solution. Each of these groups had a +AMF/-AMF sample with the +AMF samples 
undergoing a 1 hour AMF treatment (23.77 kA/m, 355 kHz) and the –AMF samples kept 
in a cell culture incubator at 37oC. An additional sample was heated in a water bath at 43oC 
for 1 hour. Two hours after the AMF treatment, the media in each sample was then replaced 
with fresh media and seeded into a 96-well plate at 5000 cells per well so that the total 
incubation time with the SPIO/SPIO-DOX/DOX was 3 hours. After 24 hours, an MTT 
assay was performed to compare the cell viabilities between each of the groups. 
Alternatively, to assess the morphological changes after the AMF treatment, the media in 
each sample was instead seeded into an 8-well chamber slide (Nunc Lab-Tek II) at 25,000 
cells per well. Phase contrast images of the live HeLa cells were taken 24 hours later using 
a Zeiss AxioVert S100 fluorescent microscope. 
HeLa xenograft tumor model  
All animal procedures were conducted with the approval of the Institutional Animal Care 
and Use Committee at the Georgia Institute of Technology. Xenograft tumors were induced 
in athymic nude mice by subcutaneously injecting 3M HeLa cells suspended in PBS into 
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the right flank. Tumors were monitored each day until they reached the appropriate size 
for experimentation. 
Circulation half-life 
The circulation half-life of the DOX-SPIOs was determined by delivering the nanoparticles 
to the mice via a 2 mg Fe/kg tail-vein injection and collecting blood samples at 5 minutes, 
15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 24 hours post-injection. The iron 
content in each sample was measured with a ferrozine assay and normalized to the baseline 
blood iron content measured in control mice. The data was fitted to a logarithmic curve 
and the half-life of the DOX-SPIOs was determined. 
Biodistribution 
The lipophilic dye, DiR, was added at a 1:100 wt ratio (DiR:SPIO) during the DMSO 
addition of the dual solvent exchange coating process to allow for incorporation into the 
lipid layer. After coating, DOX was loaded onto the SPIOs as described previously. Tumor-
bearing mice were anesthetized with isoflurane and injected with the DiR-DOX-SPIOs (2 
mg/kg Fe) via tail vein injection and sacrificed 24 hours post-injection.  Organs of interest 
were collected, blotted dry, and the DiR fluorescence was examined using the IVIS 
imaging system (IVIS Spectrum; Caliper LifeSciences, Alameda, CA). The excitation and 
emission detectors were set at 710 nm and 780 nm, respectively.  
Statistical Analysis 
For paired comparisons, Student t-tests assuming unequal variances were used to determine 
statistical significance (p < 0.05).  For comparisons across multiple groups, analysis of 
variance (ANOVA) was used followed by a Tukey’s Honest Significance Test with a 95% 





Synthesis and characterization 
Superparamagnetic iron oxide cores were synthesized using a thermal decomposition 
technique to produce monodisperse iron oxide cores of 14 nm in diameter stabilized with 
an oleic acid oleylamine surfactant layer (Fig. 3-2A,B).[51] To confer aqueous solubility 
to the nanoparticle cores, the SPIOs were coated with a layer of phospholipid-PEG (DSPE-
PEG) using a dual solvent exchange method.[64] The coated SPIOs can be stored in an 
aqueous solution for months without any aggregation. The presence of the coating layer 
was confirmed through TEM imaging of the coated SPIOs negatively stained with 
phosphotungstic acid, as demonstrated by the white halos surrounding the dark iron oxide 
cores (Fig. 3-2C). Two different DSPE-PEG lengths were used for coating with molecular 
weights of 2000 and 5000 kDa. The coated SPIOs exhibited narrow size distributions (Fig. 
3-2D) with peak hydrodynamic diameters were found to be 28.12 nm and 30.83 nm for the 
PEG 2000 and 5000 SPIOs respectively. Although the conformation of the PEG molecules 
has some effect, the size increase over the core diameter (14 nm) roughly correlates with 
the estimated size of the phospholipid-PEG molecules. It is important to note that the size 
shown on the negative stain TEM image in Fig. 3-2C does not accurately reflect the 
hydrodynamic diameter of the SPIOs, since the drying process results in contraction of the 





Fig. 3-2 Size measurements of iron oxide nanoparticles. (A) TEM image of SPIO cores 
and (B. Synthesized SPIO core size distribution. (C) PEG 2000 SPIOs negatively stained 
with phosphotungstic acid. (D) Hydrodynamic size distribution of SPIOs coated with 
DSPE-PEG 2000 and 5000 measured by dynamic light scattering. Room temperature 





Heat generation by SPIOs 
When SPIOs are exposed to an alternating magnetic field, they generate heat, which can 
be used for hyperthermia-based cancer treatment. The two main factors that influence the 
amount of local heat generation are: (1) the specific absorption rate (SAR), a measure of 
the heat generation per unit mass of SPIO and (2) the local SPIO concentration. The SAR 
is governed by the physical properties of the SPIOs and the applied magnetic field.  Thus, 
the magnetization of the SPIOs was measured using a superconducting quantum 
interference device (SQUID) magnetometer, and the magnetic saturation was found to be 
84.6 emu/g Fe, which approaches the theoretical limit of bulk magnetite (Fig. 3-3). The 
magnetization curve also displays the on/off behavior indicative of superparamagnetism, 
and the lack of hysteresis suggests that the primary mechanism of heat generation can be 
attributed to Néelian and Brownian relaxation rather than hysteretic losses.[106, 107] 
The SAR of the SPIOs was calculated to evaluate the effect of PEG length on the 
efficiency of heat generation (see details in the Methods section). Aqueous solutions 
Fig. 3-3 Room temperature magnetization curve of 14 nm SPIO cores. 
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containing coated SPIOs with 0.4 mg/ml Fe were exposed to an alternating magnetic field 
(23.77 kA/m, 355 kHz), and the temperature of the ferrofluid was measured as a function 
of time (Fig. 3-4). The SAR did not show significant differences between the PEG lengths 
and was determined to be 371 + 15 and 425 + 20 W/g Fe for SPIOs with PEG 2000 and 
5000 respectively (Fig. 3-4D), as described in the Methods section. These results are 
consistent with the theoretical prediction that for SPIOs with a 14 nm core, Neélian 
relaxation is thought to be the predominant mechanism which is unaffected by the size of 






Fig. 3-4 Specific absorption rate measurement. (A) Hyperthermia test setup: 7.5-turn, 2.54 
cm inner diameter inductor coil, polystyrene insulation, cryovials containing ferrofluid, 
fiber optic temperature probe positioned in center of sample, and (B) normalized magnetic 
field strength profile within inductor coil. (C) Temperature profile of a 1 ml aqueous 
solution containing SPIOs coated with PEG 2000 and 5000 at 0.4 mg/ml Fe during 
exposure to an alternating magnetic field of 23.77 kA/m and 355 kHz, (D) specific 
absorption rates of SPIOs coated with DSPE-PEG 2000 and 5000 calculated from the 
temperature profiles. Error bars represent standard error. 
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Doxorubicin loading into SPIOs 
The amphiphilic nature of the SPIO coating layer facilitates loading of hydrophobic and 
amphiphilic drugs into the nanoparticles. The anthracycline antibiotic Doxorubicin (DOX) 
was chosen as a model drug in this study since it is a common chemotherapeutic that suffers 
from poor solubility in physiological buffers and exhibits significant cardiotoxicity.[75] 
Further, the fluorescence of DOX enables quantification of loading and release as well as 
analysis of cellular localization using microscopy. DOX was loaded into SPIOs by 
incubation with coated SPIOs at room temperature for 72 hours. To characterize the effect 
of PEG length on DOX loading into the SPIOs, the loading capacity of the PEG 2000 and 
5000 SPIOs was compared. We found that the drug loading capacity of SPIOs with PEG 
2000 was significantly higher (30.8 ± 2.2% w/w (DOX/iron)) than the PEG 5000 (14.5 ± 
3.3%) (Fig. 3-5A). We also found that loading DOX into the coated SPIOs did not 





Fig. 3-5 Effect of PEG length on DOX loading into SPIOs. (A) DOX loading capacity of 
SPIOs coated with DSPE-PEG 2000 and 5000. Loading capacity was determined by the 
mass ratio (w/w) of loaded DOX compared to the mass of the SPIOs. Error bars represent 
standard error. * = significant difference (Tukey test p<0.01) Zeta potential of (B) SPIOs 




The drug release kinetics was assessed to ensure that the time scale of release is sufficient 
to allow for systemic circulation and subsequent sustained release in the tumor. The release 
profile was quantified using a dialysis cassette with a release medium consisting of PBS + 
5% BSA, since serum albumin has been shown to bind anticancer drugs in circulation.[136] 
As shown in Fig. 3-6, there were moderate differences in the release profiles between the 
PEG lengths though each was characterized by an initial burst release within the first six 
hours followed by a period of slow sustained release. The SPIOs with PEG 2000 had the 
highest initial burst release, but SPIOs with PEG 5000 had a similar initial release rate after 
a two-hour lag period (Fig. 3-6 inset). We believe the much higher loading capacity of 
SPIOs coated with PEG 2000 has a clear advantage in overall effectiveness as a drug 
delivery agent, although in some cases a slower, more sustained release would be favorable 






Fig. 3-6 Effect of PEG length on DOX release from SPIOs. DOX release from DOX-
SPIOs as a function of time in a PBS buffer containing 5% BSA. Inset: first 6 hours of 
release profile.  
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Cell type-specific hyperthermia sensitivity 
To better understand how hyperthermia affects different types of cancer and choose an 
appropriate cell line for further cellular studies, HeLa cervical cancer, U87 glioblastoma, 
and MCF-7 breast cancer cells were exposed to various heating conditions followed by an 
assessments of cell viability. As an initial screen, the three cell types were exposed to either 
37, 43, 44, 45, or 46oC for one hour and the percentage of apoptotic cells was measured 
via flow cytometry (Fig. 3-7A). The MCF-7 were the most thermotolerant, only showing 
apoptosis at the highest temperature tested (46oC). In contrast, the HeLa and U87 cells 
displayed high degrees of apoptosis with the 44oC treatment, 46% and 29.4% apoptotic 
cells, respectively, which decreased at the higher temperatures. To further characterize the 
thermal duration effect on the HeLa and U87 cells, the experiment was repeated for a 30 
minute heating. Both cell lines had similar responses for all five temperatures used (37, 43, 
44, 45, or 46oC) with signs of apoptosis starting at 44oC and increasing up to 30% (U87) 
and 25% (HeLa) apoptotic cells at 46oC (Fig. 3-7B). The effects of hyperthermia were 
observed in the rounded, altered morphology of the cells and evidence of cell detachment 
(Fig. 3-8). The apoptosis results were then compared to cell viability measurements using 
an MTT assay which displayed a reduction in viability at a lower 42/43oC (Fig. 3-9). The 
cell viability measurements may reveal effects of hyperthermia which were insufficient to 
trigger apoptotic programmed cell death, but did cause lasting damage to the cells which 
exist even 24 hours later. The MTT assay using the HeLa 43oC temperature baseline was 
chosen for the following studies due the higher experimental throughput and more sensitive 






Fig. 3-7 Hyperthermia-mediated apoptosis in cancer cell lines. Apoptosis rates in cells 
exposed to (A) 1 hour and (B) 30 minutes of the indicated temperatures and measured 24 




Fig. 3-8 Morphological effects of hyperthermia on cancer cells. Phase contrast images of 
HeLa and U87 cells exposed to the indicated temperatures in a cell culture incubator for 





Three poorly soluble drugs, Doxorubicin (DOX), Camptothecin (CPT), and Paclitaxel 
(PTX), were examined for their potential synergy with hyperthermia using HeLa cells.  
These additional drugs were chosen as they have each previously been loaded into 
phospholipid-PEG micelles in a similar fashion as DOX, so translation to phospholipid-
PEG coated SPIOs could be feasible.[59, 137-140] As shown in Fig. 3-10, both DOX and 
CPT exhibited an enhanced treatment efficacy with hyperthermia treatment which was 
more pronounced at higher drug concentrations suggesting synergistic behavior. By 
contrast, the combined effect of PTX and hyperthermia was additive except for the 50 nM 
concentration which was actually less effective with the addition of hyperthermia. While 
CPT is a potential candidate for combination therapy, its extremely low solubility in 
aqueous solutions (0.511 mg/ml) and lack of quantitative concentration measurement 
methods made SPIO-based drug loading studies difficult. For this reason, DOX was the 
only drug used for further SPIO studies.  
Fig. 3-9 Cell viability of HeLa and U87 cells exposed to the indicated temperatures for one 





Fig. 3-10 Combination treatment of chemotherapy and hyperthermia. HeLa cell viability 
24 hours posttreatment with a range of free DOX, CPT, or PTX concentrations with or 
without 43oC water bath heating for 60 minutes. Error bars represent standard error.    
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Intracellular DOX-SPIO localization 
Based on the results of magnetic fluid hyperthermia and drug loading and release, in all the 
subsequent cellular studies, SPIOs with PEG 2000 were used (hereafter referred to as 
SPIOs). To compare the cellular delivery efficiency of free DOX and SPIO-based DOX, 
HeLa cells were incubated with DOX-loaded SPIOs (DOX-SPIOs) or free DOX 
respectively and fluorescence microscopy was performed. DOX was observed in the 
cytoplasm and nucleus of the DOX-SPIO treated cells after 2 and 8 hours of incubation 
respectively. In contrast, the free DOX entered the cell nucleus after only 2 hours of 
incubation (Fig. 3-11). To assess SPIO internalization, the iron content of the cells was 
analysed and found to be 1.14 pg iron per cell, equivalent to ~153,000 SPIOs per cell. 
Estimating a cell volume of 2.5 pL, this correlates to an intracellular iron concentration of 
455 µg/ml Fe, which should be sufficient for strong intracellular MFH based on the SAR 
measurement. These results suggest that the DOX-SPIO based approach enables efficient 
delivery of DOX into cells and a sufficient amount of the SPIOs are internalized to achieve 






Fig. 3-11 DOX-SPIO internalization into HeLa cells. Confocal images of HeLa cells 
incubated with free DOX, (A) and (B), or DOX-loaded PEG 2000 SPIOs, (C) and (D), for 
2 or 8 hours, respectively.  The images displayed in (A-D) are overlays of two channels 
where cell nuclei are labelled in blue with Hoescht and DOX fluorescence is in red. 
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MFH-mediated intracellular release 
There is growing evidence that intracellular hyperthermia can induce disruption of 
endocytic vesicles to release their contents within the cell.[109, 141-144] This controlled 
intracellular release has important implications in both drug delivery and macromolecule 
delivery using nanoparticles. To explore whether this phenomenon was occurring in our 
system, dye-labelled SPIOs were co-delivered with fluorescently labelled dextran to 
visualize endocytic vesicle release from magnetic fluid hyperthermia. By concurrently 
incubating the cells with both dextran and the SPIOs, the endocytosis process would be 
able to internalize multiple of each macromolecule within in the same vesicle. Disruption 
of the vesicle could then be identified by a reduction in colocalization of the two fluorescent 
signals compared to non-heated controls. We found that cells exposed to the AMF and thus 
subjected to intracellular MFH, had a distinct lack of the colocalized dextran/SPIO signals 
in contrast to untreated controls which would suggest release (Fig. 3-12A). Though even 
without MFH, the dextran and SPIO signals do not show complete colocalization which 
can be attributed to the spatially heterogeneous internalization of the two macromolecules. 
The heterogeneous SPIO distribution is exacerbated by the non-uniform magnetic field 
gradients driving magnetofection.  
To quantitatively measure the difference in colocalization between the –MFH and 
+MFH cells, the Pearson correlation coefficient and the Mander’s colocalization 
coefficients were calculated for each of the images.[145] The Pearson correlation 
coefficient (PCC) is a value between -1 (complete negative correlation) and 1 (complete 
positive correlation) which describes the relationship between the two signal intensities. 
The PCC was 0.777 and 0.608 for the –MFH and +MFH cells, respectively, indicating a 
significant drop in correlation after hyperthermia (Fig. 3-12B). The Mander’s 
colocalization coefficients (MCC) range between 0 and 1 and describe the overlap of each 
signal with respect to the other (co-occurrence) which is independent of pixel intensities. 
Here M1 denotes the fraction of dextran signal compartments containing SPIO signal and 
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M2 denotes the fraction of SPIO signal compartments containing dextran signal. The M1 
coefficient was significantly lower for the +MFH cells (0.069+0.028) than the –MFH cells 
(0.477+0.159) in contrast to the M2 coefficient which showed no significant difference 
between +MFH cells (0.429+0.135) than the –MFH cells (0.313+0.014) (Fig. 3-12C). 
These data suggest that some of the smaller dextran molecules (2.36 nm) are able to escape 
the vesicles with hyperthermia thus decreasing the fraction of dextran that overlaps with 
the SPIO signal (M1), but the SPIO may still be trapped in the vesicles with any remaining 





Fig. 3-12 Intracellular hyperthermia-mediated endosome disruption. (A) Representative 
confocal images of HeLa cells incubated with both Alexafluor 488-conjugated dextran and 
DiI-labelled SPIO then exposed to an AMF (23.77 kA/m, 355 kHz) or left in the incubator 
for 2 hours.  The cell nuclei are labelled in blue with Hoescht, DiI-SPIO is in red, and 
Alexafluor 488-dextran is in green. Arrows indicate areas of SPIO and dextran 
colocalization displayed in yellow. Scale bar = 10 µm. (B) Pearson Correlation Coefficient 
and (C) Mander’s Correlation Coefficients were determined for each set of images for 
quantitative colocalization analysis using the JACoP ImageJ plugin. Error bars represent 
standard error. *P < 0.05, **P<0.01 using the Student's t-test. 
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DOX-SPIO Dose response 
The cytotoxic effect of the DOX-SPIOs was assessed and compared to free DOX in a dose 
response experiment. HeLa cells were incubated with either free DOX or DOX-SPIOs for 
48 hours at a range of equivalent DOX concentrations and subsequently assessed for 
viability to generate a dose response curve. As shown in Fig. 3-13, the DOX-SPIOs had a 
slightly higher IC50 (2.42 µg/ml DOX, determined via curve fitting) compared to the free 
DOX (1.40 µg/ml DOX). The higher IC50 observed for the DOX-SPIOs may be due to the 
slower and incomplete release of DOX from DOX-SPIOs.  These results suggest that 






Fig. 3-13 Comparative dose response. Cell viability of HeLa cells incubated with 
equivalent DOX concentrations of either free DOX or DOX-loaded PEG 2000 SPIOs for 
48 hours. Measurements were taken with an MTT assay normalized to an untreated control. 




Combinatorial MFH and DOX delivery 
In order to demonstrate the potential of SPIOs for combined cancer chemotherapy and 
hyperthermia, the effect of SPIO-induced MFH together with SPIO-based DOX delivery 
was determined through the assessment of cell viability. To observe a combinatorial effect, 
a mild thermal dose and short DOX-SPIO incubation with cells were chosen such that the 
combined effect would not be concealed by the death of the entire cell population by either 
treatment individually. By varying the treatment parameters, it was found that with a 100 
µg Fe/ml (16.6 µg DOX/ml) concentration of DOX-SPIOs, neither a 1-hour MFH nor 3-
hour DOX-SPIO incubation resulted in total cell death. Fig. 3-14A shows the temperature 
profile for the media, SPIO, and DOX-SPIO samples when exposed to the AMF for one 
hour. The SPIO and DOX-SPIO solutions reached 43oC within 20 minutes while the media 
held a temperature of ~37oC (Fig. 3-14A). The oscillation in the temperature curves is due 
to the water running through the inductor coil used to maintain the baseline temperature of 
37oC. Thus, applying AMF for 1 hour should subject HeLa cells to the apoptotic 
temperature regime (43-46oC) with the necessary duration (~30 minutes) to trigger 
apoptosis.[146]  
As shown in Fig. 3-14B, incubation with SPIOs alone (i.e., without DOX loading) 
or the presence of an AMF in the absence of SPIOs did not cause a significant drop in cell 
viability, indicating that SPIO incubation or magnetic field exposure alone does not affect 
cell viability. We found that water bath heating of HeLa cells at 43°C for 1 hour and SPIO-
based MFH for 1 hour decreased cell viability to 57 + 7% and 54 + 10%, respectively, 
showing a comparable effect.  SPIO-based DOX delivery decreased cell viability to 64 + 
11% after 3 hours of incubation, although it was not as dramatic as the free DOX, which is 
in agreement with the results from the dose response experiment. Based on the results of 
the release study shown in Fig. 3-6, only ~15% of the loaded DOX was released from the 
SPIOs after 3 hours, equivalent to a 2.49 µg/mL DOX concentration available to affect the 
cells (in comparison with 16.6 μg/mL in the free DOX case). Using the dose response curve 
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shown in Fig. 3-13 a DOX concentration of ~2.5 μg/mL correlates to a reduction in cell 
viability by ~50%, consistent with the result shown in Fig. 3-14B.  
HeLa cells subjected to the multimodal approach of DOX-SPIO delivery and SPIO-
based MFH exhibited a lower cell viability (32 + 9%) than either of the single modality 
treatments, namely drug delivery with DOX-SPIOs (64 + 11%) or SPIO-based MFH (54 
+ 10%) alone (Fig. 3-14). As shown in Fig. 3-15, we observed a reduction in cell 
attachment and an altered cell morphology of the DOX, MFH or DOX/MFH combinatorial 
treated cells (c, d, f, g) compared to the control cells (a, b, e), further confirming the effect 
of DOX-SPIO delivery and SPIO-based MFH. The combinatorial effect was consistent 
with the calculated additive response based on the decrease in cell viability observed in the 





Fig. 3-14 Combined SPIO-based DOX delivery and SPIO-induced MFH. The viability of 
HeLa cells was determined following treatment with media alone, water bath heating 
(43oC), just PEG 2000 SPIO (without DOX), DOX-loaded PEG 2000 SPIOs, or free DOX. 
Each of the indicated groups had samples with or without a 1 hour exposure to an AMF 
(23.77 kA/m, 355 kHz). (A) Temperature profiles during AMF treatment of media, SPIO, 
DOX-SPIO samples. (B) Cell viability measured 24 hours after treatment using an MTT 
assay. Error bars represent standard error. *P < 0.05, **P<0.01 using ANOVA coupled with 






Fig. 3-15 Cell morphology following DOX/hyperthermia treatment. Phase contrast images 
of HeLa cells 24 hours post treatment with media alone, just SPIOs without DOX), DOX-
SPIOs, or free DOX. Each of the indicated groups had samples with or without a 1 hour 





Circulation half-life and biodistribution 
To understand the fate of the DOX-SPIO’s following systemic injection, circulation half-
life and biodistribution studies were performed. Following a tail vein injection, the blood 
concentration of the DOX-SPIOs exhibited an exponential decay with a calculated 
circulation half-life of approximately 100 minutes (Fig. 3-16A). This is a significant 
improvement over free DOX where 90% is removed from circulation within the first few 
minutes following injection.[77] Despite Doxorubicin’s inherent fluorescence, DiR was 
co-loaded onto the SPIOs because it has a much higher extinction coefficient and quantum 
yield suitable for ex vivo fluorescent imaging.[147] The DiR-DOX-SPIOs were 
intravenously injected and sacrificed 24 hours later for ex vivo organ analysis using the 
IVIS imaging system (IVIS Spectrum; Caliper LifeSciences, Alameda, CA). The majority 
of the SPIOs were localized in organs associated with the RES (liver and spleen) and the 
kidneys though there was noticeable uptake in the tumor indicating good tumor targeting 
through the EPR effect. There was minimal uptake in the heart and lungs and no detectable 
signal in the muscle tissue (Fig. 3-16B) which is promising for limiting nonspecific toxicity 
of Doxorubicin which is known for its cardiotoxicity.[75] These results are consistent with 






Fig. 3-16 Circulation half-life and biodistribution. (A) Normalized blood SPIO 
concentration measurements following intravenous injection of DOX-SPIOs (100 µg Fe) 
(n=3) of blood draws measured using ferrozine assay. (B) Ex vivo fluorescent imaging of 
mouse organs one day after intravenous injection of DiI-labelled DOX-SPIOs (100 µg Fe) 






In the present work a combinatorial chemotherapy-hyperthermia cancer treatment was 
developed utilizing a phospholipid-PEG coating for SPIOs. Two different PEG lengths 
(2000, 5000 Da) were used to examine the influence on drug loading/release and MFH. 
Phospholipid-PEG is an amphiphilic molecule that associates with the surface of the SPIO 
through interdigitation of its lipid tails with the hydrophobic carbon chains of the oleic acid 
surfactant layer present on the iron oxide cores from the thermal decomposition 
synthesis.[64] The hydrophilic outer PEG chains are exposed to the aqueous environment, 
preventing protein opsonization and macrophage recognition.[148, 149] Longer PEG 
lengths have been associated with reduced protein adsorption and longer circulation half-
life.[149, 150]   
The amphiphilic nature of the coating layer enables drug loading due to 
hydrophobic/hydrophilic and electrostatic interactions between DOX and phospholipid-
PEG.[151] This drug loading method does not require complex conjugation steps and can 
achieve high payloads similar to micelle-based drug delivery.[59, 125, 151] The negatively 
charged phosphate group in the phospholipid-PEG layer may aid drug loading through 
electrostatic interactions with the positively charged amine group on the DOX. The results 
shown in Fig. 3-5 suggests that PEG 5000 shielded the negatively charged phosphate group 
more than that of PEG 2000, demonstrating that the high loading capacity is driven by a 
combination of electrostatic and hydrophobic/hydrophilic interactions between DOX and 
the SPIO coating layer. These interactions are consistent with previous results on DOX 
loading into lipid-PEG micelles.[151] The sustained release of DOX from the SPIOs helps 
maintain relevant drug concentrations within a tumor over long periods of time which can 
increase treatment efficacy and reduce dosing frequency. The slower release rate for SPIOs 
with PEG 5000 suggests the longer PEG length inhibits diffusion of DOX out of the SPIOs. 
Furthermore, the incomplete drug release found with both PEG lengths suggests that some 
DOX molecules were buried deep in the coating layer, thus difficult to be released due to 
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their interactions with the hydrophobic lipid layer. The maximum loading capacity with 
our SPIO formulation (31% wt) is significantly higher than the ionic bond-based loading 
(0.8 % wt) employed by Alexiou to deliver mitoxantrone to rabbits using their starch coated 
SPIOs.[20] The loading was also much higher than a similar passive loading into pluronic 
coated SPIOs (8.2% wt).[84] The high drug loading allows for lower overall iron delivery 
to achieve a therapeutic response.  
The susceptibility to heat varies between different types of cancer in terms of 
duration and temperature, eliciting a range of cellular responses.[90, 146] While a one hour 
44oC treatment HeLa and U87 cells triggered a large increase in apoptosis rates, MCF7 
cells were relatively resistant to hyperthermia through 45oC. Reducing the duration to thirty 
minutes shifted the apoptosis peak temperature up to 46oC for the HeLa and U87 cells (Fig 
3-7). Cells are most sensitive to heat during mitosis, so the lower efficacy of hyperthermia 
with the MCF7 cells could be a result of the longer doubling time (38 hours) compared to 
HeLa (18 hours) and U87 (24 hours).[97, 152-154]  
The complicated interactions of chemotherapeutics and hyperthermia depend on 
the mechanism of action of the drug and if proteins involved are denatured by the 
hyperthermia. The enhancement of cell death with hyperthermia was studied for 
Doxorubicin and two other drugs, Camptothecin, and Paclitaxel, which have been shown 
to be amenable for phospholipid-PEG loading.[137-140, 155, 156] Paclitaxel is a 
microtubule stabilizing agent which interferes with cell division, and the lack of a 
synergistic response in HeLa cells agrees with results for other cancer cell types.[157-159] 
On the other hand, Camptothecin acts by stabilizing the topoisomerase I-DNA complex to 
prevent DNA religation and disrupt DNA replication during mitosis. Combining 
Camptothecin with hyperthermia has been less studied, but a few reports indicate that the 
interplay could be timing and drug concentration dependent.[160, 161] For the concurrent 
delivery and range of concentrations (0-1000 nM) used in this study, an enhanced effect 
was seen above 50 nM. The exact interaction between DOX and elevated temperature 
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remains elusive, since there are conflicting reports on whether the combined effect is 
additive, superadditive, or threshold-like when used in conjunction with 
hyperthermia.[100-103] Our results with water bath heating display a potential synergistic 
behavior at concentrations near the IC50 (1 µg/ml) (Fig 3-10). 
Applying the DOX-loaded SPIOs to HeLa cells, we observed a slower 
accumulation of DOX into the cell nucleus when delivered via SPIOs compared to free 
DOX which may be attributed to the facts that DOX must be released from SPIOs prior to 
translocation and that burst release takes ~6 hours. The SPIOs were also internalized into 
the cells and could provide an alternative form of drug entry into the cell instead of relying 
on diffusion through the cell membrane. This pathway for drug delivery could prevent 
triggering of drug efflux pumps that reduce intracellular drug concentrations and factor 
into multidrug resistance. Once within the cell, the intracellular MFH appears to trigger 
vesicle disruption allowing the contents to be released. Similar macromolecule release has 
been observed with gold nanospheres and EGFR-targeted iron oxide nanoparticles.[109, 
162] Additional studies are needed to further characterize the release, though there are 
exciting opportunities for cytosolic delivery of genetic material and other macromolecules. 
One of the benefits of the passive loading used here is the drug can be loaded in its 
native form without any chemical medication. By comparing the efficacy of the free drug 
against the delivery via SPIO, the IC50 was only marginally increased, most likely due to 
release kinetics rather than a loss in drug function. The higher IC50 could be mitigated by 
increased accumulation of the drug to the tumor through SPIO delivery. While a synergistic 
response could not be determined with the combination of MFH and DOX-SPIO delivery, 
nevertheless, our results suggest that a combinatorial treatment is more effective than using 
either treatment alone. Furthermore, the drug delivery kinetics coupled with the narrow 




Besides drug loading, the phospholipid-PEG’s main function is to impart favorable 
pharmacokinetics to the nanoparticle and thus the drug cargo. Stability in biological fluids, 
prevention of macrophage recognition, and proper size are all necessary for in vivo 
performance following systemic injection. The 28 nm hydrodynamic diameter is within the 
ideal size range to avoid glomerular filtration in the kidney (> 6nm) and small enough to 
extravasate through fenestrations within the tumor endothelial layer for EPR targeting 
(<100 nm).[163, 164] Thus, the long circulation half-life (~100 minutes) seen with our 
SPIO allows for multiple passes through the circulation to enable accumulation within the 
tumor (Fig 3-16). Although the fluorescent signal in the tumor indicates SPIO 
accumulation, MFH requires high iron concentrations to reach therapeutically viable 
temperatures for cancer treatment. An intratumoral delivery strategy was used to attain the 
local SPIO concentration needed for MFH and is described in Chapter 6. 
Conclusion 
Conventional chemotherapy of cancer is often compromised by systemic toxicity and 
hyperthermia alone does not have the required efficacy for therapeutically viable cancer 
treatment. To address these limitations, in this work, we demonstrate that phospholipid-
PEG coated SPIOs have the potential to concurrently deliver Doxorubicin and generate 
heat for an enhanced multimodal cancer treatment. We investigated the role of PEG length 
in both treatment modalities, and identified phospholipid-PEG 2000 as the optimal coating 
that offers a high drug loading capacity of 30.8 ± 2.2% w/w (DOX/iron). We found that 
the phospholipid-PEG coated SPIOs were capable of raising the local temperature to 
apoptotic levels and a sustained DOX release without affecting drug activity. The 
multimodal hyperthermia-DOX treatment delivered by these SPIOs was more effective in 
causing cell death over the individual modalities. This SPIO-based approach offers many 
potential benefits for more effective cancer treatment. In addition to the capability of 
combined chemotherapy and hyperthermia, the superparamagnetic property of the SPIOs 
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provides T2 contrast for magnetic resonance imaging (MRI) as well as the ability to 
accumulate in specific tissues or organs by applying an external magnetic field locally.[8, 
9, 11, 13, 165] The phospholipid-PEG coating can also facilitate specific cell targeting by 
covalently attaching targeting ligands to the PEG chain, and fluorescence imaging by 
loading a lipophilic dye into the coating layer.[9, 65] Therefore, by utilizing these 
multifunctional abilities, it is possible to integrate diagnostic imaging with targeted drug 
delivery and hyperthermia to track drug-loaded SPIOs in vivo and further enhance the 





DEVELOPING SUPERPARAMAGNETIC IRON OXIDE 
NANOPARTICLES FOR HYPERTHERMIA-INDUCED 
CONTROLLED RELEASE 
Abstract 
Superparamagnetic iron oxide nanoparticles (SPIOs) are a unique drug delivery platform 
able to generate a local stimuli (heat) deep within the body which could be used to trigger 
a payload release mechanism. To investigate this potential, we synthesized SPIOs with a 
mixed coating composition of different phospholipid (DPPC) and phospholipid-
polyethylene glycol conjugates (DSPE-PEG 2000) molar ratios using the dual solvent 
exchange technique. The mixed coating composition did not alter loading of the dye 
rhodamine 6G nor heat generation through magnetic fluid hyperthermia.  Further, the phase 
transition of the DPPC was not observed when integrated in our SPIO system. This study 
demonstrates the flexibility of the dual solvent exchange method to control the 
incorporation of different amphiphilic molecules into the SPIO coating layer.  
Introduction 
Chemotherapy is currently one of the most common forms of treatment for patients with 
various forms of cancer. Although existing anti-cancer drugs are effective in inhibiting 
tumor growth and killing cancer cells, patients often suffer significant side effects which 
can be as harmful as the cancer itself. For this reason, better localization and accumulation 
of chemotherapy agents in the tumor through controlled drug release could avoid systemic 




 Nanoparticle-based drug delivery was envisioned to address the systemic toxicity 
problem by favorable biodistribution into the tumor through the enhanced permeability and 
retention effect and active targeting mechanisms such as the attachment of cancer cell-
specific ligands to the surface of the particle. Initial results with liposomal carriers showed 
some improvement over free drug administration, leading to the development of the FDA 
approved DOXIL, but clinical outcomes did not reach expected levels.[75] Most 
nanoparticle delivery systems rely on concentration gradients to drive drug release, so 
release begins upon entering circulation and also occurs in nonspecific tissues where the 
nanoparticles accumulate. Furthermore, the initial burst release characteristic of many of 
these systems can cause a majority of the drug to be released during the circulation time. 
Therefore, uncontrolled release could potentially offset the advantages of using 
nanoparticle carriers.   
To achieve better control of drug delivery when using nanoparticle carriers, a 
number of controlled release mechanisms have been studied such as enzymatically 
degradable and pH sensitive drug release methods which take advantage of the abundance 
of specific enzymes or the low pH found in the tumor microenvironment.[10, 166, 167] 
Other methods employ an exogenous activation modality such as light, ultrasound, or heat 
to trigger the drug release.[168-170] Thermal sensitive liposomes utilized phase transition 
lipids in their construction for enhanced release when brought above a specific 
temperature.[171-174] A critical factor with stimuli-responsive release is the source of the 
activation energy and ensuring that the stimulus can reach the location of the drug carrier 
in vivo, providing sufficient energy to trigger the release mechanism. A novel strategy to 
address this spatial issue is to couple the energy source and drug carrier regionally. The 
most well-studied of these coupled systems involve gold nanoparticles which convert 
infrared light to heat, triggering a release of the drug payload.[175-177] Gold nanoparticle 
are able to convert light energy to heat at high efficiencies, but limited by the penetration 
depth of light through tissue.   
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Superparamagnetic iron oxide nanoparticles (SPIOs) have been proposed as a drug 
delivery agent that can overcome the penetration limitations of other systems since their 
heat generation is mediated by exposure to an alternating magnetic field (AMF) which is 
not attenuated by biological tissue. The majority of the work on temperature-sensitive 
coatings for SPIOs has focused on the phase transition polymer poly(N-
isopropylacrylamide) (PNIPAM),[178-183] but the biocompatibility of PNIPAM has come 
under question.[184] Further, the release profiles following phase transition only show 
moderate increases in the release rate over those measured at body temperature, so 
alternative phase transition coatings are sought after.[185] Phospholipids are naturally 
occurring molecules that make up the cell membrane and their PEG conjugates have been 
widely used in liposome and micelle nanoparticle formulations.[59, 60, 76, 186] 
Phospholipids have a sharp phase transition from a conformationally ordered gel phase to 
a conformationally disordered liquid fluid phase which coincides with a 20% decrease in 
size.[187] The phase transition temperature for these molecules can be tuned to above body 
temperature for thermally controlled release by varying the chain length and the phosphate 
head group of the molecule.[188, 189] Temperature sensitive liposomes have shown 
promising results by taking advantage of this phase transition for a controlled release of 
doxorubicin, but they require an exogenous heat source to trigger the release.[171, 190, 
191]  
This study aimed to develop a thermo-responsive coating for SPIOs to enable a 
specific and effective release through magnetic fluid hyperthermia. To this end, we 
incorporated a 16 carbon chain lipid (DPPC), whose transition temperature is 41oC, into 
the DSPE-PEG coating of our SPIOs. Although a temperature dependent release was not 
observed with the inclusion of DPPC, the particles could still achieve high loading 





Synthesis of iron oxide nanoparticles 
Iron oxide nanoparticle cores of 14 nm diameter were synthesized by an adapted published 
procedure.29 Iron acetylacetonate (12 mmol), 1,2-hexadecanediol (60 mmol), oleic acid (72 
mmol), and oleylamine (72 mmol) were mixed in benzyl ether (60 ml) in a 500 ml round 
bottom flask and magnetically stirred. A vacuum was applied for 40 minutes, then the 
solution was raised to 120oC by a heating mantle attached to a temperature controller. After 
another 40 minutes, the vacuum was removed and replaced by a flow of Nitrogen. The 
solution was then raised to 200oC and held for 2 hours before ramping to 300oC and holding 
for 1 hour. The solution was then cooled to room temperature and ethanol (240 ml) was 
added to separate and precipitate the nanoparticle cores via three rounds of centrifugation. 
Finally, the cores were redispersed in toluene. 
Dual solvent exchange coating method 
To coat 1 mg Fe of SPIOs, 200 µl of the ferrofluid at 5 mg/ml Fe was varying ratios of  
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG-amine) in 400 
µl of chloroform in a 100 ml round bottom flask. The amount of coating molecules was 
determined based on a ratio of 8 coating molecules per nm2 SPIO surface area. Then, 4 ml 
of DMSO was incrementally added followed by a 30-minute incubation at room 
temperature. The toluene and chloroform was removed via vaporization under vacuum. 
Afterwards, 20 ml of deionized water was then slowly added to the solution. DMSO was 
removed and replaced with deionized water through three rounds of centrifugation in 
Vivaspin 20 centrifugal filter tubes with molecular weight cut-off 100 kDa (Sartorius, 
Goettingen, Germany). Finally, the solution was passed through a 0.2 µm HT Tuffryn 
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syringe filter membrane (Pall Life Sciences, Ann Arbor, MI) and stored in deionized water 
at 4oC. 
Iron concentration measurement 
Iron content of samples was determined using a ferrozine assay. Briefly, 50 µl of sample 
was mixed with 50 µl of 12 M HCl and incubated at room temperature for 30 minutes. 
Then, 240 µl of 2 M NaOH, 50 µl of 4 M ammonium acetate, 110 µl 5% hydroxylamine 
HCl, and 500 µl water were added to the solution sequentially. After 30 minutes of 
incubation, 50 µl of the solution were mixed with 0.02% ferrozine solution in a 384 well 
plate. Light absorption was read at 562 nm with 810 nm as the reference wavelength using 
a microplate reader (Safire2, Tecan Group Ltd., Männedorf, Switzerland). The absorption 
was compared to a molecular iron standard to determine the concentration. The number of 
SPIOs per gram of iron was estimated to be 1.35E17 based on the volume of a spherical 
14 nm diameter SPIO and the density of magnetite (5.17 g/cm3) assuming the cores were 
made up of Fe3O4. 
 
Characterization 
Transmission electron microscopy (TEM)  
The average core diameter of the SPIOs was measured via transmission electron 
microscopy. The polymer coating layer on the SPIOs was visualized by negative staining 
with phosphotungstic acid on glow discharged copper grids prior to imaging. TEM images 
were recorded with a transmission electron microscope (Hitachi H-7500, Tokyo, Japan) 
connected to a CCD camera. The negative staining and TEM procedures were conducted 
by the Robert P. Apkarian Integrated Electron Microscopy Core at Emory University. The 
images were analyzed using ImageProPlus® software. 
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Quantification of total lipid on SPIOs 
The amount of lipid coating molecules (DPPC and DSPE-PEG-amine) was quantified 
based on the phosphate concentration. Each of the lipids contains a phosphate group. To 
release the phosphate group from the lipid molecule, 50 µg Fe of coated SPIO was pipetted 
into a glass test tube and heated in an oil bath to 100oC to evaporate the water. 300 µl of 
perchloric acid was then added to each sample and heated to 160oC for 20 min. The samples 
were then allowed to cool to room temperature before adding 300 µl of 10 N NaOH 
followed by 2.4 ml of DI water to neutralize the perchloric acid. The total phosphate in the 
solution was then quantified with a Malachite green phosphate detection assay kit (R&D 
Systems) using a standard made of free DSPE-PEG-amine. The phosphate concentrations 
were then normalized to the amount of SPIO in the solution as measured by a ferrozine 
assay.  
Quantification of DSPE-PEG-amine on SPIOs 
The amount of DSPE-PEG-amine on the SPIOs was measured using a fluorescamine assay. 
Briefly, the SPIO samples were dispersed in PBS at 100 µg/ml Fe and then 200 µl was 
pipetted into a 96-well quartz plate. To each well, 50 µl 3 mg/ml fluorescamine dispersed 
in acetone was added and incubated for 20 minutes. The fluorescence intensity was then 
measured with a microplate reader (ex = 395, em = 470). The data was compared against 
a standard composed of DSPE-PEG-amine and 100 µg/ml Fe of DSPE-PEG-coated SPIOs 
and normalized to the amount of SPIO in the solution as measured by a ferrozine assay.  
Dynamic light scattering 
The hydrodynamic diameter of the coated SPIOs was measured using a dynamic light 
scattering device (DynaPro Nanostar, Wyatt Technology, Santa Barbara, CA). The SPIOs 
were dispersed in deionized water at 100 µg/ml Fe and measured at 25oC. The mass-
weighted size distribution was reported.  
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Differential scanning calorimetry 
The phase transition temperature was measured using a differential scanning calorimeter 
(TA DSCQ200, TA Instruments, New Castle, DE). A 20 µl sample of coated SPIO at 300 
µg/ml Fe was prepared in a hermetically sealed aluminum pan and measured with a 
temperature range of 25 – 65oC and heating rate of 10oC min-1 under a nitrogen atmosphere. 
A reference water sample was used to normalize the heat flow data. The pans were 
equilibrated in the DSC cell at 25oC for 10 minutes before the heating run.  
Dye loading 
SPIOs were incubated for 24 hours at 100 µg/ml overnight at 4oC in a solution containing 
40 µg/ml Rhodamine 6-G to allow for incorporation into the coating. The loading capacity 
was determined by centrifuging the SPIOs and separating the top and bottom fractions for 
dye absorbance and iron concentration measurements with a UV-vis spectrophotometer 
and a colorimetric ferrozine assay, respectively.  
Dye release 
The drug release profile was characterized by first concentrating 200 µg Fe of dye loaded 
SPIOs through a 2100 g centrifugation for 30 min. The supernatant was removed to take 
out any free dye in solution and replaced with 400 µl of fresh DI water. 200 µl samples 
were then transferred to a 96-well plate along with equivalent concentration free dye 
controls. The transient absorbance was measured at 525 nm using a microplate reader with 
a measurement time of 30 minutes and 1 minute read intervals. For the hyperthermia 
release measurements, a 15 minute temperature ramp to 43oC was added to the beginning 
of the measurement procedure.  
Hyperthermia properties 
A 1 ml volume of coated SPIOs at 0.4 mg/ml Fe was placed inside a polystyrene-insulated 
7.5-turn, 2.54 cm inner diameter inductor coil (EasyHeat 2.4kW, Ameritherm, Scottsville, 
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NY). An alternating magnetic field (23.77 kA/m, 355 kHz) was generated within the coil, 
causing the SPIOs to produce heat. The resulting temperature rise in the ferrofluid was 
measured over three minutes with a fiber optic temperature probe (FLUOTEMP, Photon 
Control Inc., Burnaby BC, Canada) and recorded in real time. The slope of the linear region 
of the temperature vs. time plot was normalized to a water sample and used to calculate the 








where 𝑚𝐹𝑒 is the mass of the iron in the sample, 𝐶𝐻2𝑂 is the specific heat of water, 𝑚𝐻2𝑂 
is the mass of the water, and 
𝑑𝑇
𝑑𝑡
 is the temperature rise of the fluid.  
Results 
Nanoparticle synthesis  
Superparamagnetic iron oxide cores were synthesized using a thermal decomposition 
technique to produce monodisperse iron oxide cores of 6 nm in diameter stabilized with an 
oleic acid oleylamine surfactant layer.[51] To confer aqueous solubility to the nanoparticle 
cores, the SPIOs were coated with a combination of 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000] (DSPE-PEG-amine) at different percentages (0-75%) 
of the total lipid using a dual solvent exchange method.[64] The presence of the coating 
layer was confirmed through TEM imaging of the coated SPIOs negatively stained with 
phosphotungstic acid, as demonstrated by the white halos surrounding the dark iron oxide 
cores (Fig. 4-1A,B). Comparing the TEM images, the incorporation of DPPC does not 





Fig. 4-1 Size measurements of iron oxide nanoparticles. Negatively stained TEM images 
of SPIOs coated with (A) 100% DSPE-PEG-Amine and (B) 50% DSPE-PEG-Amine and 
50% DPPC. (C) Hydrodynamic size measurements of coated SPIOs measured by dynamic 




To examine the hydrodynamic diameter of the particles after coating, the sizes of the 
particles were measured using dynamic light scattering. The 0% and 20% DPPC cores 
displayed a single sharp peak at 23 and 66 nm, respectively, while the rest of the DPPC 
samples displayed multiple peaks between 50-100 nm (Fig. 4-1C). The 23 nm 
hydrodynamic diameter displayed by the 0% DPPC cores is consistent with the estimated 
size of the DSPE-PEG-amine coating (~14 nm) and suggests stable, single cores 
surrounded by the phospholipid-PEG coating.  The larger sizes of the 25-75% DPPC coated 
SPIOs suggests clustering of the iron oxide cores within the phospholipid coating. The lack 
of clustering in the TEM images could be masked by artifact from the sample preparation. 
The change in coating above 20% DPPC is in agreement with a study of DPPC/DSPE-PEG 
micelles which saw a sharp increase in aggregation numbers and size above the 20% DPPC 
mark.[186] 
Coating composition 
 To investigate how the initial ratios of DPPC to DSPE-PEG-amine used in the 
coating process relate to the final surface composition of the coated SPIOs, the relative 
amount of amine groups to total phosphates was measured for the 0, 25, 50, 75% DPPC 
samples. The amine and phosphate content were measured using a fluorescamine assay and 
malachite green assay, respectively, using standards made with free DSPE-PEG-amine and 
then normalized to the iron content measured with a ferrozine assay. As the DPPC 
percentage was increased from 0 to 75%, the phosphates per nanoparticle increased linearly 
from 3000 to 6900 (Fig. 3-3a). To determine the surface density of the coating molecules, 
the number of phosphates was related to the surface area of the nanoparticles and found to 
increase from 3.74 to 8.58 phosphates per nm2 between 0 to 75% DPPC (Fig. 3-3a). For 
amine content, the opposite trend was seen as the number of amines per particle decreased 
from 2860 to 1080 for 0 to 75% DPPC, corresponding to a decrease of 1.78 to 0.67 amines 
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per nm2 (Fig. 3-3b). The amine content displayed a large decrease between 0% and 25% 
DPPC which corresponds to a fifty percent reduction in amines with smaller changes for 
50% and 75% DPPC. The total number of amines for the 0% DPPC SPIOs (2860 amines 
per particle) was consistent with the total number of phosphates (3000 phosphates per 
particle) which follows that all of the phosphates on those particles should be contributed 
by the DSPE-PEG-amine. The percentage of DSPE-PEG-amine to total phospholipid on 
the particles was determined by normalizing the amine quantities to the total phosphates 





Fig. 4-2 Coating composition of nanoparticles. (A) Malachite green phosphate 
measurements and (B) fluorescamine amine group measurements of SPIOs coated with 
varying percentages of DPPC and DSPE-PEG-amine. (C) Calculated percentage of DSPE 
of total coating molecules based on phosphate and amine measurements.  
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Phase transition temperature 
To examine the phase transition temperature of the lipids coating the SPIOs, endothermic 
transitions of the 75% DPPC SPIO sample were measured with a differential scanning 
calorimeter (DSC). The lack of a clear endothermic peak indicates that a phase transition 
could not be identified in this manner (Fig. 4-3).  
 
Dye loading 
The dye rhodamine 6G was used as an analog for a poorly soluble drug to determine 
loading and release properties with the DPPC SPIOs. The dye was mixed with the SPIOs 
and incubated overnight for the dye to partition into the hydrophobic lipid layer due to 
hydrophilic/hydrophobic interactions. The loading ratio was ~4.5% w/w dye/Fe for the 
three DPPC percentage samples tested, suggesting that the addition of DPPC to the coating 
layer did not affect the loading kinetics for rhodamine 6G (Fig. 4-4A).  
  




Fig. 4-4 Rhodamine 6G loading and release from DPPC/DSPE-PEG coated SPIOs. (A) 
Loading capacity of 0, 33, and 66% DPPC coated SPIOs following 24 hour incubation. 
Transient changes in normalized dye absorbance at (B) room temperature and (C) ramp to 




The existence of a temperature-dependent release of rhodamine 6G from the DPPC SPIOs 
was tested by monitoring transient changes in the dye absorbance resulting from 
precipitation of the dye molecule in the aqueous environment. There was no detectable 
change in the rhodamine signal throughout the measurement time at 25oC suggesting that 
the dye remained within the SPIO coating and was not released (Fig. 4-4B). When heated 
to 43oC, there was still no change in absorbance which is in agreement with the DSC results 
that did not display evidence of a phase transition in this temperature range.  
Coating composition effect on heat generation 
To examine if the coating composition of the SPIOs affects their efficiency in magnetic 
fluid hyperthermia applications, the specific absorption rates of the SPIOs was compared. 
The specific absorption rates ranged between 220-360 W/g, but there were no significant 
differences between the DPPC coating compositions (Fig. 4-5).  
 
Fig. 4-5 Specific absorption rates of 0, 33, and 66% DPPC coated SPIOs determined by 
heating aqueous samples during exposure to an alternating magnetic field of 23.77 kA/m 





DPPC was incorporated into the phospholipid-PEG coating of SPIOs with the goal of 
thermosensitive release. Replacing some of the phospholipid-PEG with DPPC 
compromised the stability of the coated SPIOs as noted by the large size and multimodal 
populations (Fig 4-1). The dual solvent exchange coating process is governed by the 
amphiphilic nature of the phospholipid-PEG coating molecules to trigger self-assembly in 
polar solvents. The lack of the long hydrophilic PEG chain on the DPPC molecules may 
not be amphiphilic enough for single core coating to be energetically favorable.[192] The 
poor coating was also evident in the low yield of the SPIOs after coating which limited the 
breadth and extent of the subsequent experiments. These results suggest that while 
incorporation of other molecules into the coating layer is possible, careful consideration of 
the amphiphilicity is required when replacing large amounts of the DSPE-PEG. 
Despite the heterogeneous size distributions, the initial lipid ratios used in the 
coating translated well to the final relative lipid surface composition on the SPIOs, 
illustrating the fine level of control possible with the dual solvent exchange coating 
method. The increasing lipid surface density with increasing DPPC percentage suggests 
that there is less steric hindrance and/or electrostatic repulsion from the small, neutral 
charge head group of the DPPC compared to the long PEG chain on the DSPE-PEG-amine. 
The lack of the long PEG chain on the DPPC could allow the molecule to fit into gaps on 
the SPIO surface which the DSPE-PEG would be too large for. It is worth noting that the 
higher lipid surface density conflicts with the larger hydrodynamic size for the DPPC 
particles, as an increase in size would reduce the total surface area for the same number of 
particles. The sharp drop in the amine density with only a low percentage of DPPC suggests 
that initially the DPPC replaces positions originally held by the DSPE-PEG-amine on the 
SPIO surface, but a certain amount of hydrophilic PEG is needed for the structure to be 
structurally stable. The stability of the micelle-SPIO structure is in contrast to liposomes 
whose phospholipid bilayers do not rely upon large amounts of PEG for stabilization.   
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Both dye loading and heat generation were unaffected by the DPPC.  Ashok et al. 
observed a similar trend in the solubilization of the drug diazepam in mixed DPPC/DSPE-
PEG 2000 micelles, but with DPPC/DSPE-PEG 5000 micelles, increasing DPPC coating 
composition corresponded to a two-fold higher drug loading.[186] In comparison to a 
similar study involving micelles composed of DSPE-PEG and DPPC, the incorporation of 
DPPC increased loading of the poorly soluble drug paclitaxel  by 50% for the same lipid 
concentration.[140] The differences in loading seen with our SPIO system could reflect 
either the unique structure of the lipid layer surrounding the iron oxide or specific 
interactions of drugs with the phospholipid.  
The large differences in hydrodynamic radius with increasing DPPC percentages 
would suggest that the heat generation is occurring through Néelian relaxation which is 
unaffected by coating size. If the increase in size is attributed to clustering of iron oxide 
cores within phospholipid-PEG micelles, there should be magnetic interactions between 
the closely spaced magnetic cores that would alter the heat generation, further putting into 
question the dynamic light scattering data.[193, 194]  
Taken together, the lack of a noticeable endothermic peak in the differential 
scanning calorimetry measurements and unchanging rhodamine absorbance throughout 
heating to 43oC preclude the potential for temperature sensitive release with the mixed 
DPPC coating. With the limited amount of material available for the DSC measurement, 
the instrument could have lacked the sensitivity required to accurately register a phase 
transition in the sample. On the other hand, it has been shown in mixed lipid/lipid-PEG 
bilayers that increasing the molar percentage of lipid-PEG reduces the main transition 
enthalpy, and the reduction is exacerbated with longer lipid and PEG lengths.[188, 189, 
195] The DSPE-PEG percentage of coating may still be too high even with 75% DPPC to 
elicit a sharp phase change response at the relevant hyperthermia temperatures.The dye 
release study confirms that the SPIOs are insensitive to the temperature change, though a 




In this study we have demonstrated a well-controlled incorporation of DPPC and DSPE-
PEG through the dual solvent exchange coating method. The initial coating ratios between 
the DPPC and DSPE-PEG matched well with the final composition of the SPIO coatings, 
though the stability of the SPIO structure at higher DPPC percentages is debatable. The 
poorly soluble dye rhodamine 6G was loaded into the SPIOs, demonstrating the potential 
for loading poorly soluble drugs. Increasing the amount of DPPC in the coating did not 
affect drug loading nor heat generation efficiencies. In order to achieve true temperature-
controlled release, incorporation of higher amounts of DPPC in relation to DSPE-PEG 
while maintaining particle stability may be required to show a strong phase transition 





ANALYZING THE EFFECT OF IRON OXIDE CORE SIZE ON 
MAGNETIC FLUID HYPERTHERMIA AND MAGNETIC 
RESONANCE IMAGING  
Abstract 
Iron oxide nanoparticles (IONP) possess the unique ability to be used in both a diagnostic 
and therapeutic capacity for cancer treatment by utilizing their inherent magnetic resonance 
contrast and potential to generate local heat when exposed to an alternating magnetic field 
(AMF). In order to minimize the delivered dose and ensure peak efficiency for clinical 
translation, the optimal design criteria for IONP are under investigation. To this end, we 
synthesized an extensive array of iron oxide cores from 6 to 40 nm to study the effects of 
core size on heat generation and MRI contrast in vitro and in a xenograft mouse tumor 
model. Heat generation and T2 relaxivity increased linearly with core size up to 2844 W/g 
Fe and 850 mM-1s-1, respectively, which are the highest values recorded for IONPs. 
Further, the intratumoral IONP distribution could be visualized using MRI, and the 40 nm 
particles generated sufficient heat to reach apoptotic temperatures in vivo. This study 
demonstrates the importance of considering core size when developing IONPs for MRI 
and hyperthermia in cancer treatment.  
Introduction 
Magnetic nanoparticles have tremendous potential to improve cancer therapy and 
diagnostics through their heat generation and magnetic resonance contrast properties, 
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though current clinical use has been limited due to inadequate efficiencies in these areas. 
In order to achieve translational success, significant improvements in the specific 
absorption rate (SAR) and relaxivity of magnetic nanoparticles are required.  The magnetic 
behavior governing SAR and relaxivity is strongly dependent on the particle core size. 
Recent advances in the synthesis of iron oxide nanoparticles (IONPs) through thermal 
decomposition have given researchers the ability to finely tune the particle size to within a 
few nanometers for distinct and monodisperse populations.[45, 51, 196] This level of size 
control prompts an in-depth, well-controlled investigation of the influence of core size to 
enhance magnetic fluid hyperthermia (MFH) and magnetic resonance imaging (MRI) for 
theranostic cancer therapy. 
Magnetic fluid hyperthermia is the mechanism by which magnetic particles 
generate local heat when exposed to an alternating magnetic field (AMF).[106]  The 
increased local temperature can be applied as a cancer therapy, as raising the temperature 
to ~43oC for 30-60 minutes can trigger apoptosis in cancer cells.[88, 90, 91] Reaching the 
proper temperature while minimizing the delivered dose is a critical goal for effective and 
efficient treatment, thus optimizing the physicochemical properties of the particles for 
maximum heat generation has been the focus of current research in the field.[194, 197-
199] For small, superparamagnetic particles (<25 nm), theoretical predictions suggest that 
the heating mechanism occurs through its fastest relaxation process, Néelian or Brownian, 
but for larger, ferrimagnetic particles, hysteretic losses dominate.[106, 200] Previous 
studies have found that heat generation is core size-dependent but have been relatively 
narrow in scope with only a small number of sizes tested without encompassing the full 
spectrum of sizes now obtainable with modern synthesis methods.[199, 201-204]  
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In the diagnostic field, magnetic particles are being developed for their contrast 
capabilities in magnetic resonance cancer imaging. The local magnetic fields created by 
IONPs when influenced by an external magnetic field accelerate the dephasing rate of 
Larmor precession in nearby water protons, resulting in negative contrast on a T2-weighted 
MRI scan.[114, 115] Previous reported work suggests that MR contrast has a size cutoff 
above which the particles shift from the size-dependent motion averaging regime (MAR) 
to the size-independent static dephasing regime (SDR).[114, 115, 205] Specifically, work 
from Lee et al. indicates that increasing the size of iron oxide nanocubes above 22 nm 
results in decreased relaxivity, though the core size increase was coupled with a large 
increase in the hydrodynamic radius (>200 nm) so that the particles would be too large for 
either of the MAR or SDR.[206] Other studies investigating the core size effect on MR 
contrast have also been fairly limited in number of sizes to compare or do not take into 
account sizes above 20 nm.[49, 107, 207, 208] Therefore, experimental validation of the 
MAR and SDR transition by comparing particles systematically spanning the expected 
cutoff is essential for determining the optimal size for MRI applications. 
Although there have been a number of solution-based studies examining the effects 
of core size on MR contrast and MFH, only limited efforts have examined how the size 
effects translate to a physiological environment. In this work, we synthesized an extensive 
array of stable, monodisperse IONPs ranging from 6-40 nm to enable investigation of core 
size-dependent parameters and to test the theoretical size regimes on both MFH and MR 
contrast. To date, the described work  utilizes the largest range of sizes for IONPs, spanning 
across the presumed superparamagnetic limit.[200, 209] With this complete array of eight 
different sizes, we investigated the effect of core size on the MFH and MRI capability of 
the IONPs in solution, when incubated with cancer cells in vitro, and in a mouse xenograft 
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tumor model. Nanoparticles with a 40 nm core were determined to be the optimal size for 
visualization of the distribution within the tumor through MRI and for heating to apoptotic 
temperatures in vivo with a minimal injected dose of 50 µg Fe. The results of this study 
highlight the potential of IONP above the superparamagnetic size cutoff to deliver 
therapeutically viable heating and diagnostically relevant MR contrast for cancer therapy. 
Methods 
Chemicals 
Iron acetylacetonate (Fe(acac)3 99%), 1,2-hexadecanediol (technical grade, 90%), oleic 
acid (technical grade, 90%), and oleylamine (technical grade, 70%), toluene (>99.9%), 
chloroform (99%), dimethyl sulfoxide (DMSO 99%) benzyl ether (98%), hydrochloric 
acid, hydroxylamine HCl, sodium hydroxide, ammonium acetate, ferrozine, and 
thioglycolic acid (>98%) were purchased from Sigma-Aldrich and used as received; 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(ammonium salt) (DSPE-PEG 2000) were purchased from Avanti Polar Lipids.  
Numerical simulations of magnetic fluid hyperthermia 
Numerical simulations were conducted on Matlab using the linear response theory 
equations developed by Rosensweig.[106] The parameters used in the studies are based on 
previously determined properties in Chapter 3 and reports by Lartigue et al. and 






Synthesis of iron oxide nanoparticles  
Iron oxide nanoparticle cores were synthesized by an adapted published procedure.[51] 
Iron acetylacetonate (12 mMol), 1,2-hexadecanediol (60 mMol), oleic acid (72 mMol), and 
oleylamine (72 mMol) were mixed in benzyl ether (60 ml) in a 500 ml round bottom flask 
and magnetically stirred. A vacuum was applied for 40 minutes, then the solution was 
raised to 120oC by a heating mantle attached to a temperature controller. After another 40 
minutes, the vacuum was removed and replaced by a flow of Nitrogen. The solution was 
then raised to 200oC and held for 2 hours before ramping to 300oC and holding for 1 hour. 
The solution was then cooled to room temperature and ethanol (240 ml) was added to 
separate and precipitate the nanoparticle cores via three rounds of centrifugation. Finally, 
the cores were redispersed in toluene. 
Parameter Value 
Boltzman Constant 1.38E-23 m2kg/s2K 
Temperature 298K 
Magnetic Permeability of Free Space 1.26E-6 
Volume Fraction of IONP 1.9E-4  
Viscosity of Water 6.92E-4 Ns/m2 
τ0 1E-9 
Magnetic Saturation 437 kA/m (84.6 emu/g) 
AMF Field Strength 36 kA/m 
AMF Frequency 355 kHz 
Magnetic Anisotropy 50 kJ/m3 
Table. 5-1 Magnetic fluid hyperthermia numerical simulation parameters. 
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Dual solvent exchange coating method 
To coat 1 mg Fe of IONPs, 200 µl of the ferrofluid was mixed with DSPE-PEG in 400 µl 
of chloroform in a 100 ml round bottom flask. The amount of DSPE-PEG was determined 
based on a ratio of 8 DSPE-PEG molecules per nm2 IONP surface area. Then, 4 ml of 
DMSO was incrementally added followed by a 30-minute incubation at room temperature. 
The toluene and chloroform was removed via vaporization under vacuum. Afterwards, 20 
ml of deionized water was then slowly added to the solution. DMSO was removed and 
replaced with deionized water through three rounds of centrifugation in centrifugal filter 
tubes (Vivaspin 20, 100 kDa cutoff size). Finally, the solution was passed through a 0.2 
µm syringe filter (Acrodisc, 0.2 µm, d13mm) and stored in deionized water at 4oC.  
SQUID magnetization measurements  
Magnetization measurements on uncoated iron oxide cores were carried out using a 
superconducting quantum interference device (SQUID) magnetometer (Quantum Design 
MPMS-5S, San Diego, CA). Field-dependent magnetization curves were measured at 5 K 
and 300 K as a function of the external magnetic field in the range of 0-5x104 Gauss. 
Transmission electron microscopy (TEM)  
The average core diameter of the IONPs was measured via transmission electron 
microscopy. The polymer coating layer on the IONPs was visualized by negative staining 
with phosphotungstic acid on glow discharged copper grids prior to imaging. TEM images 
were recorded with a transmission electron microscope (Hitachi H-7500, Tokyo, Japan) 
connected to a CCD camera. The negative staining and TEM procedures were conducted 
by the Robert P. Apkarian Integrated Electron Microscopy Core at Emory University. The 
average diameter of the core populations were analyzed using ImageProPlus® software.  
Dynamic light scattering 
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The hydrodynamic diameter of the coated IONPs was measured using a dynamic light 
scattering device (DynaPro Nanostar, Wyatt Technology, Santa Barbara, CA). The IONPs 
were dispersed in deionized water at 100 µg/ml Fe and measured at 25oC. The mass 
weighted diameter and polydispersity index were reported.  
Iron concentration measurement 
Iron content of samples was determined using a ferrozine assay. Briefly, 50 µl of sample 
was mixed with 50 µl of 12 M HCl and incubated at room temperature for 30 minutes. 
Then, 240 µl of 2 M NaOH, 50 µl of 4 M ammonium acetate, 110 µl 5% hydroxylamine 
HCl, and 500 µl water were added to the solution sequentially. After 30 minutes of 
incubation, 50 µl of the solution were mixed with 0.02% ferrozine solution in a 384 well 
plate. Light absorption was read at 562 nm with 810 nm as the reference wavelength using 
a microplate reader (Tecan Safire2, Switzerland). The absorption was compared to a 
molecular iron standard to determine the concentration.  
T2 relaxivity  
The T2 relaxivity of the IONPs was measured with a 0.47T Minispec Analyzer MQ20 
(Bruker, Fremont, CA) using the Carr-Purcell-Meiboom-Gill (CPMB) pulse sequence. 
Each core size was prepared by diluting in deionized water at a range of concentrations 
from 0.04-0.72 mM Fe. The T2 relaxivity was calculated as 1/T2 divided by the molar iron 
concentration by fitting the data to a linear regression.  
Magnetic fluid hyperthermia  
A 1 ml volume of coated IONPs at 400 µg/ml was placed inside either a 5-turn, 2.54 cm 
inner diameter or 5-turn, 5.00 cm inner diameter (large coil) inductor coil which was 
insulated with polystyrene (Ameritherm 1kW, Scottsville, NY). An alternating magnetic 
field with a field strength of 23.8 kA/m or 13.3 kA/m, for the 2.54 cm and 5.00 cm coils 
respectively, and a frequency of 325 kHz was generated within the coil, causing the IONPs 
92 
 
to produce heat. The resulting temperature rise in the ferrofluid was measured with a fiber 
optic temperature probe (Lumasense m3300, Oakland, NJ) and recorded in real time. The 
slope of the linear region of the temperature vs. time plot was normalized to a water sample 








where 𝑚𝐹𝑒 is the mass of the iron in the sample, 𝐶𝐻2𝑂 is the specific heat of water, 𝑚𝐻2𝑂 
is the mass of the water, and 
𝑑𝑇
𝑑𝑡
 is the temperature rise of the fluid.  
MRI solution phantom  
Aqueous solutions of each of the core sizes were prepared at 5 µg/ml and a water control. 
MR imaging was performed using a Bruker 7 T small animal MRI instrument with a 60 
mm surface coil (Pharmascan, Bruker). The samples were imaged using a spin-echo 
sequence (TR = 1000 ms. TE 67.5 ms, matrix size = 256×256, FOV = 4 cm). 
Cell culture 
U87 glioblastoma cells were obtained from ATCC, USA and cultured in T75 cell culture 
dishes following ATCC instructions. Cells were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Sigma-Aldrich) supplemented with 10% fetal bovine serum (ATCC). 
Cultures were replenished with fresh media every other day and passaged upon reaching 
70% confluence. 
In vitro magnetic hyperthermia treatment  
500,000 U87 cells were put into cryovials along with either 6, 19, or 40 nm IONPs at 200 
µg/ml or untreated and suspended in media with 10 mM HEPES. Each condition had a –
MFH and +MFH sample, and the –MFH samples were put in the cell culture incubator 
while the +MFH samples were placed in the 5.00 cm inductor coil surrounded by 
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polystyrene insulation. The +MFH samples were exposed to an AMF (13.3 kA/m, 325 
kHz) for one hour. Following the treatment, the –MFH and +MFH cells were seeded into 
96 well plates at 15,000 cells per well. After 24 hours, the cell viability was measured using 
an MTT assay.  Briefly, the media in the wells was replaced with phenol red-free DMEM 
with 0.5 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
Invitrogen) and incubated at 37oC for 2 h. The formazan crystals were dissolved in 200 µl 
of DMSO and the absorbance was read at 570 nm with 810 nm as the reference. The cell 
viability was normalized to the untreated control.  
To visually study cell death, 20,000 cells were seeded into a –AMF or +AMF strip 
of a 96 well stripwell plate and left overnight for attachment. The media was replaced with 
fresh media, or media with 200 µg/ml Fe of 6 nm, 19 nm, or 40 nm IONP. The –AMF 
strips were put in the cell culture incubator while the +AMF strips were placed in the 5.00 
cm inductor coil surrounded by polystyrene insulation. The +AMF strips were exposed to 
an AMF (13.3 kA/m, 325 kHz) for one hour and then returned to the incubator. After 24 
hours, the cells were stained with propidium iodide (PI, 4 µM) and calcein AM (2 µM) for 
30 minutes at room temperature. The cells were then imaged under a confocal microscope.  
Glioblastoma xenograft tumor model  
All animal procedures were conducted with the approval of the Institutional Animal Care 
and Use Committee at the Georgia Institute of Technology. Xenograft tumors are induced 
in athymic nude mice by subcutaneously injecting 3M U87 cells suspended in PBS into the 
right flank. Tumors were monitored until they reached the appropriate size for 
experimentation.  
In vivo magnetic fluid hyperthermia  
Tumor-bearing mice with tumors ~750 mm3 in size were anesthetized with 1.5% isoflurane 
and injected intratumorally with either 10 µl of 6, 19, 40 nm IONPs (50 µg Fe) or saline 
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over 10 minutes using a syringe pump. The animal was then placed within the large 
inductor coil and the fiber optic temperature probe was inserted into the center of the tumor 
cannulated with an 18G syringe needle. The animal was then exposed to an AMF (13.3 
kA/m, 325 kHz) for one hour while recording the intratumoral temperature.  
In vivo MR imaging 
In vivo MR imaging was performed using a Bruker 7 T small animal MRI instrument with 
a 38 mm surface coil (Pharmascan, Bruker). Tumor-bearing mice were imaged using a 
spin-echo sequence (TR = 1000 ms. TE increased from 12 ms to 144 ms with an increment 
of 12 ms. Matrix size = 256×256, FOV = 30 mm). Images were taken before and after 
intratumoral injection of IONPs (50 µg in 10 µl), and following the 1 hour AMF treatment. 
Tumor Growth 
Tumor-bearing mice with tumors ~175 mm3 in size were anesthetized with 1.5% isoflurane 
and injected intratumorally with 10 µl saline, IONP (5 mg/ml Fe), IONP-DOX (5 mg/ml 
Fe, 1.7 mg/ml DOX), or free DOX (1.7 mg/ml DOX) over 10 minutes using a syringe 
pump. The IONP mice were further divided into –/+MFH groups with the +MFH mice 
undergoing a one hour AMF exposure (13.25 kA/m, 325 kHz) following IONP injection. 
Tumors were measured daily via calipers and the size was determined by calculating the 





where V is volume, a is the larger axis radius and b is the smaller axis radius. Mice were 





Magnetic fluid hyperthermia theoretical parameter dependencies 
An initial investigation of the core size effect on heat generation in relation to both intrinsic 
and extrinsic properties of MFH was conducted. For single domain superparamagnetic 
IONPs, the linear response theory can be used to estimate the heat generation from Néelian 
or Brownian relaxation. Néelian relaxation describes the realignment of the particle’s 
magnetic moment with the external field by overcoming the anisotropic energy barrier. The 
relaxation time is a product of the anisotropy constant K, nanoparticle core volume VM, and 











where  𝜏0 is generally 10
-9s. The competing relaxation process, Brownian, involves the 
physical rotation of the particle to align the dipole with the field direction and operates on 





where 𝜂 is the viscosity of the solution and 𝑉𝐻 is the hydrodynamic volume.[106, 210] The 
faster of the two processes determines the total relaxation time according to 1/τ = 
1/𝜏𝑁+1/𝜏𝐵, and for an aqueous solution of phospholipid-PEG SPIOs, the relaxation time 
with respect to core size is given in Figure 5-1. Néelian relaxation clearly dominates for 




All nanoparticles have some degree of polydispersity within their populations. 
Knowing the strict size dependency on heat generation, it was important to understand how 
controlling the polydispersity through improved synthesis techniques could enhance MFH. 
Using the model developed by Rosensweig,[106] the theoretical heat dissipation could be 









where 𝜇0 is the vacuum magnetic permeability, p is the volume fraction of nanoparticles, 
τ is the total relaxation time, 𝑥0 is the chord susceptibility, H0 and v are the external 
magnetic field strength and frequency, respectively. The chord susceptibility can be 
expressed as 𝜇0Ms
2VM H0 / (kBT)L(ξ)/ξ, with L(ξ) as the Langevin function, 
ξ=𝜇0Ms
2VMH/(kBT), and Ms as the saturation magnetization of the nanoparticles. The 
specific absorption rate, a measure of the heat generation per mass of IONP, was estimated 
and plotted as a function of size and polydispersity as shown in Fig 5-2. The highest heating 
efficiencies are found in the size range of Néelian relaxation with size increases above 15 
Fig. 5-1 Effect of core size on relaxation times estimated for an aqueous solution of 
phospholipid-PEG coated SPIOs at room temperature (K=50 kJ/m3). 
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nm showing minimal heating. The strong size dependence of specific absorption rate is 
observed by the very narrow peak for maximum heating which drops dramatically beyond 
~1 nm from the critical size. The peak broadens with increasing polydispersity, as the 
population distribution has more particles outside of the optimal heating size. There is also 
a peak shift towards smaller sizes due to Brownian relaxation remaining unchanged as core 
polydispersity increases and minimal Néelian heating at smaller core sizes (<6 nm). 
 
To examine the extent of magnetic anisotropy’s influence on the Néelian 
relaxation-size relationship, a range of anisotropy values reported in the literature for iron 
oxide nanoparticles in the superparamagnetic size regime were modeled.[107] Increasing 
magnetic anisotropy of the material shifted the Néelian relaxation curves toward longer 
relaxation times which causes the shift to Brownian relaxation to occur at smaller particle 
sizes (Fig. 5-2A). Further, when the anisotropy was increased from 25 kJ/m3 to 200 kJ/m3, 
the size for peak heating efficiency decreased from ~14 nm to ~6.5 nm, respectively (Fig. 
5-2B).   





The alternating magnetic field is the extrinsic factor determining how heat 
generation changes with respect to core size. As shown in Fig. 5-4, increasing AMF 
frequency has a linear relationship with SAR, but also slightly shifts the SAR maximum 
toward smaller core sizes. In contrast, the heat generation increases proportionally to the 
square of the magnetic field strength, though there is no change in the optimal core size.  
As stated previously, the linear response theory only applies to superparamagnetic 
single domain nanoparticles, larger multidomain and ferrimagnetic particles are assumed 
to generate heat through hysteretic losses which are dependent on the size of the hysteresis 
Fig. 5-3 Effect of magnetic anisotropy on (A) Néelian relaxation time and (B) specific 
absorption rate.  
Fig. 5-4 Effect of magnetic anisotropy on (A) Néelian relaxation time and (B) specific 
absorption rate.  
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loop in the MH curve rather than a direct dependence on core size.[211] While Néelian 
relaxation is thought to be the most efficient heating process, recent reports of IONPs in 
the ferrimagnetic regime and at the transition size between single and multidomain have 
shown remarkable heating efficiencies.[212, 213] The numerical simulations shown here 
prompted us to experimentally examine the core size-SAR relationship to determine the 
transition size between the heating mechanisms and confirm the trends observed for the 
different parameters.  
Nanoparticle synthesis and coating  
Iron oxide cores were synthesized using a thermal decomposition iterative regrowth 
technique to produce monodisperse iron oxide cores of 6 nm in diameter which can then 
be grown to larger sizes through iterative regrowth steps to achieve an array of eight 
different core sizes up to 40 nm (Fig. 5-5A-H).[51] The 40 nm size was the limit for stable 
and monodisperse populations that could be synthesized in this manner. The narrow core 
size distribution allows for valid comparison between IONP populations with average core 
sizes that differ by only a few nanometers and demonstrates the advantage of using the 
thermal decomposition synthesis method over co-precipitation methods which result in 
polydisperse core populations.[214]  
To confer aqueous solubility and prevent protein opsonization and macrophage 
recognition, the IONPs were coated with phospholipid-PEG 2000 using a dual solvent 
exchange method.[64, 148, 149] The average size increase over the core diameter after 
coating (~14 nm), is consistent with the estimated size of the coating molecule (Table 1). 
The uniform size of the coating layer across the different cores is necessary to control for 
influences of hydrodynamic radius on the distance of water molecules to the core surface, 
which is important for MRI and friction induced by Brownian relaxation for MFH.[65, 
106] Negative staining of the TEM grid reveals the presence of the coating layer as 
demonstrated by the white halos surrounding the dark iron oxide cores (Error! Reference 
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source not found.I). It is important to note that the size shown on the negative stain TEM 
image does not accurately reflect the hydrodynamic diameter of the IONP, since the drying 
process results in contraction of the PEG chains.  
 
Fig. 5-5 Transmission electron microscopy images of uncoated SPIOs core: (A) 6 nm, (B) 
8 nm, (C) 10 nm, (D) 15 nm, (E) 19 nm, (F) 25 nm, (G) 32 nm, and (H) 40 nm. (I) Coated 
15 nm SPIOs negatively stained with phosphotungstic acid. Scale bar represents 100 nm. 
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Magnetic properties  
Iron oxide particles in the nanometer size range are characterized by their 
superparamagnetism which describes the random orientation switching of the internal 
magnetic moment at room temperature due to the low thermal energy barrier.[215] The 
superparamagnetic property is inherently size-dependent, as above an estimated threshold 
diameter (~25 nm), iron oxide particles transition to a ferrimagnetic state possessing 
remnant magnetization, thus rendering them unsuitable for biomedical use due to self-
aggregation.[209, 216-218] To assess whether the range of cores in this study remain in 
the superparamagnetic regime, the magnetization of the IONP samples was measured. The 
M-H curves for the IONPs of all core sizes exhibit superparamagnetic behavior at room 
temperature with no hysteresis, minimal coercivity and remanent magnetization, and high 
magnetic saturation up to ~125 emu/g, which approaches that of bulk magnetite (Fig. 5-6). 
The smaller cores below 10 nm in diameter exhibit a reduced saturation magnetization in 
contrast to larger sizes, suggesting a nonferrimagnetic frustrated surface layer having a 
greater influence on the total magnetization due to the larger surface-area-to-volume ratio 
at smaller diameters (Fig. 5-6B).[203, 219-221] Comparing the 300K and 5K data, there 
was little change in terms of saturation magnetization and only a small increase in magnetic 
Table. 5-2 Average core sizes and hydrodynamic diameters of IONP populations. 
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remanence, suggesting the blocking temperature is above room temperature (Fig. 5-
6C,D).To investigate the blocking temperature, the magnetizations of the cores during 
zero-field cooling (ZFC) and field cooling (FC) were measured. Interestingly, only the 6 
and 8 nm cores displayed distinct blocking temperatures of 53K and 80K, respectively, 
while the magnetization of the 15 and 19 nm cores increased up through 300K (Fig 5-
7A,B). The blocking temperature below room temperature is one of the defining properties 
of superparamagnetism as it implies the anisotropic energy barrier has been overcome to 
allow random magnetization reversals. At ~100K, the 25, 30, and 40 nm cores suddenly 
increase in magnetization followed by a slow increase through 300K which may indicate a 
mixed population of superparamagnetic and ferrimagnetic cores. The transition from the 
superparamagnetic single domain to the ferrimagnetic multidomain is expected to coincide 
with a rapid increase in coercivity, but no size dependent coercivity change was observed 
in the array of cores tested.[212, 222-224] Furthermore, the lack of hysteresis in the field 
dependent magnetization curves for all the cores provides additional evidence for 
superparamagnetism at room temperature. While it is difficult to properly identify the 
magnetic regime of the cores, the lack of remanent magnetization upon removal of the 





Fig. 5-6 Magnetic properties of IONP cores. Field-dependent magnetization curves at (A) 
300K and (B) 5K.  (C) Magnetic saturation and (D) coercivity of different core sizes at 5 




Fig. 5-7 Zero-field cooling (ZFC) and field cooling (FC) magnetic susceptibility of (A) 6 
and 8 nm, (B) 15 and 19 nm, and (C) 25, 32, and 40 nm cores measured at 100 Oe. 
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Magnetic fluid hyperthermia properties  
When magnetic nanoparticles are exposed to an alternating magnetic field, they generate 
heat through either hysteretic losses or a combination of Néelian relaxation and/or 
Brownian relaxation.[106, 107] The type of heating mechanism determines how the 
specific absorption rate (SAR), a measure of the heat generation per unit mass of magnetic 
material, is influenced by the size both in terms of the average core diameter and 
polydispersity of the population. For all of the cores in this study, the magnetization curves 
display superparamagnetic behavior with minimal hysteresis (Fig. 5-6) suggesting that the 
primary mechanism of heat generation can be attributed to Néelian and Brownian 
relaxation rather than hysteretic losses.[106, 107]  
To determine the effect of core size on heat generation, aqueous solutions of the 
coated cores (400 µg Fe/ml) were exposed to an alternating magnetic field at two different 
field strengths (23.8 kA/m and 13.3 kA/m). The temperatures of the ferrofluids were 
measured as a function of time and the slopes of the heating profiles (Fig. 5-8A,B) were 
used to calculate the SAR for each of the core sizes, as described in the Methods section. 
By increasing the field strength from 13.3 kA/m to 23.8 kA/m, there was an average 1.99-
fold increase in SAR which is roughly equivalent to the 1.79-fold difference in field 
strengths for the range of sizes tested (Fig. 5-8C). The linear increase of SAR with 
increasing field strength is consistent with previous studies that examined how AMF 
parameters relate to SAR, though is inconsistent with the theoretical predictions (Fig. 5-
4).[204, 225] For both field strengths, there was very low heating below 10 nm and a linear 
relationship between core size and SAR above 10 nm in size (Fig. 5-8C). The consistent 
trend in the SAR for all the samples above 10 nm in size suggests that the same heat 
generation mechanism is occurring for this size range. The samples less than 10 nm in size 
may produce too little heat to be accurately measured with the experimental setup used. 
The maximum SAR was achieved with the 40 nm cores at 1535 W/g and 2844 W/g with 
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the 13.3 kA/m to 23.8 kA/m field strengths, respectively, and surpasses the highest reported 






Fig. 5-8 Heat generation core size dependence. Transient heating profiles of the coated 
core samples for an AMF of (A) 23.8 kA/m, 325 kHz and (B) 13.3 kA/m, 325 kHz, and 




To test whether Néelian or Brownian relaxation was the underlying heat generation 
mechanism, the SARs of IONPs with 6, 19, and 40 nm diameters suspended in a high 
viscosity solution was compared to the SAR values obtained in water samples (Fig. 5-9). 
The higher viscosity should increase heat generation if Brownian relaxation is dominant 
by increasing the rotational friction of the particles in the solution.[201] The lack of an 
increase in SAR with the glycerol compared to water suggests that Brownian relaxation is 
not a major contributing factor to heat generation and that Néelian relaxation is dominating.  
 
Core size effect on magnetic resonance contrast  
To study the relationship between the magnetic core size of iron oxide nanoparticles and 
their relaxometric property for MRI, the T2 contrast of the IONPs was assessed by 
measuring the T2 relaxivity (defined as 1/T2 normalized by molar concentration of Fe 
Fig. 5-9 Effect of solvent viscosity on heat generation. Calculated specific absorption rates 




atoms) for each of the IONP samples at a range of iron concentrations using a 0.47 T 
device. A linear increase in the relaxivity was observed with respect to core size (Fig. 5-
10A,B), with the highest relaxivity occurring in the 40 nm IONPs at 850 mM-1s-1, higher 
than the previously thought maximum found with iron oxide nanocubes.[206] The 
difference in contrast can also be visually observed in the MR image taken with a 7 T MRI 






Fig. 5-10 T2 relaxation of core sizes.  (A) T2 relaxation times, (B) T2 relaxivity, and (C) T2 
contrast of the coated core samples at 5 µg/ml Fe. 
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Effect of hyperthermia on cell viability  
Glioblastoma multiforme (GBM) is an aggressive and invasive brain cancer in which 
surgical resection is difficult to perform and thus alternative treatment measures such as 
local hyperthermia treatment are sought after.[227] For this reason, the U87 glioblastoma 
cell line was chosen to investigate the effect of core size on the efficacy of magnetic fluid 
hyperthermia treatment using three core sizes (6, 19, 40 nm) which encompass the general 
size range used in this study. AMF treatment itself did not affect cell viability, nor did the 
IONPs display toxicity (Fig. 5-11A). The effect of magnetic fluid hyperthermia ranged 
from little effect for the 6 nm cores, to a partial decrease (24%) in cell viability for the 19 
nm cores, to complete cell death for the 40 nm cores (Fig. 5-11A). These cellular responses 
correspond to the maximum temperatures attained: 34oC, 45oC and 75oC for the 6, 19, and 
40 nm cores, respectively (Fig. 5-11B), as apoptosis in cancer cells is triggered between 
41-46oC and higher temperatures cause thermal ablation.[88-91] A live dead assay was 
also performed on U87 cells attached to a stripwell during AMF treatment to visually 
confirm the results of the MTT assay.  Only cells treated with 40 nm SPIOs and exposed 
to an AMF displayed substantial cell death, consistent with the MTT results (Fig. 5-12). It 
is worth noting that the temperatures attained under MFH depend on IONP concentration, 
AMF parameters, and thermodynamics of the environment, thus the viability results 






Fig. 5-11 MFH effect on cell viability. (A) Temperature profiles of SPIOs suspended in 
cell culture media at 200 µg/ml when exposed to an AMF (13.25 kA/m, 325 kHz). (B) Cell 
viability of U87 cells 24 hours after treatment of untreated media alone, 6 nm, 19 nm, and 
40 nm coated SPIOs with and without a one hour AMF treatment. Measurements were 





Fig. 5-12 Live/dead stain of magnetic fluid hyperthermia-mediated cell death. Confocal 
images of U87 cells co-stained with Calcein AM and PI 24 hours after treatment of media 
alone, 6 nm, 19 nm, or 40 nm coated SPIOs with and without a one hour AMF treatment 
in a stripwell.  
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In vivo magnetic fluid hyperthermia and magnetic resonance imaging  
The tumor tissue represents a heterogeneous microenvironment for MRI in terms of water 
content and complicated thermodynamics for MFH due to homeostatic temperature 
regulation mechanisms which are difficult to recapitulate in an in vitro model. Thus, in 
order to evaluate the IONPs in a more clinically relevant cancer model, the three core sizes 
used in the in vitro study (6, 19, 40 nm) were tested in a mouse xenograft tumor model. 
U87 tumors were grown subcutaneously in athymic mice and injected intratumorally with 
50 µg Fe of IONPs or 10 µl of saline. MR images taken before and after injection display 
the sharp contrast of the IONPs inside the tumor (Fig. 5-13). The border of the injection 






Fig. 5-13 In vivo MRI contrast.  T2 weighted MRI images of mouse tumors before and 
after 10 µl injection of saline, 6 nm, 19 nm, or 40 nm IONPs at 5 mg/ml Fe. 
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Following imaging, the mice were exposed to an AMF (13.25 kA/m, 325 kHz) 
within an inductor coil for one hour (Fig. 5-14) which did not change IONP distribution 
within the tumor (Fig. 5-15). During AMF treatment, the temperature within the tumor was 
measured using the fiber optic temperature probe. The tumors injected with the 6 nm cores 
did not exhibit an increase in temperature when compared to the saline control, while the 
19 nm and 40 nm cores caused a temperature increase of 2.5oC and 10.1oC, respectively 
(Fig. 5-16). The differences in the temperatures attained in vivo roughly correspond to the 
differences in SAR values measured in solution and during heating in vitro. Only the 40 
nm cores were able to reach the apoptotic temperature threshold of 41oC during the course 
of the treatment. In comparison with other studies that inject on the order of milligrams of 
iron or field strengths up to 56 kA/m, we were able to achieve substantial in vivo heating 
using only 50 µg of IONP and an AMF of 13.25 kA/m and 325 kHz.[39, 228, 229] 
 
  
Fig. 5-14 In vivo MFH set up. Tumor-bearing mouse is placed within 5.00 cm inner 
diameter coil with heating pad underneath to maintain whole body temperature while under 






Fig. 5-15 MRI images pre-injection, post-injection, and post-MFH for 19 nm IONP. T2-
weighted MRI images of mouse tumors before and after 10 µl injection of 19 nm at 5 mg/ml 






Fig. 5-16 In vivo MFH. Temperature profiles of three mouse xenograft tumors injected 
with 10 µl of (A) saline, (B) 6 nm, (C) 19 nm, or (D) 40 nm SPIOs at 5 mg/ml Fe and 
exposed to an AMF (13.25 kA/m, 325 kHz) for one hour, and (E) average maximum 
intratumoral temperature during treatment. Error bars denote standard error. 
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To observe the physiological effects of the hyperthermia, the tumors were analyzed 
histologically with a TUNEL apoptosis stain directly following treatment (Fig. 5-17). Only 
the 40 nm IONP-treated tissue exhibits strong TUNEL staining, which is consistent with 
the temperature measurements since the 40 nm IONPs were the only tested size that 
reached the apoptotic temperatures during the AMF treatment (Fig. 5-16).  
  
Fig. 5-17 TUNEL apoptosis stain of tumors treated with (A) saline, (B) 6 nm, (C) 19 nm, 
or (D) 40 nm IONPs at 5 mg/ml Fe and exposed to an AMF of 13.25 kA/m, 325 kHz for 
one hour. The images displayed in (A-D) are overlays of two channels where cell nuclei 
are labelled in blue with Hoechst and TUNEL staining is in green. 
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Combined effect of magnetic fluid hyperthermia and DOX delivery on tumor 
growth 
With the high intratumoral temperatures and evidence of apoptosis attained through 
MFH with the 40 nm IONPs, we next investigated the efficacy on tumor growth inhibition. 
This study also opened the opportunity to reexamine IONP-based DOX delivery in an in 
vivo setting. The 40 nm IONPs were able to load DOX at 34% w/w (DOX/Fe) which is 
consistent with the loading efficiency of the 14 nm IONPs in Chapter 3. Mice bearing ~175 
mm3 tumors were intratumorally injected with 10 µl saline, IONP (5 mg/ml Fe), IONP-
DOX (5 mg/ml Fe, 1.7 mg/ml DOX), or free DOX (1.7 mg/ml DOX). The IONP-treated 
mice were further divided into –/+MFH groups with the +MFH mice undergoing a one 
hour AMF exposure (13.25 kA/m, 325 kHz) following IONP injection. Free DOX 
displayed the most growth inhibition most likely due to the high immediate availability of 
the drug compared to IONP release. Compared to the saline control, all of the treatments 
excluding free DOX displayed similar growth inhibition through day six (Fig 5-18). At day 
7, differences between the treatment groups were seen with IONP-based MFH having 
slightly improved efficacy compared to IONP-DOX, and the combination of the two 
treatment modalities further reducing tumor growth. It is expected that continuing growth 
to further time points would expand the differences between treatments as the growth rates 
became more exponential, but IACUC protocol limits the extent of such tumor growth and 







In order for IONPs to realistically impact the fields of cancer hyperthermia therapy and 
diagnostics, significant efficiency benchmarks must be overcome before they will be 
viewed as a worthwhile technology for clinical and commercial translation. Due to the 
body’s natural homeostatic temperature regulation methods such as vascular perfusion, 
power densities up to 20-40 W/kg at the intended location are necessary to reach 
therapeutically viable temperatures above 42oC.[230, 231] Even for small tumors, a large 
quantity of heat-mediating IONP would need to be distributed throughout the tumor to 
ensure total cell death and eliminate the chance of remission. While it is conceivable to 
increase the heat delivered by raising the magnetic field strength and frequency, there are 
physiological limits before induction of eddy currents cause non-specific heating in the 
tissue. Atkinson and Brezovich determined that a field strength-frequency product of 4.85 
x 108 A m-1s-1 was the limit before patients felt discomfort and could no longer tolerate the 
treatment, though this maximum tolerable dose would vary depending on the size of the 
Fig. 5-18 In vivo magnetic fluid hyperthermia and DOX treatment tumor growth inhibition. 
Error bars represent standard error based on 5-7 mice per group.  
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region exposed to the AMF, duration of the treatment, and the equipment producing the 
AMF.[232, 233] Moreover, the concentration of IONP delivered is limited by cost and 
safety concerns with the long term biocompatibility of the particles. Therefore, 
enhancement of MFH must come from optimizing the efficiencies of the particles 
themselves. As an imaging contrast agent, IONP rely upon MRI which offers high spatial 
resolution and depth penetration, but sensitivity is far below other modalities such as 
positron emission tomography (PET) or near-infrared fluorescence (NIRF). While several 
IONP formulations have been FDA approved and are commercially available for use as 
MR contrast agents, many have been discontinued due to poor clinical performance. These 
IONPs were synthesized using coprecipitation methods and characterized by poor control 
of the size and crystallinity. There is much room for improvement and optimization using 
modern advanced synthesis techniques that could enhance T2 relaxivity and bring about the 
next generation of IONP contrast agents.  
There are many nanoparticle properties which contribute to SAR and T2 relaxivity 
such as size, shape, crystallinity, and magnetic response to an external field, though core 
size is the one property that researchers have the most direct control over and is tied to 
many of the other factors. The MFH numerical simulations in Fig. 5-1 through 5-4 illustrate 
the interdependence of core size with polydispersity, magnetic anisotropy, and the external 
field, but these trends are only relevant in the context of superparamagnetism. As the size 
increases, IONPs are theorized to transition from superparamagnetic to single then 
multidomain ferrimagnetism which corresponds with heat generation transitioning from 
Néelian to Brownian relaxation and finally hysteretic losses. MR contrast is expected to 
follow similar regime shifts from the MAR to SDR at a certain particle size. Other works 
have examined core size arrays that encompass solely one magnetic regime, but it is 
difficult to accurately compare results between these studies due to inconsistent particle 
compositions and magnetizations stemming from unique synthesis protocols. By using a 
single thermal decomposition method to synthesize a systematic array of IONP between 6-
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40 nm in size, we expected to encounter the multiple transition states for magnetic 
response, MFH, and MR contrast. The linear increase of both T2 relaxivity and SAR with 
increasing core size does not support the existence of regime transitions within the size 
range tested here (Figs. 5-8 and 5-10). According to previous findings on T2 relaxivity, the 
theoretical size limit where the MAR transitions to SDR is ~30 nm.[114, 115] This 
transition marks the size where water diffusion no longer occurs at a faster time scale than 
the resonance frequency shift caused by the IONPs, and the relaxivity becomes core size-
independent. The linear increase in relaxivity up to 40 nm suggests that the cores are all in 
the MAR and the size limit of this regime is still yet to be reached for our IONPs.  
While the size relationship for MR contrast could be justified by assuming all of 
the particles are within the MAR, the MFH size dependence cannot be neatly described in 
the existing theoretical frameworks. The room temperature SQUID magnetization curves 
of the cores are characteristic of superparamagnetism such that hysteretic losses for heat 
generation would be minimal and thus could not explain the increase in SAR past the 
optimal size predicted by the numerical simulations (Figs. 5-6). Deviations from the linear 
response theory have been observed by others with respect to the SAR dependences on 
size, anisotropy, and external field parameters.[203, 213, 225] The linear increase in SAR 
is inconsistent with iron oxide nanocube studies that investigated cores above 20 nm in size 
that found a decrease in SAR above this size threshold.[201, 204, 213] Guardia et al. 
determined that for iron oxide nanocubes, the relationship of edge length to SAR was 
dependent on the AMF field strength; a shift occurs between 12-24 kA/m causing 35 nm 
particles to greatly increase in SAR relative to 14, 19, and 24 nm particles.[225] The 
described phenomenon with nanocubes does not appear to apply to our nanoparticles, as a 
linear increase in SAR was observed with field strengths of 13.3 and 23.8 kA/m. A 
reexamination of the assumptions behind the linear response theory and transition to 
hysteretic losses may be necessary to characterize the SAR results described here. 
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The importance of optimizing for SAR and T2 relaxivity was demonstrated through 
the translation to in vitro and in vivo environments. For the same concentration of 6, 19, 
and 40 nm IONPs, local temperatures vary between remaining unchanged, reaching 
apoptotic levels, or inducing thermal ablation, respectively (Fig. 5-11). The range of these 
temperatures correspond to stark differences in the cellular response to the treatment. 
Delivery of IONP to the tumor remains challenging even with intratumoral injection due 
to the poor control over distribution through the tissue. The theranostic utility of the IONP 
platform aided in identifying the borders of the ferrofluid within the tumor through MRI. 
Intratumoral temperature homogeneity is necessary for successful therapy and is facilitated 
by proper distribution of IONP. Unfortunately with the thermal probe available, a spatial 
profile of the temperature distribution could not be measured. 
The 40 nm cores were able to increase the tumor temperature to apoptotic levels by 
delivering only 50 µg of iron to the tumors, demonstrating the reduction in dose afforded 
by the high heating efficiency compared to other studies requiring milligrams of IONPs 
(Fig. 5-16).[111, 228, 234-236] The reduced temperatures achieved during tumor MFH 
compared to the in vitro studies could be attributed to thermal energy transfer through the 
skin and to other tissues through blood flow. Although cell death could be observed 
histologically after the treatment, the overall inhibition of tumor growth even with 
combined DOX delivery was underwhelming (Fig. 5-18). The subpar efficacy of this 
preliminary in vivo study prompts the use of a multiday treatment regimen similar to the 
one used in the study by Troyer et al. Higher concentrations of IONPs or increased AMF 
field strength could also be utilized, but care was taken to prioritize apoptosis over 
induction of thermal ablation which could harm adjacent healthy tissue. Tuning the 
delivered thermal dose in conjunction with drug delivery to elicit a controlled apoptotic 
response within the growing tumor will require a more comprehensive parametric study to 





Developing IONPs for MRI and/or MFH biomedical applications requires careful 
consideration of the physicochemical properties of the particles in order to achieve peak 
efficiencies. Magnetic core size plays a critical role in the optimization process, as there 
exists strong dependencies for relaxivity and SAR that encompass specific size regimes 
where the governing mechanisms of these processes shift. In this work, we examined the 
influence of core size for MRI and MFH in solution, in vitro, and in vivo using a systematic 
array of IONPs from 6-40 nm in diameter with a controlled and uniform phospholipid-PEG 
coating. For both relaxivity and SAR, there was a linear dependence on core size up 
through 40 nm in size, suggesting the particles are within the size-dependent motion 
averaging regime for MR contrast, but the heating generation mechanism is unclear. Using 
an intratumoral injection, nanoparticles with cores of 6, 19, and 40 nm provided a high 
degree of contrast to clearly delineate the IONP distribution within the tumor. The 40 nm 
cores displayed the highest recorded T2 contrast and heat generation, causing cell death in 
vitro and in vivo even at low concentrations. Future studies will require further refinement 
of the synthesis process in order to create larger, monodisperse superparamagnetic core 
populations to experimentally probe the limits of the MRI and MFH size regimes. This 
work describes the therapeutic and diagnostic potential of iron oxide nanoparticles above 
the presumed superparamagnetic limit to reach clinically relevant levels in order to 




FUTURE CONSIDERATIONS  
In this work, phospholipid-PEG coated iron oxide nanoparticles were developed and 
optimized in terms of their core size and coating for effective drug delivery, heat 
generation, and magnetic resonance contrast. The drug loading mechanism utilizes 
partitioning of poorly soluble molecules into the lipid coating layer of the IONPs to create 
a drug delivery platform with high loading capacity which does not require chemical 
conjugation. Combining the drug delivery and hyperthermia potential of these IONPs has 
enabled an enhanced cancer therapy that could be a novel tool for oncologists looking to 
use multimodal treatments for their patients. By increasing the core size to 40 nm, the heat 
generation and MR contrast reached the highest recorded values to date. This work 
systematically covers a large range of sizes that span the magnetic regimes of magnetic 
nanoparticles and examines how the trends seen in vitro translate to a physiological 
environment. The observed results suggest that the predicted size cutoffs for these magnetic 
regimes may need to be reconsidered in the light of the experimental evidence. 
The studies in Chapter 3 illustrate how the concurrent delivery of Doxorubicin and 
heat contributed to an enhanced cell death. The discrepancies between the interaction of 
chemotherapeutics and hyperthermia amongst other work demonstrate the complexity of 
this interaction. The timing and sequence of the two treatment modalities has been shown 
to play a role in the cellular response where a clear difference in efficacy is observed 
between heat treatment before, during, or after drug exposure.[97, 100, 237, 238] In the 
context of SPIO-based hyperthermia and drug delivery, the asynchronous timing of each 
modality is further complicated by the transient release profile of the drug from the 
nanoparticles. Future studies aiming to maximize the therapeutic response to combination 
treatment should plan the timing of hyperthermia in relation to the drug release kinetics.  
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To better understand the interplay between magnetic fluid hyperthermia and 
chemotherapy, studies could be designed to probe components of the signaling pathway 
leading to apoptosis. Cleavage of Caspase-3 and PARP1 are well-characterized late-stage 
events in the mitochondrial pathway of apoptosis that can be identified via western 
blotting.[239-242] Bcl-2 and Bcl-xL are anti-apoptotic proteins upstream of mitochondrial 
cytochrome c release, and their suppression is another viable marker for apoptosis.[243-
245] By monitoring various stages of the apoptotic pathway, the protective effect of heat 
shock proteins can be examined. The heat shock proteins, the most prominent being HSP 
70, are the cell’s inherent defense against heat stress by acting as chaperones to refold 
denatured proteins and inhibiting multiple stages of the apoptotic signaling cascade.[246, 
247] The upregulation of the heat shock proteins following hyperthermia is associated with 
the development of thermal tolerance to subsequent heat treatments. The anti-apoptotic 
capacity of the heat shock proteins can also reduce drug efficacy due to the shared apoptotic 
pathways of hyperthermia and chemotherapy. Minimizing the induction and impact of the 
heat shock proteins through proper timing of hyperthermia will help prevent resistance to 
the overall therapy. Another strategy used by Ito et al. involved co-delivery of the HSP 90 
inhibitor, geldanamycin, and ferromagnetic particle hyperthermia resulting in a complete 
tumor regression compared to the individual treatments.[248] Future studies could 
investigate loading HSP inhibitors onto our IONPs for a similar goal.  
There are several areas where the in vivo studies in this work could be expanded. 
The setup and protocol used for the mouse magnetic fluid hyperthermia was an initial proof 
of concept to characterize the transient temperature profiles using the various core sizes. 
To design the experiments for maximum therapeutic response, a number a modifications 
could be employed. The ectopic subcutaneous xenograft tumor model suffices as a first 
step for testing treatments due to the ease and speed of induction, but it does not properly 
recapitulate the actual tumor microenvironment of the cancer cells in the native tissue.  An 
orthotopic tumor model where the human cancer cells are transplanted into the same tissue 
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in the mouse as the cancer cells originated from would be a more realistic model. The 
tumors would not be amenable to caliper measurement, so in order to measure tumor 
growth, the cancer cell line used would need to express a fluorescent protein or luciferase 
to be monitored with an optical imaging system. In the case of glioblastoma, an orthotopic 
model is especially challenging with respect to transplantation and imaging due to the 
presence of the skull surrounding the tissue. Magnetic resonance imaging would need to 
be used to measure tumor size, though the extremely low throughput makes large scale 
studies difficult.  
A larger animal model would also be beneficial for the hyperthermia studies. With 
intratumoral injections, the tumor needed to reach approximately 750 mm3 before the 
syringe could be properly inserted. At that stage of tumor development, the growth rate is 
very rapid with the tumor reaching the IACUC mandated size endpoint within a week’s 
time. This left a narrow window to perform the treatment and monitor the effects on tumor 
growth. Working with larger tumors in a rat model would facilitate longer growth studies 
that could be started at an earlier stage in tumor development. Further, multiday treatment 
regimens and an intratumoral injection spread across several sites within the tumor could 
be realized to improve overall treatment efficacy. Multiple hyperthermia treatment would 
allow for an analysis of the heat generation efficiency over repeated AMF applications, 
and the therapy would mirror the multiple dosing regimens of conventional chemotherapy 
and radiotherapy. Spreading the SPIO delivery into multiple smaller injections allows for 
better spatial control that can be tailored to the dimensions of the tumor, ensuring a more 
homogeneous heating throughout the tumor. 
The in vivo MFH temperature measurements in Chapter 5 were limited to a single 
point within the tumor due to the relative size of the thermal probe to the tumor. A critical 
factor in cancer treatment is ensuring that the entirety of the tumor tissue receives the 
necessary treatment dose for cell death. Hyperthermia therapy works on the same principle, 
so an understanding of the spatial temperature profile within the tumor would improve 
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thermal dosimetry and could prevent unwanted heating in the surrounding tissue. The MRI 
IONP distribution information could be used to model the temperature profile with 
knowledge of the SAR of the particles. Quantitative IONP concentration data is difficult 
to determine with MRI, and the concentrations used for MFH intratumoral injection are 
high enough to saturate the MR signal. A rough estimate could be determined based on the 
volume of distribution and the known amount of SPIO injected. A modeling approach 
using Pennes bioheat equation similar to the one used by Kappiyoor et al. and Salloum et 
al. could then map spatial temperature profiles during MFH.[249, 250]  
As eluded to previously, longer term in vivo studies that focus on biodistribution, 
metabolic breakdown, and the measurement of the IONP properties over time would aid 
our understanding of the interactions between IONPs and the body. The long term fate of 
the IONPs following intratumoral injection is worth investigating as a single nanoparticle 
injection could facilitate continued hyperthermia treatment, sustained drug release, and MR 
contrast long after the initial delivery. Clearance out of the tumor and degradation of the 
nanoparticles are two mechanisms that could hinder long term functionality of the IONPs. 
Clearance could occur through diffusion into lymphatic vessels or assisted by macrophage 
uptake. The DSPE-PEG coating stability has not yet been characterized for extended 
periods of time in a physiological environment, and if compromised, it may not effectively 
prevent macrophage recognition. It would be interesting to examine how the core size plays 
a role in IONP clearance since previous work using polymeric nanoparticles found larger 
particles were phagocytized more efficiently by macrophages.[251] 
Metabolism of iron oxide nanoparticles once in the body is still poorly understood. 
A few studies investigating how IONPs are metabolized by cells in the RES found evidence 
of the nanoparticles breaking down over the course of three months with a characteristic 
decrease in their superparamagnetic property.[23, 252] Loss of superparamagnetism and 
reduction in saturation magnetization would thus hinder long term use as contrast agents 
or mediators for hyperthermia. It is presumed that the iron is converted to poorly magnetic 
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species which are incorporated into the proteins ferritin and hemosiderin. In this context, 
core size and the PEG length would be important factors affecting the rate of SPIO 
degradation to study. The smaller surface area to volume ratio for larger sized cores would 
be beneficial to slow the degradation process and maintain superparamagnetism for longer 
periods of time. Furthermore, a longer PEG length could protect the metallic core from 
enzymatic degradation as well.  
One of the main issues faced in this work and with the current state of nanoparticle 
development is that only a few percent of systemically delivered nanoparticles localize to 
the tumor when relying upon the EPR effect. In order for systemic deliver of nanoparticles 
to be viable for magnetic fluid hyperthermia, IONP accumulation in the tumor needs to be 
improved. Active targeting through the conjugation of targeting ligands to the surface of 
the nanoparticle, whether they be antibodies, peptides, or small molecules, allows specific 
binding of the nanoparticles to a cell type of interest. It is critical to choose the proper target 
as the receptor needs to be highly expressed on the targeted cell for efficient binding, but 
under expressed on off-target cells to prevent nonspecific interactions. This issue is most 
prevalent with cancer therapy as it is difficult to find targets solely unique to the malignant 
cells which are not expressed by their healthy neighboring cells.[253] Another 
complication is the inherent heterogeneity such that even for a particular type of cancer, a 
universally effective target is rare and requires in-depth characterization of the subclass of 
an individual’s cancer.  
Conventional targeting has focused on receptors present on the cancer cells 
themselves, though these studies have been met with modest success as there is limited 
penetration into the tumor interstitium following extravasation from the vasculature.[254] 
One possible targeting strategy is the use of ligands specific to tumor vasculature 
endothelial markers. The angiogenic vessels within the tumor overexpress both ανβ3 and 
ανβ5 integrins which could be targeted without needing penetration into the tumor for 
binding.[255-257] By not relying upon the initial extravasation due to the EPR effect, early 
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stage tumors or metastases that have yet to develop the leaky vasculature necessary for the 
EPR effect could be targeted.  
An alternative targeting strategy would be to utilize methods to increase tissue 
penetration. Drug penetration through the tumor is reliant upon Fick’s law and due to the 
high interstitial pressure, diffusion only occurs to distances of about 40-50 µm, leaving 
many cells at sublethal drug concentrations.[258, 259] Nanoparticles are much larger in 
size in comparison to small molecules, further reducing diffusion distances as characterized 
by the Stokes-Einstein equation. Recent work involving tumor-penetrating peptides such 
as iRGD can bind to the tumor vasculature through the RGD motif and then be shuttled 
through tumor tissue along an endocytic bulk transport pathway due to the CendR 
motif.[260-262] Conjugating this peptide to the IONPs could enhance distribution within 
the tumor following systemic or intratumoral injection.  
The superparamagnetic property of the IONPs can also be applied towards 
accumulation and penetration into the tumor through either magnetic targeting or magnetic 
fluid hyperthermia. Magnetic targeting relies upon the response of IONPs within a 
magnetic field gradient to cause an attractive or repulsive force. The magnitude of the force 





where ∇𝐵 is the gradient of the magnetic field, χ is the magnetic susceptibility of the IONP, 
𝑉𝑐 is the magnetic core volume, and µ0 is the magnetic permeability of free space.[263] A 
larger core size will be beneficial for this function as it was for MR contrast and MFH. The 
magnetic force can be used to move IONPs to the perimeter of the tumor blood vessels to 
promote extravasation and/or resist the hydrodynamic drag forces from blood flow to 
enhance retention within the tumor. This approach has seen success in a squamous cell 
carcinoma rabbit model to deliver the drug mitoxantrone using an intraarterial injection 
and an electromagnet to generate the magnetic field gradient.[264] Schleich et al., 
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combined magnetic targeting with ανβ3 integrin targeting to improve delivery of Paclitaxel 
to colon carcinomas in mice.[265] Once within the tumor, the magnetic force could be used 
to drag the IONPs past conventional diffusion limits for a wider intratumoral distribution. 
Designing the appropriate setup to generate magnetic field gradients for clinical use will 
be challenging especially for tumors located deep in the body and will require extensive 
magnetic field modeling.[266, 267] 
Hyperthermia has been shown to enhance extravasation of liposomes by increasing 
the size of the pores in the tumor endothelium.[164] With IONPs capable of generating 
local heat within the tumor through MFH, a feedforward mechanism could be envisioned 
where accumulation of IONPs within the tumor could help additional IONPs extravasate 
into the tumor, increasing the local concentration and thus increasing the local temperature. 
The timing and temperatures used for hyperthermia-enhanced IONP accumulation would 
need to be well-controlled as has been seen with liposomes.[268] The increased blood flow 
associated with inflammation temperatures (up to 42oC) can also enhance extravasation 
until nanoparticle concentrations able to sustain apoptotic temperatures are reached.  
A conscious design choice when developing the IONPs in this work was to avoid 
using chemical conjugation for drug loading in order to leave open the potential for 
additional functionalities. The PEG chains on the outer surface of the IONPs can easily 
incorporate functional groups such as amine, carboxyl, or maleimide for a host of 
conjugation methods to employ. Previous work in our lab has utilized this conjugation 
potential to attach antibodies targeting folate and VEGF, chelators for radiolabeling, and 
the RGD peptide.[64, 65] Radiolabeling offers an accurate quantitative measure to perform 
biodistribution studies through PET imaging, and targeting ligand conjugation enables 
active targeting to further enhance specificity for IONP delivery. Drugs not amenable to 
passive loading into the lipid layer of the SPIO could be conjugated to the surface which 
also facilitates multi-drug loading and triggered drug release mechanisms. Dilnawaz et al. 
developed an IONP capable of loading both Paclitaxel and Rapamycin into the glycerol 
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monooleate coating and conjugated the HER2 antibody for cancer targeting.[85] This type 
of multidrug loading and active targeting could be applied to our DSPE-PEG coated 
IONPs.  
Conjugation of additional functionalities comes at the price of raising the 
complexity of the particle, making synthesis more costly, difficult, and time-consuming. 
Optimization for each of the functionalities can also lead to conflicting priorities such that 
the final design incorporates many functions, but is subpar at each.[253] Lastly, increased 
complexity raises the bar for regulatory hurdles that must be overcome to eventually 
achieve the ultimate goal of clinical translation. The greater number of moieties present on 
the nanoparticle necessitate further characterization to ensure safety in a regulatory 
landscape already cautious to the idea nanoparticle therapeutics. These tradeoffs should be 
weighed early in design as well as during evaluation before each transition step in 
development. Thus, the design and development of nanoparticles for biomedical 
applications walks a fine line between achieving greater utility and efficacy against 
creating an over-engineered particle that loses sight of its original purpose. The tradeoffs 
of additional functionalities must be weighed against the potential benefits  
The iron oxide nanoparticle platform described in this work is unique in relation to 
other classes of nanoparticles because most of its multifunctionality stems solely from the 
magnetic metallic core. Magnetic resonance imaging, magnetic fluid hyperthermia, and 
magnetic guidance all benefit from optimization of similar parameters such as high 
saturation magnetization, minimal coercivity, high magnetic anisotropy, and large core 
size. With the exception of very large core size, these properties should not affect biological 
performance in terms of circulation half-life, biodistribution, extravasation, cell 
internalization, metabolism, excretion, and overall biocompatibility. We found the 40 nm 
cores to generate the largest amount of heat and MR contrast, and even with the coating 
hydrodynamic diameter of 52 nm, the size should not compromise biological performance. 
The phospholipid-PEG coating that interacts with the environment can be tuned 
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independent of the core size for the particular functionalities to be utilized. From this work 
and previous work in the lab, the PEG 2000 length should be optimal for hyperthermia, 
MRI, and drug delivery.[65] At this point, what remains to be decided is the appropriate 
surface functionalization, whether it be targeting, tumor penetration, or addition of a 
secondary imaging modality, that has the most favorable cost/benefit ratio for clinical 






[1] P. Weiss, "La variation du ferromagnétisme avec la température," Comptes 
Rendus, vol. 143, p. 1136, 1906. 
[2] E. C. Stoner and E. Wohlfarth, "A mechanism of magnetic hysteresis in 
heterogeneous alloys," Philosophical Transactions of the Royal Society of London 
A: Mathematical, Physical and Engineering Sciences, vol. 240, pp. 599-642, 
1948. 
[3] J. Eisenmenger and I. K. Schuller, "Magnetic nanostructures: overcoming thermal 
fluctuations," Nature materials, vol. 2, pp. 437-438, 2003. 
[4] L. Néel, "Theory of the magnetic after-effect in ferromagnetics in the form of 
small particles, with applications to baked clays," Ann. Geophys.(CNRS), vol. 5, 
pp. 99-136, 1949. 
[5] W. F. Brown Jr, "Thermal fluctuations of a single‐domain particle," Journal of 
Applied Physics, vol. 34, pp. 1319-1320, 1963. 
[6] M. Etheridge, N. Manuchehrabadi, R. Franklin, and J. Bischof, 
"Superparamagnetic iron oxide nanoparticle heating: A basic tutorial," 
Nanoparticle Heat Transfer and Fluid Flow, pp. 97-121, 2012. 
[7] P. Chandrasekharan, D. Maity, C. X. Yong, K. H. Chuang, J. Ding, and S. S. 
Feng, "Vitamin E (D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) 
micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy 
and MRI," Biomaterials, vol. 32, pp. 5663-72, Aug 2011. 
[8] V. S. Kalambur, B. Han, B. E. Hammer, T. W. Shield, and J. C. Bischof, "In vitro 
characterization of movement, heating and visualization of magnetic 
nanoparticles for biomedical applications," Nanotechnology, vol. 16, pp. 1221-
1233, 2005. 
[9] N. Landazuri, S. Tong, J. Suo, G. Joseph, D. Weiss, D. J. Sutcliffe, et al., 
"Magnetic targeting of human mesenchymal stem cells with internalized 
superparamagnetic iron oxide nanoparticles," Small, vol. 9, pp. 4017-26, Dec 9 
2013. 
[10] G. Y. Lee, W. P. Qian, L. Wang, Y. A. Wang, C. A. Staley, M. Satpathy, et al., 
"Theranostic nanoparticles with controlled release of gemcitabine for targeted 
therapy and MRI of pancreatic cancer," ACS Nano, vol. 7, pp. 2078-2089, 2013. 
[11] T. R. Sathe, A. Agrawal, and S. Nie, "Mesoporous silica beads embedded with 
semiconductor quantum dots and iron oxide nanocrystals dual-function 
microcarriers for optical encoding and magnetic separation," Analytical 
Chemistry, vol. 78, pp. 5627-5632, 2006. 
[12] C. Sun, K. Du, C. Fang, N. Bhattarai, O. Veiseh, F. M. Kievit, et al., "PEG-
Mediated Synthesis of Highly Dispersive Multifunctional Superparamagnetic 
Nanoparticles: Their Physicochemical Properties and Function In Vivo," ACS 
Nano, vol. 4, pp. 2402-2410, 2010. 
136 
 
[13] C. T. Yavuz, J. T. Mayo, W. W. Yu, A. Prakash, J. C. Falkner, S. Yean, et al., 
"Low-field magnetic separation of monodisperse Fe3O4 nanocrystals," Science, 
vol. 314, pp. 964-7, Nov 10 2006. 
[14] Y. Ling, K. Wei, Y. Luo, X. Gao, and S. Zhong, "Dual 
docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting 
magnetic resonance imaging and cancer therapy," Biomaterials, vol. 32, pp. 7139-
7150, 2011. 
[15] X. Yang, J. J. Grailer, I. J. Rowland, A. Javadi, S. A. Hurley, D. A. Steeber, et al., 
"Multifunctional SPIO/DOX-loaded wormlike polymer vesicles for cancer 
therapy and MR imaging," Biomaterials, vol. 31, pp. 9065-73, Dec 2010. 
[16] X. Yang, H. Hong, J. J. Grailer, I. J. Rowland, A. Javadi, S. A. Hurley, et al., 
"cRGD-functionalized, DOX-conjugated, and 64 Cu-labeled superparamagnetic 
iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR 
imaging," Biomaterials, vol. 32, pp. 4151-4160, 2011. 
[17] H. J. Broxterman, J. Lankelma, and K. Hoekman, "Resistance to cytotoxic and 
anti-angiogenic anticancer agents: similarities and differences," Drug resistance 
updates, vol. 6, pp. 111-127, 2003. 
[18] S. Goodwin, C. Peterson, C. Hoh, and C. Bittner, "Targeting and retention of 
magnetic targeted carriers (MTCs) enhancing intra-arterial chemotherapy," 
Journal of Magnetism and Magnetic Materials, vol. 194, pp. 132-139, 1999. 
[19] B. Chertok, B. A. Moffat, A. E. David, F. Yu, C. Bergemann, B. D. Ross, et al., 
"Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic 
targeting of brain tumors," Biomaterials, vol. 29, pp. 487-496, 2008. 
[20] C. Alexiou, R. Jurgons, R. J. Schmid, C. Bergemann, J. Henke, W. Erhardt, et al., 
"Magnetic drug targeting--biodistribution of the magnetic carrier and the 
chemotherapeutic agent mitoxantrone after locoregional cancer treatment," J 
Drug Target, vol. 11, pp. 139-49, Apr 2003. 
[21] L. Gu, R. H. Fang, M. J. Sailor, and J.-H. Park, "In vivo clearance and toxicity of 
monodisperse iron oxide nanocrystals," ACS nano, vol. 6, pp. 4947-4954, 2012. 
[22] R. a. Weissleder, D. Stark, B. Engelstad, B. Bacon, C. Compton, D. White, et al., 
"Superparamagnetic iron oxide: pharmacokinetics and toxicity," American 
Journal of Roentgenology, vol. 152, pp. 167-173, 1989. 
[23] K. Briley-Saebo, A. Bjørnerud, D. Grant, H. Ahlstrom, T. Berg, and G. M. 
Kindberg, "Hepatic cellular distribution and degradation of iron oxide 
nanoparticles following single intravenous injection in rats: implications for 
magnetic resonance imaging," Cell and tissue research, vol. 316, pp. 315-323, 
2004. 
[24] B. S. Spinowitz, A. T. Kausz, J. Baptista, S. D. Noble, R. Sothinathan, M. V. 
Bernardo, et al., "Ferumoxytol for treating iron deficiency anemia in CKD," J Am 
Soc Nephrol, vol. 19, pp. 1599-605, Aug 2008. 
[25] S. Qu, H. Yang, D. Ren, S. Kan, G. Zou, D. Li, et al., "Magnetite nanoparticles 
prepared by precipitation from partially reduced ferric chloride aqueous 
solutions," Journal of colloid and interface science, vol. 215, pp. 190-192, 1999. 
[26] Y. S. Kang, S. Risbud, J. F. Rabolt, and P. Stroeve, "Synthesis and 
characterization of nanometer-size Fe3O4 and γ-Fe2O3 particles," Chemistry of 
Materials, vol. 8, pp. 2209-2211, 1996. 
137 
 
[27] R. S. Molday and D. Mackenzie, "Immunospecific ferromagnetic iron-dextran 
reagents for the labeling and magnetic separation of cells," Journal of 
immunological methods, vol. 52, pp. 353-367, 1982. 
[28] R. Weissleder, G. Elizondo, J. Wittenberg, C. Rabito, H. Bengele, and L. 
Josephson, "Ultrasmall superparamagnetic iron oxide: characterization of a new 
class of contrast agents for MR imaging," Radiology, vol. 175, pp. 489-493, 1990. 
[29] M. Pileni, "Reverse micelles as microreactors," The Journal of physical 
chemistry, vol. 97, pp. 6961-6973, 1993. 
[30] Y. Deng, L. Wang, W. Yang, S. Fu, and A. Elaıssari, "Preparation of magnetic 
polymeric particles via inverse microemulsion polymerization process," Journal 
of magnetism and magnetic materials, vol. 257, pp. 69-78, 2003. 
[31] V. Pillai, P. Kumar, M. Hou, P. Ayyub, and D. Shah, "Preparation of 
nanoparticles of silver halides, superconductors and magnetic materials using 
water-in-oil microemulsions as nano-reactors," Advances in Colloid and Interface 
Science, vol. 55, pp. 241-269, 1995. 
[32] C. T. Seip, E. E. Carpenter, C. J. Connor, V. T. John, and S. Li, "Magnetic 
properties of a series of ferrite nanoparticles synthesized in reverse micelles," 
Magnetics, IEEE Transactions on, vol. 34, pp. 1111-1113, 1998. 
[33] X. Wang, J. Zhuang, Q. Peng, and Y. Li, "A general strategy for nanocrystal 
synthesis," Nature, vol. 437, pp. 121-124, 2005. 
[34] K. S. Suslick, M. Fang, and T. Hyeon, "Sonochemical synthesis of iron colloids," 
Journal of the American Chemical Society, vol. 118, pp. 11960-11961, 1996. 
[35] T. G. Carreño, A. Mifsud, C. Serna, and J. Palacios, "Preparation of homogeneous 
ZnCo mixed oxides by spray pyrolysis," Materials chemistry and physics, vol. 27, 
pp. 287-296, 1991. 
[36] S. Veintemillas‐Verdaguer, M. Morales, and C. Serna, "Effect of the oxidation 
conditions on the maghemites produced by laser pyrolysis," Applied 
organometallic chemistry, vol. 15, pp. 365-372, 2001. 
[37] T. Tillotson, A. Gash, R. Simpson, L. Hrubesh, J. Satcher, and J. Poco, 
"Nanostructured energetic materials using sol–gel methodologies," Journal of 
Non-Crystalline Solids, vol. 285, pp. 338-345, 2001. 
[38] Y. Okamura, H. Takeyama, and T. Matsunaga, "A Magnetosome-specific GTPase 
from the Magnetic BacteriumMagnetospirillum magneticum AMB-1," Journal of 
Biological Chemistry, vol. 276, pp. 48183-48188, 2001. 
[39] E. Alphandery, S. Faure, O. Seksek, F. o. Guyot, and I. Chebbi, "Chains of 
magnetosomes extracted from AMB-1 magnetotactic bacteria for application in 
alternative magnetic field cancer therapy," ACS nano, vol. 5, pp. 6279-6296, 
2011. 
[40] C. Murray, D. J. Norris, and M. G. Bawendi, "Synthesis and characterization of 
nearly monodisperse CdE (E= sulfur, selenium, tellurium) semiconductor 
nanocrystallites," Journal of the American Chemical Society, vol. 115, pp. 8706-
8715, 1993. 
[41] S. Sun and H. Zeng, "Size-controlled synthesis of magnetite nanoparticles," 
Journal of the American Chemical Society, vol. 124, pp. 8204-8205, 2002. 
[42] T. Hyeon, S. S. Lee, J. Park, Y. Chung, and H. B. Na, "Synthesis of highly 
crystalline and monodisperse maghemite nanocrystallites without a size-selection 
138 
 
process," Journal of the American Chemical Society, vol. 123, pp. 12798-12801, 
2001. 
[43] T.-D. Nguyen and T.-O. Do, Size-and shape-controlled synthesis of monodisperse 
metal oxide and mixed oxide nanocrystals: INTECH Open Access Publisher, 
2011. 
[44] J. Park, K. An, Y. Hwang, J. G. Park, H. J. Noh, J. Y. Kim, et al., "Ultra-large-
scale syntheses of monodisperse nanocrystals," Nat Mater, vol. 3, pp. 891-5, Dec 
2004. 
[45] J. Park, E. Lee, N. M. Hwang, M. Kang, S. C. Kim, Y. Hwang, et al., "One-
nanometer-scale size-controlled synthesis of monodisperse magnetic iron oxide 
nanoparticles," Angew Chem Int Ed Engl, vol. 44, pp. 2873-7, May 6 2005. 
[46] W. W. Yu, J. C. Falkner, C. T. Yavuz, and V. L. Colvin, "Synthesis of 
monodisperse iron oxide nanocrystals by thermal decomposition of iron 
carboxylate salts," Chem Commun (Camb), pp. 2306-7, Oct 21 2004. 
[47] J. Cheon, N.-J. Kang, S.-M. Lee, J.-H. Lee, J.-H. Yoon, and S. J. Oh, "Shape 
evolution of single-crystalline iron oxide nanocrystals," Journal of the American 
Chemical Society, vol. 126, pp. 1950-1951, 2004. 
[48] Y. Yin and A. P. Alivisatos, "Colloidal nanocrystal synthesis and the organic-
inorganic interface," Nature, vol. 437, pp. 664-70, Sep 29 2005. 
[49] U. I. Tromsdorf, N. C. Bigall, M. G. Kaul, O. T. Bruns, M. S. Nikolic, B. 
Mollwitz, et al., "Size and surface effects on the MRI relaxivity of manganese 
ferrite nanoparticle contrast agents," Nano letters, vol. 7, pp. 2422-2427, 2007. 
[50] S. Sun, H. Zeng, D. B. Robinson, S. Raoux, P. M. Rice, S. X. Wang, et al., 
"Monodisperse MFe2O4 (M= Fe, Co, Mn) nanoparticles," Journal of the 
American Chemical Society, vol. 126, pp. 273-279, 2004. 
[51] J. Xie, S. Peng, N. Brower, N. Pourmand, S. X. Wang, and S. Sun, "One-pot 
synthesis of monodisperse iron oxide nanoparticles for potential biomedical 
applications," Pure and Applied Chemistry, vol. 78, 2006. 
[52] A. P. Khandhar, R. M. Ferguson, J. A. Simon, and K. M. Krishnan, "Tailored 
magnetic nanoparticles for optimizing magnetic fluid hyperthermia," J Biomed 
Mater Res A, vol. 100, pp. 728-37, Mar 2012. 
[53] M. F. Kircher, U. Mahmood, R. S. King, R. Weissleder, and L. Josephson, "A 
multimodal nanoparticle for preoperative magnetic resonance imaging and 
intraoperative optical brain tumor delineation," Cancer research, vol. 63, pp. 
8122-8125, 2003. 
[54] A. Koch, F. Reynolds, M. Kircher, H. Merkle, R. Weissleder, and L. Josephson, 
"Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells," 
Bioconjugate chemistry, vol. 14, pp. 1115-1121, 2003. 
[55] S. J. DeNardo, G. L. DeNardo, L. A. Miers, A. Natarajan, A. R. Foreman, C. 
Gruettner, et al., "Development of tumor targeting bioprobes ((111)In-chimeric 
L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer 
therapy," Clin Cancer Res, vol. 11, pp. 7087s-7092s, Oct 1 2005. 
[56] W. Y. William, E. Chang, C. M. Sayes, R. Drezek, and V. L. Colvin, "Aqueous 
dispersion of monodisperse magnetic iron oxide nanocrystals through phase 
transfer," Nanotechnology, vol. 17, p. 4483, 2006. 
139 
 
[57] T. Pellegrino, L. Manna, S. Kudera, T. Liedl, D. Koktysh, A. L. Rogach, et al., 
"Hydrophobic nanocrystals coated with an amphiphilic polymer shell: a general 
route to water soluble nanocrystals," Nano letters, vol. 4, pp. 703-707, 2004. 
[58] A. L. Klibanov, K. Maruyama, V. P. Torchilin, and L. Huang, "Amphipathic 
polyethyleneglycols effectively prolong the circulation time of liposomes," FEBS 
letters, vol. 268, pp. 235-237, 1990. 
[59] Z. G. Gao, A. N. Lukyanov, A. Singhal, and V. P. Torchilin, "Diacyllipid-
polymer micelles as nanocarriers for poorly soluble anticancer drugs," Nano 
Letters, vol. 2, pp. 979-982, Sep 2002. 
[60] A. Gabizon and D. Papahadjopoulos, "Liposome formulations with prolonged 
circulation time in blood and enhanced uptake by tumors," Proceedings of the 
National Academy of Sciences, vol. 85, pp. 6949-6953, 1988. 
[61] B. Dubertret, P. Skourides, D. J. Norris, V. Noireaux, A. H. Brivanlou, and A. 
Libchaber, "In vivo imaging of quantum dots encapsulated in phospholipid 
micelles," Science, vol. 298, pp. 1759-62, Nov 29 2002. 
[62] L. E. LaConte, N. Nitin, O. Zurkiya, D. Caruntu, C. J. O'Connor, X. Hu, et al., 
"Coating thickness of magnetic iron oxide nanoparticles affects R2 relaxivity," J 
Magn Reson Imaging, vol. 26, pp. 1634-41, Dec 2007. 
[63] C. Glaus, R. Rossin, M. J. Welch, and G. Bao, "In vivo evaluation of 64Cu-
labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent," 
Bioconjugate chemistry, vol. 21, pp. 715-722, 2010. 
[64] S. Tong, S. Hou, B. Ren, Z. Zheng, and G. Bao, "Self-assembly of phospholipid-
PEG coating on nanoparticles through dual solvent exchange," Nano Lett, vol. 11, 
pp. 3720-6, Sep 14 2011. 
[65] S. Tong, S. Hou, Z. Zheng, J. Zhou, and G. Bao, "Coating optimization of 
superparamagnetic iron oxide nanoparticles for high T2 relaxivity," Nano Lett, 
vol. 10, pp. 4607-13, Nov 10 2010. 
[66] C. A. Lipinski, "Poor aqueous solubility-an industry wide problem in ADME 
screening," American Pharmaceutical Review, vol. 5, pp. 82-85, 2002. 
[67] C. A. Lipinski, "Lipinski Drug-like properties and the causes of poor solubility 
and poor permeability," Journal of Pharmacological and Toxicological Methods, 
vol. 44, pp. 235-249, 2000. 
[68] T. M. Allen and P. R. Cullis, "Drug delivery systems: entering the mainstream," 
Science, vol. 303, pp. 1818-22, Mar 19 2004. 
[69] M. E. Davis, Z. G. Chen, and D. M. Shin, "Nanoparticle therapeutics: an 
emerging treatment modality for cancer," Nat Rev Drug Discov, vol. 7, pp. 771-
82, Sep 2008. 
[70] Y. Matsumura and H. Maeda, "A New Concept for Macromolecular Therapeutics 
in Cancer Chemotherapy : Mechanism of Tumoritropic Accumulation of Proteins 
and the Antitumor Agent Smancs A New Concept for Macromolecular 
Therapeutics in Cancer Chemotherapy : Mechanism of Tumoritropic Accum," 
Cancer Research, vol. 46, pp. 6387-6392, 1986. 
[71] M. M. Gottesman, T. Fojo, and S. E. Bates, "Multidrug resistance in cancer: role 
of ATP-dependent transporters," Nat Rev Cancer, vol. 2, pp. 48-58, Jan 2002. 
140 
 
[72] F. M. Kievit, F. Y. Wang, C. Fang, H. Mok, K. Wang, J. R. Silber, et al., 
"Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in 
cancer in vitro," J Control Release, vol. 152, pp. 76-83, May 30 2011. 
[73] A. N. Gordon, J. T. Fleagle, D. Guthrie, D. E. Parkin, M. E. Gore, and A. J. 
Lacave, "Recurrent epithelial ovarian carcinoma: a randomized phase III study of 
pegylated liposomal doxorubicin versus topotecan," Journal of clinical oncology, 
vol. 19, pp. 3312-3322, 2001. 
[74] R. E. Eliaz, S. Nir, C. Marty, and F. C. Szoka, "Determination and modeling of 
kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in 
targeted liposomes," Cancer research, vol. 64, pp. 711-718, 2004. 
[75] M. E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, et al., 
"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated 
liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin 
for first-line treatment of metastatic breast cancer," Ann Oncol, vol. 15, pp. 440-9, 
Mar 2004. 
[76] A. Gabizon, H. Shmeeda, and Y. Barenholz, "Pharmacokinetics of pegylated 
liposomal Doxorubicin: review of animal and human studies," Clin 
Pharmacokinet, vol. 42, pp. 419-36, 2003. 
[77] A. Rahman, D. Carmichael, M. Harris, and J. K. Roh, "Comparative 
pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin 
liposomes," Cancer Res, vol. 46, pp. 2295-9, May 1986. 
[78] V. P. Torchilin, "Recent advances with liposomes as pharmaceutical carriers," Nat 
Rev Drug Discov, vol. 4, pp. 145-60, Feb 2005. 
[79] F. M. Kievit, Z. R. Stephen, O. Veiseh, H. Arami, T. Wang, V. P. Lai, et al., 
"Targeting of primary breast cancers and metastases in a transgenic mouse model 
using rationally designed multifunctional SPIONs," ACS nano, vol. 6, pp. 2591-
2601, 2012. 
[80] K. Kaaki, K. Herve-Aubert, M. Chiper, A. Shkilnyy, M. Souce, R. Benoit, et al., 
"Magnetic nanocarriers of doxorubicin coated with poly(ethylene glycol) and 
folic acid: relation between coating structure, surface properties, colloidal 
stability, and cancer cell targeting," Langmuir, vol. 28, pp. 1496-505, Jan 17 
2012. 
[81] J. L. Arias, M. Ruiz, V. Gallardo, and A. V. Delgado, "Tegafur loading and 
release properties of magnetite/poly(alkylcyanoacrylate) (core/shell) 
nanoparticles," J Control Release, vol. 125, pp. 50-8, Jan 4 2008. 
[82] C. A. Lipinski, "Drug-like properties and the causes of poor solubility and poor 
permeability," Journal of pharmacological and toxicological methods, vol. 44, 
pp. 235-249, 2000. 
[83] T. K. Jain, M. K. Reddy, M. A. Morales, D. L. Leslie-Pelecky, and V. 
Labhasetwar, "Biodistribution, clearance, and biocompatibility of iron oxide 
magnetic nanoparticles in rats," Molecular pharmaceutics, vol. 5, pp. 316-327, 
2008. 
[84] T. K. Jain, M. A. Morales, S. K. Sahoo, D. L. Leslie-Pelecky, and V. 
Labhasetwar, "Iron oxide nanoparticles for sustained delivery of anticancer 
agents," Molecular Pharmaceutics, vol. 2, pp. 194-205, 2005. 
141 
 
[85] F. Dilnawaz, A. Singh, C. Mohanty, and S. K. Sahoo, "Dual drug loaded 
superparamagnetic iron oxide nanoparticles for targeted cancer therapy," 
Biomaterials, vol. 31, pp. 3694-706, May 2010. 
[86] M. M. Yallapu, S. P. Foy, T. K. Jain, and V. Labhasetwar, "PEG-functionalized 
magnetic nanoparticles for drug delivery and magnetic resonance imaging 
applications," Pharm Res, vol. 27, pp. 2283-95, Nov 2010. 
[87] T. K. Jain, S. P. Foy, B. Erokwu, S. Dimitrijevic, C. A. Flask, and V. 
Labhasetwar, "Magnetic resonance imaging of multifunctional pluronic stabilized 
iron-oxide nanoparticles in tumor-bearing mice," Biomaterials, vol. 30, pp. 6748-
56, Dec 2009. 
[88] Y. Sakaguchi, L. C. Stephens, M. Makino, T. Kaneko, F. R. Strebel, L. L. 
Danhauser, et al., "Apoptosis in tumors and normal tissues induced by whole 
body hyperthermia in rats," Cancer Res, vol. 55, pp. 5459-64, Nov 15 1995. 
[89] T. Komata, T. Kanzawa, T. Nashimoto, H. Aoki, S. Endo, M. Nameta, et al., 
"Mild heat shock induces autophagic growth arrest, but not apoptosis in U251-
MG and U87-MG human malignant glioma cells," J Neurooncol, vol. 68, pp. 101-
11, Jun 2004. 
[90] E. Vorotnikova, R. Ivkov, A. Foreman, M. Tries, and S. J. Braunhut, "The 
magnitude and time-dependence of the apoptotic response of normal and 
malignant cells subjected to ionizing radiation versus hyperthermia," Int J Radiat 
Biol, vol. 82, pp. 549-59, Aug 2006. 
[91] B. V. Harmon, Y. S. Takano, C. M. Winterford, and G. C. Gobe, "The role of 
apoptosis in the response of cells and tumours to mild hyperthermia," Int J Radiat 
Biol, vol. 59, pp. 489-501, Feb 1991. 
[92] K. S. Sellins and J. J. Cohen, "Hyperthermia induces apoptosis in thymocytes," 
Radiation Research, vol. 126, pp. 88-95, 1991. 
[93] J. L. Roti Roti, H. H. Kampinga, R. S. Malyapa, W. D. Wright, R. P. vanderWaal, 
and M. Xu, "Nuclear matrix as a target for hyperthmic killing of cancer cells," 
Cell Stress & Chaperones, vol. 3, pp. 245-255, 1998. 
[94] C. W. Song, J. G. Rhee, and S. H. Levitt, "Blood flow in normal tissues and 
tumors during hyperthermia," Journal of the National Cancer Institute, vol. 64, 
pp. 119-124, 1980. 
[95] C. W. Song, M. S. Kang, J. G. Rhee, and S. H. Levitt, "The effect of hyperthermia 
on vascular function, pH, and cell survival," Radiology, vol. 137, pp. 795-803, 
1980. 
[96] C. W. Song, "Effect of local hyperthermia on blood flow and microenvironment: 
a review," Cancer Research, vol. 44, pp. 4721s-4730s, 1984. 
[97] B. Hildebrandt, P. Wust, O. Ahlers, A. Dieing, G. Sreenivasa, T. Kerner, et al., 
"The cellular and molecular basis of hyperthermia," Critical Reviews in Oncology 
Hematology, vol. 43, pp. 33-56, 2002. 
[98] P. Wust, B. Hildebrandt, G. Sreenivasa, B. Rau, J. Gellermann, H. Riess, et al., 
"Hyperthermia in combined treatment of cancer," The Lancet Oncology, vol. 3, 
pp. 487-497, 2002. 
[99] P. Wust, H. Stahl, K. Dieckmann, S. Scheller, J. Loffel, H. Riess, et al., "Local 
hyperthermia of N2/N3 cervical lymph node metastases: correlation of 
142 
 
technical/thermal parameters and response," Int. J. Radiation Oncology Biol. 
Phys., vol. 34, pp. 635-646, 1996. 
[100] J. M. C. Bull, "An update on the anticancer effects of a combination of 
chemotherapy and hyperthermia," Cancer Research, vol. 44, pp. 4853s-4856s, 
1984. 
[101] J. Marmor, F. Hilerio, and G. Hahn, "Tumor eradication and cell survival after 
localized hyperthermia induced by ultrasound," Cancer Research, vol. 39, pp. 
2166-2171, 1979. 
[102] H. Kawai, Y. Minamiya, M. Kitamura, I. Matsuzaki, M. Hashimoto, H. Suzuki, et 
al., "Direct measurement of doxorubicin concentration in the intact, living single 
cancer cell during hyperthermia," Cancer Cell, vol. 79, pp. 214-219, 1997. 
[103] G. Hahn, J. Braun, and I. Har-Kedar, "Thermochemotherapy: Synergism Between 
Hyperthermia (42-43) and Adriamycin (or Bleomycin) in Mammalian Cell 
Inactivation," Proceedings of the National Academy of Sciences, vol. 72, pp. 937-
940, 1975. 
[104] M. I. Shliomis, A. F. Pshenichnikov, K. I. Morozov, and I. Y. Shurubor, 
"Magnetic Properties of Ferrocolloids," Journal of magnetism and magnetic 
materials, vol. 85, pp. 40-46, 1990. 
[105] M. Hanson, "The frequency dependence of the complex susceptibility of magnetic 
liquids," Journal of magnetism and magnetic materials, vol. 96, pp. 105-113 
1991. 
[106] R. E. Rosensweig, "Heating magnetic fluid with alternating magnetic field," 
Journal of magnetism and magnetic materials, vol. 252, pp. 370-374, 2002. 
[107] L. Lartigue, C. Innocenti, T. Kalaivani, A. Awwad, M. Sanchez Duque Mdel, Y. 
Guari, et al., "Water-dispersible sugar-coated iron oxide nanoparticles. An 
evaluation of their relaxometric and magnetic hyperthermia properties," J Am 
Chem Soc, vol. 133, pp. 10459-72, Jul 13 2011. 
[108] L. C. Kennedy, L. R. Bickford, N. A. Lewinski, A. J. Coughlin, Y. Hu, E. S. Day, 
et al., "A new era for cancer treatment: gold-nanoparticle-mediated thermal 
therapies," Small, vol. 7, pp. 169-83, Jan 17 2011. 
[109] M. Domenech, I. Marrero-Berrios, M. Torres-Lugo, and C. Rinaldi, "Lysosomal 
membrane permeabilization by targeted magnetic nanoparticles in alternating 
magnetic fields," ACS nano, vol. 7, pp. 5091-5101, 2013. 
[110] R. Gilchrist, R. Medal, W. D. Shorey, R. C. Hanselman, J. C. Parrott, and C. B. 
Taylor, "Selective inductive heating of lymph nodes," Annals of surgery, vol. 146, 
p. 596, 1957. 
[111] M. Sato, T. Yamashita, M. Ohkura, Y. Osai, A. Sato, T. Takada, et al., "N-
propionyl-cysteaminylphenol-magnetite conjugate (NPrCAP/M) is a nanoparticle 
for the targeted growth suppression of melanoma cells," J Invest Dermatol, vol. 
129, pp. 2233-41, Sep 2009. 
[112] M. T. Basel, S. Balivada, H. Wang, T. B. Shrestha, G. M. Seo, M. Pyle, et al., 
"Cell-delivered magnetic nanoparticles caused hyperthermia-mediated increased 
survival in a murine pancreatic cancer model," Int J Nanomedicine, vol. 7, pp. 
297-306, 2012. 
[113] P. Wust, U. Gneveckow, P. Wust, U. Gneveckow, M. Johannsen, D. Böhmer, et 
al., "Magnetic nanoparticles for interstitial thermotherapy – feasibility, tolerance 
143 
 
and achieved temperatures," International Journal of Hyperthermia, vol. 22, pp. 
673-685, 2006. 
[114] R. A. Brooks, F. Moiny, and P. Gillis, "On T2‐shortening by weakly magnetized 
particles: The chemical exchange model†," Magnetic Resonance in Medicine, vol. 
45, pp. 1014-1020, 2001. 
[115] R. A. Brooks, "T(2)-shortening by strongly magnetized spheres: a chemical 
exchange model," Magn Reson Med, vol. 47, pp. 388-91, Feb 2002. 
[116] P. Gillis and S. H. Koenig, "Transverse relaxation of solvent protons induced by 
magnetized spheres: Application to ferritin, erythrocytes, and magnetite," 
Magnetic Resonance in Medicine, vol. 5, pp. 323-345, 1987. 
[117] M. Lewin, N. Carlesso, C.-H. Tung, X.-W. Tang, D. Cory, D. T. Scadden, et al., 
"Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and 
recovery of progenitor cells," Nature biotechnology, vol. 18, pp. 410-414, 2000. 
[118] R. Weissleder, A. Moore, U. Mahmood, R. Bhorade, H. Benveniste, E. A. 
Chiocca, et al., "In vivo magnetic resonance imaging of transgene expression," 
Nature medicine, vol. 6, pp. 351-354, 2000. 
[119] W. S. Enochs, G. Harsh, F. Hochberg, and R. Weissleder, "Improved delineation 
of human brain tumors on MR images using a long‐circulating, 
superparamagnetic iron oxide agent," Journal of Magnetic Resonance Imaging, 
vol. 9, pp. 228-232, 1999. 
[120] M. E. Kooi, V. Cappendijk, K. Cleutjens, A. Kessels, P. Kitslaar, M. Borgers, et 
al., "Accumulation of ultrasmall superparamagnetic particles of iron oxide in 
human atherosclerotic plaques can be detected by in vivo magnetic resonance 
imaging," Circulation, vol. 107, pp. 2453-2458, 2003. 
[121] S. G. Ruehm, C. Corot, P. Vogt, S. Kolb, and J. F. Debatin, "Magnetic resonance 
imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of 
iron oxide in hyperlipidemic rabbits," Circulation, vol. 103, pp. 415-422, 2001. 
[122] N. V. Evgenov, Z. Medarova, G. Dai, S. Bonner-Weir, and A. Moore, "In vivo 
imaging of islet transplantation," Nature medicine, vol. 12, pp. 144-148, 2006. 
[123] H. Huang, Q. Xie, M. Kang, B. Zhang, H. Zhang, J. Chen, et al., "Labeling 
transplanted mice islet with polyvinylpyrrolidone coated superparamagnetic iron 
oxide nanoparticles for in vivo detection by magnetic resonance imaging," 
Nanotechnology, vol. 20, p. 365101, 2009. 
[124] M. N. G. Kwon, M. Yokoyama, T. Okano, Y. Sakurai, K. Kataoka, "Block 
copolymer micelles for drug delivery: loading and release of doxorubicin," 
Journal of Controlled Release, vol. 48, pp. 195-201, 1999. 
[125] N. Tang, G. Du, N. Wang, C. Liu, H. Hang, and W. Liang, "Improving 
penetration in tumors with nanoassemblies of phospholipids and doxorubicin," J 
Natl Cancer Inst, vol. 99, pp. 1004-15, Jul 4 2007. 
[126] V. Weissig, K. R. Whiteman, and V. P. Torchilin, "Accumulation of protein-
loaded long-circulating micelles and liposomes in subcutaneous Lewis lung 
carcinoma in mice," Pharmaceutical Research, vol. 15, pp. 1552-1556, Oct 1998. 
[127] C. Fang, B. Shi, Y. Y. Pei, M. H. Hong, J. Wu, and H. Z. Chen, "In vivo tumor 
targeting of tumor necrosis factor-α-loaded stealth nanoparticles: Effect of 
MePEG molecular weight and particle size," European Journal of 
Pharmaceutical Sciences, vol. 27, pp. 27-36, 2006. 
144 
 
[128] K. F. Chu and D. E. Dupuy, "Thermal ablation of tumours: biological 
mechanisms and advances in therapy," Nat Rev Cancer, vol. 14, pp. 199-208, Mar 
2014. 
[129] R. D. Issels, "Hyperthermia adds to chemotherapy," Eur J Cancer, vol. 44, pp. 
2546-54, Nov 2008. 
[130] J. Otte, "Hyperthermia in cancer therapy," Eur J Pediatr, vol. 147, pp. 560-9, Aug 
1988. 
[131] T. Sadhukha, T. S. Wiedmann, and J. Panyam, "Enhancing therapeutic efficacy 
through designed aggregation of nanoparticles," Biomaterials, vol. 35, pp. 7860-
7869, 2014. 
[132] K. Pala, A. Serwotka, F. Jelen, P. Jakimowicz, and J. Otlewski, "Tumor-specific 
hyperthermia with aptamer-tagged superparamagnetic nanoparticles," Int J 
Nanomedicine, vol. 9, pp. 67-76, 2014. 
[133] M. Liong, J. Lu, M. Kovochich, T. Xia, S. G. Ruehm, A. E. Nel, et al., 
"Multifunctional inorganic nanoparticles for imaging, targeting, and drug 
delivery," ACS Nano, vol. 2, pp. 889-96, May 2008. 
[134] O. Taratula, R. K. Dani, C. Schumann, H. Xu, A. Wang, H. Song, et al., 
"Multifunctional nanomedicine platform for concurrent delivery of 
chemotherapeutic drugs and mild hyperthermia to ovarian cancer cells," Int J 
Pharm, vol. 458, pp. 169-80, Dec 15 2013. 
[135] C. Riccardi and I. Nicoletti, "Analysis of apoptosis by propidium iodide staining 
and flow cytometry," Nature protocols, vol. 1, pp. 1458-1461, 2006. 
[136] J. Ghuman, P. A. Zunszain, I. Petitpas, A. A. Bhattacharya, M. Otagiri, and S. 
Curry, "Structural basis of the drug-binding specificity of human serum albumin," 
J Mol Biol, vol. 353, pp. 38-52, Oct 14 2005. 
[137] J. Wang, D. Mongayt, and V. P. Torchilin, "Polymeric micelles for delivery of 
poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel 
incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate 
and positively charged lipids," J Drug Target, vol. 13, pp. 73-80, Jan 2005. 
[138] L. Mu, T. A. Elbayoumi, and V. P. Torchilin, "Mixed micelles made of 
poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-
tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for 
camptothecin," Int J Pharm, vol. 306, pp. 142-9, Dec 8 2005. 
[139] O. M. Koo, I. Rubinstein, and H. Onyuksel, "Camptothecin in sterically stabilized 
phospholipid micelles: a novel nanomedicine," Nanomedicine, vol. 1, pp. 77-84, 
Mar 2005. 
[140] A. Krishnadas, I. Rubinstein, and H. Önyüksel, "Sterically stabilized phospholipid 
mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs," 
Pharmaceutical research, vol. 20, pp. 297-302, 2003. 
[141] M. P. Alvarez-Berrios, A. Castillo, J. Mendez, O. Soto, C. Rinaldi, and M. 
Torres-Lugo, "Hyperthermic potentiation of cisplatin by magnetic nanoparticle 
heaters is correlated with an increase in cell membrane fluidity," Int J 
Nanomedicine, vol. 8, pp. 1003-13, 2013. 
[142] L. Tong, Y. Zhao, T. B. Huff, M. N. Hansen, A. Wei, and J. X. Cheng, "Gold 
Nanorods Mediate Tumor Cell Death by Compromising Membrane Integrity," 
Adv Mater, vol. 19, pp. 3136-3141, 2007. 
145 
 
[143] E. Amstad, J. Kohlbrecher, E. Muller, T. Schweizer, M. Textor, and E. Reimhult, 
"Triggered release from liposomes through magnetic actuation of iron oxide 
nanoparticle containing membranes," Nano Lett, vol. 11, pp. 1664-70, Apr 13 
2011. 
[144] H. Kim, D. Lee, J. Kim, T.-i. Kim, and W. J. Kim, "Photothermally triggered 
cytosolic drug delivery via endosome disruption using a functionalized reduced 
graphene oxide," ACS nano, vol. 7, pp. 6735-6746, 2013. 
[145] E. Manders, F. Verbeek, and J. Aten, "Measurement of co‐localization of objects 
in dual‐colour confocal images," Journal of microscopy, vol. 169, pp. 375-382, 
1993. 
[146] R. J. Palzer and C. Heidelberger, "Studies on the quantitative biology of 
hyperthermic killing of Hela cells," Cancer Research, vol. 33, pp. 415-321, 1973. 
[147] B. S. Packard and D. E. Wolf, "Fluorescence lifetimes of carbocyanine lipid 
analogs in phospholipid bilayers," Biochemistry, vol. 24, pp. 5176-5181, 1985. 
[148] D. E. Owens, 3rd and N. A. Peppas, "Opsonization, biodistribution, and 
pharmacokinetics of polymeric nanoparticles," Int J Pharm, vol. 307, pp. 93-102, 
Jan 3 2006. 
[149] R. Gref, M. Luck, P. Quellec, M. Marchand, E. Dellacherie, S. Harnisch, et al., 
"'Stealth' corona-core nanoparticles surface modified by polyethylene glycol 
(PEG): influences of the corona (PEG chain length and surface density) and of the 
core composition on phagocytic uptake and plasma protein adsorption," Colloids 
Surf B Biointerfaces, vol. 18, pp. 301-313, Oct 1 2000. 
[150] R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin, and R. 
Langer, "Biodegradable long-circulating polymeric nanospheres," Science, vol. 
263, pp. 1600-1603, 1994. 
[151] Y. Wang, R. Wang, X. Lu, W. Lu, C. Zhang, and W. Liang, "Pegylated 
phospholipids-based self-assembly with water-soluble drugs," Pharm Res, vol. 
27, pp. 361-70, Feb 2010. 
[152] J. R. Lepock, "Cellular effects of hyperthermia: relevance to the minimum dose 
for thermal damage," International Journal of Hyperthermia, vol. 19, pp. 252-
266, 2003. 
[153] J. Barnes, D. Dix, B. Collins, C. Luft, and J. Allen, "Expression of inducible 
Hsp70 enhances the proliferation of MCF-7 breast cancer cells and protects 
against the cytotoxic effects of hyperthermia," Cell stress & chaperones, vol. 6, p. 
316, 2001. 
[154] T. A. Kato, A. Tsuda, M. Uesaka, A. Fujimori, T. Kamada, H. Tsujii, et al., "In 
vitro characterization of cells derived from chordoma cell line U-CH1 following 
treatment with X-rays, heavy ions and chemotherapeutic drugs," Radiat Oncol, 
vol. 6, p. 116, 2011. 
[155] R. D. Dabholkar, R. M. Sawant, D. A. Mongayt, P. V. Devarajan, and V. P. 
Torchilin, "Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-
based mixed micelles: some properties, loading with paclitaxel, and modulation of 
P-glycoprotein-mediated efflux," Int J Pharm, vol. 315, pp. 148-57, Jun 6 2006. 
[156] M. R. Wenk, A. Fahr, R. Reszka, and J. Seelig, "Paclitaxel partitioning into lipid 
bilayers," Journal of pharmaceutical sciences, vol. 85, pp. 228-231, 1996. 
146 
 
[157] F. Mohamed, P. Marchettini, O. A. Stuart, M. Urano, and P. H. Sugarbaker, 
"Thermal enhancement of new chemotherapeutic agents at moderate 
hyperthermia," Annals of surgical oncology, vol. 10, pp. 463-468, 2003. 
[158] B. Leal, M. Meltz, N. Mohan, J. Kuhn, T. Prihoda, and T. Herman, "Interaction of 
hyperthermia with Taxol in human MCF-7 breast adenocarcinoma cells," 
International journal of hyperthermia, vol. 15, pp. 225-236, 1999. 
[159] R. Rietbroek, D. Katschinski, M. Reijers, H. Robins, A. Geerdink, K. Tutsch, et 
al., "Lack of thermal enhancement for taxanes in vitro," International journal of 
hyperthermia, vol. 13, pp. 525-533, 1997. 
[160] T. Kondo, K. Ueda, and E. Kano, "Combined effects of hyperthermia and CPT-11 
on DNA strand breaks in mouse mammary carcinoma FM3A cells," Anticancer 
research, vol. 15, pp. 83-86, 1994. 
[161] C. Ng, A. Bussey, and G. Raaphorst, "Sequence of treatment is important in the 
modification of camptothecin induced cell killing by hyperthermia," International 
Journal of Hyperthermia, vol. 12, pp. 663-678, 1996. 
[162] W. Lu, G. Zhang, R. Zhang, L. G. Flores, Q. Huang, J. G. Gelovani, et al., 
"Tumor site–specific silencing of NF-κB p65 by targeted hollow gold 
nanosphere–mediated photothermal transfection," Cancer research, vol. 70, pp. 
3177-3188, 2010. 
[163] H. S. Choi, W. Liu, P. Misra, E. Tanaka, J. P. Zimmer, B. I. Ipe, et al., "Renal 
clearance of quantum dots," Nature biotechnology, vol. 25, pp. 1165-1170, 2007. 
[164] G. Kong, R. D. Braun, and M. W. Dewhirst, "Hyperthermia enables tumor-
specific nanoparticle delivery: effect of particle size," Cancer Res, vol. 60, pp. 
4440-5, Aug 15 2000. 
[165] B. Chertok, B. A. Moffat, A. E. David, F. Yu, C. Bergemann, B. D. Ross, et al., 
"Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic 
targeting of brain tumors," Biomaterials, vol. 29, pp. 487-96, Feb 2008. 
[166] C. Bremer, C.-H. Tung, and R. Weissleder, "In vivo molecular target assessment 
of matrix metalloproteinase inhibition," Nature medicine, vol. 7, pp. 743-748, 
2001. 
[167] K. Cheng, S. Peng, C. Xu, and S. Sun, "Porous hollow Fe3O4 nanoparticles for 
targeted delivery and controlled release of cisplatin," Journal of the American 
Chemical Society, vol. 131, pp. 10637-10644, 2009. 
[168] P. Mohan and N. Rapoport, "Doxorubicin as a molecular nanotheranostic agent: 
effect of doxorubicin encapsulation in micelles or nanoemulsions on the 
ultrasound-mediated intracellular delivery and nuclear trafficking," Molecular 
pharmaceutics, vol. 7, pp. 1959-1973, 2010. 
[169] W. Li, X. Cai, C. Kim, G. Sun, Y. Zhang, R. Deng, et al., "Gold nanocages 
covered with thermally-responsive polymers for controlled release by high-
intensity focused ultrasound," Nanoscale, vol. 3, pp. 1724-30, Apr 2011. 
[170] Y. Ma, X. Liang, S. Tong, G. Bao, Q. Ren, and Z. Dai, "Gold Nanoshell 
Nanomicelles for Potential Magnetic Resonance Imaging, Light‐Triggered Drug 




[171] M. L. Hauck, S. M. LaRue, W. P. Petros, J. M. Poulson, D. Yu, I. Spasojevic, et 
al., "Phase I trial of doxorubicin-containing low temperature sensitive liposomes 
in spontaneous canine tumors," Clin Cancer Res, vol. 12, pp. 4004-10, Jul 1 2006. 
[172] J. K. Mills and D. Needham, "Lysolipid incorporation in 
dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability 
and drug release rates at the membrane phase transition," Biochim Biophys Acta, 
vol. 1716, pp. 77-96, Oct 15 2005. 
[173] P. S. Yarmolenko, Y. Zhao, C. Landon, I. Spasojevic, F. Yuan, D. Needham, et 
al., "Comparative effects of thermosensitive doxorubicin-containing liposomes 
and hyperthermia in human and murine tumours," Int J Hyperthermia, vol. 26, pp. 
485-98, 2010. 
[174] G. R. Anyarambhatla and D. Needham, "Enhancement of the phase transition 
permeability of DPPC liposomes by incorporation of MPPC: a new temperature-
sensitive liposome for use with mild hyperthermia," Journal of Liposome 
Research, vol. 9, pp. 491-506, 1999. 
[175] M. S. Yavuz, Y. Cheng, J. Chen, C. M. Cobley, Q. Zhang, M. Rycenga, et al., 
"Gold nanocages covered by smart polymers for controlled release with near-
infrared light," Nat Mater, vol. 8, pp. 935-9, Dec 2009. 
[176] J. You, R. Zhang, G. Zhang, M. Zhong, Y. Liu, C. S. Van Pelt, et al., 
"Photothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: 
A platform for near-infrared light-trigged drug release," J Control Release, vol. 
158, pp. 319-28, Mar 10 2012. 
[177] J. H. Park, G. von Maltzahn, L. L. Ong, A. Centrone, T. A. Hatton, E. Ruoslahti, 
et al., "Cooperative nanoparticles for tumor detection and photothermally 
triggered drug delivery," Adv Mater, vol. 22, pp. 880-5, Feb 23 2010. 
[178] R. A. Frimpong and J. Z. Hilt, "Poly(n-isopropylacrylamide)-based hydrogel 
coatings on magnetite nanoparticles via atom transfer radical polymerization," 
Nanotechnology, vol. 19, p. 175101, Apr 30 2008. 
[179] S. R. Deka, A. Quarta, R. Di Corato, A. Riedinger, R. Cingolani, and T. 
Pellegrino, "Magnetic nanobeads decorated by thermo-responsive PNIPAM shell 
as medical platforms for the efficient delivery of doxorubicin to tumour cells," 
Nanoscale, vol. 3, pp. 619-29, Feb 2011. 
[180] S. Purushotham, P. E. Chang, H. Rumpel, I. H. Kee, R. T. Ng, P. K. Chow, et al., 
"Thermoresponsive core-shell magnetic nanoparticles for combined modalities of 
cancer therapy," Nanotechnology, vol. 20, p. 305101, Jul 29 2009. 
[181] A. Aqil, S. Vasseur, E. Duguet, C. Passirani, J. P. Benoît, R. Jérôme, et al., 
"Magnetic nanoparticles coated by temperature responsive copolymers for 
hyperthermia," Journal of Materials Chemistry, vol. 18, p. 3352, 2008. 
[182] M. Pernia Leal, A. Torti, A. Riedinger, R. La Fleur, D. Petti, R. Cingolani, et al., 
"Controlled release of doxorubicin loaded within magnetic thermo-responsive 
nanocarriers under magnetic and thermal actuation in a microfluidic channel," 
ACS Nano, vol. 6, pp. 10535-45, Dec 21 2012. 
[183] S. Balasubramaniam, N. Pothayee, Y. Lin, M. House, R. C. Woodward, T. G. St. 
Pierre, et al., "Poly(N-isopropylacrylamide)-Coated Superparamagnetic Iron 
Oxide Nanoparticles: Relaxometric and Fluorescence Behavior Correlate to 
148 
 
Temperature-Dependent Aggregation," Chemistry of Materials, vol. 23, pp. 3348-
3356, 2011. 
[184] H. Vihola, A. Laukkanen, L. Valtola, H. Tenhu, and J. Hirvonen, "Cytotoxicity of 
thermosensitive polymers poly (N-isopropylacrylamide), poly (N-
vinylcaprolactam) and amphiphilically modified poly (N-vinylcaprolactam)," 
Biomaterials, vol. 26, pp. 3055-3064, 2005. 
[185] S. Purushotham and R. V. Ramanujan, "Thermoresponsive magnetic composite 
nanomaterials for multimodal cancer therapy," Acta Biomater, vol. 6, pp. 502-10, 
Feb 2010. 
[186] B. Ashok, L. Arleth, R. P. Hjelm, I. Rubinstein, and H. Onyuksel, "In vitro 
characterization of PEGylated phospholipid micelles for improved drug 
solubilization: effects of PEG chain length and PC incorporation," J Pharm Sci, 
vol. 93, pp. 2476-87, Oct 2004. 
[187] O. Mouritsen, K. Jorgensen, and T. Honger, "Permeability of lipid bilayers near 
the phase transition," Permeability and stability of lipid bilayers, pp. 137-160, 
1995. 
[188] A. K. Kenworthy, S. A. Simon, and T. J. McIntosh, "Structure and phase behavior 
of lipid suspensions containing phospholipids with covalently attached poly 
(ethylene glycol)," Biophysical journal, vol. 68, p. 1903, 1995. 
[189] H. Heerklotz, "The microcalorimetry of lipid membranes," Journal of Physics: 
Condensed Matter, vol. 16, pp. R441-R467, 2004. 
[190] D. Needham, G. Anyarambhatla, G. Kong, and M. W. Dewhirst, "A new 
temperature-sensitive liposome for use with mild hyperthermia: characterization 
and testing in a human tumor xenograft model," Cancer research, vol. 60, pp. 
1197-1201, 2000. 
[191] G. Kong, G. Anyarambhatla, W. P. Petros, R. D. Braun, O. M. Colvin, D. 
Needham, et al., "Efficacy of liposomes and hyperthermia in a human tumor 
xenograft model: importance of triggered drug release," Cancer Research, vol. 
60, pp. 6950-6957, 2000. 
[192] L. Arleth, B. Ashok, H. Onyuksel, P. Thiyagarajan, J. Jacob, and R. P. Hjelm, 
"Detailed structure of hairy mixed micelles formed by phosphatidylcholine and 
PEGylated phospholipids in aqueous media," Langmuir, vol. 21, pp. 3279-3290, 
2005. 
[193] L. n. Lartigue, P. Hugounenq, D. Alloyeau, S. P. Clarke, M. Lévy, J.-C. Bacri, et 
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